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1.1 Clinical and histopathological aspects of ovarian tumors
1.1.1 Diagnosis and clinical aspects
Ovarian cancer is the leading cause of death from gynecologic malignancies,
and the fifth most common malignant condition among women in the United States,
with an annual incidence of 25.400 and approximately 14.500 deaths each year
(Landis et al. 1998). The majority of women, approximately 70%, present with
advanced stage disease with either regional or distant metastases at the time of
diagnosis (Landis et al. 1998).
The incidence of ovarian cancer increases with age and peaks in the eighth
decade. The rate increases from 15.7/100,000 in the 40 to 44 age group to a peak rate
of 54/100,000 in the 75 to 79 age group. The median age at diagnosis is 61 years
(Averette et al. 1995). The risk of developing ovarian cancer in a lifetime is only 1.4%
in women with negative family history, but can increase to 14.6%- 32.2% in women
with a family history and germline mutations of the BRCA1 gene at the age of 60 years
(Tortolero-Luna et al. 1994, Laplace-Marieze et al. 1999, Whittemore et al. 1997).
Epidemiologic studies have shown weak or mixed degrees of correlation with
increased risk for ovarian cancer for tobacco smoke, radiation exposure, talc in genital
hygiene, psychotropic medication, the mumps virus, high level physical activity, and
dietary factors (as reviewed by Holschneider and Berek, 2000). Infertility has been
found to be a significant risk factor for ovarian cancer, while parity, lactation, and oral
contraceptive use have a protective effect (as reviewed by Holschneider and Berek,
2000). This supports the „incessant ovulation„ hypothesis for ovarian cancer.
According to this hypothesis, ovarian cancer develops from an aberrant repair process
of the surface epithelium which is ruptured and repaired during each ovulatory cycle
(Fathalla, 1971). Long term use of oral contraceptives reduces the risk of developing
ovarian cancer by 50% (Whittemore et al. 1992).
The diagnosis of ovarian cancer is mainly based on bimanual palpation and
transvaginal sonography. CT and MRT can be useful to obtain information about the
spread of the disease, lymph node involvement and liver metastases. The ultrasound
criteria of an adnexal mass suspicious for malignancy are the presence of cystic or
polycystic tumors with solid structures, completely solid structures, thick irregular
septae, ascites, and evidence of infiltration into adjacent organs (Reles et al. 1997,
1998). The sensitivity of transvaginal ultrasound for the diagnosis of ovarian cancer in
this tumor cohort was as high as 95% and specificity was found to be 82% (Reles et al.
2
1998). Transvaginal color Doppler sonography is also routinely used for the diagnosis
of ovarian cancer since the blood vessel resistance in malignant ovarian tumors is
significantly lower than in benign tumors due to tumor neovascularization. The value
of the method though is limited by a relatively low specificity of 69% (Reles et al.
1998).
1.1.2 Histological classification of epithelial ovarian tumors
Malignant epithelial ovarian tumors, including tumors of borderline
malignancy, account for almost 90% of all ovarian carcinomas (Scully, 1979). The
tumors of "common epithelial origin„ arise from the surface epithelium of the ovary.
During embryonic life the celomic cavity forms and is lined by a layer of mesothelium,
parts of which become specialized to form the serosal epithelium covering the gonadal
ridge. By a process of invagination, this same mesothelial lining gives rise to the
müllerian ducts, from which arise the fallopian tube, uterus, and vagina (Kurman,
1987).
As the ovary develops, the surface epithelium extends into the ovarian stroma
to form inclusion glands and cysts (Clement, 1987). The epithelium, in becoming
malignant, exhibits a variety of müllerian type differentiations: serous (resembling
fallopian tube), mucinous (resembling the endocervix), endometrioid (resembling
endometrium), and clear cell (cells resembling endometrial glands in pregnancy)
tumors. The ovarian surface epithelium, within its repertoire of differentiation, can
also exhibit urothelial differentiation in the form of transitional cells. Table 1 presents
the histologic classification scheme which has been developed and continuously
updated under the auspices of WHO, International Federation of Gynecology and
Obstetrics (FIGO), International Society of Gynecologic Pathologists, and Society of
Gynecologic Oncologists (Scully, 1979).
1.1.3 Therapeutic aspects of epithelial ovarian tumors
The standard of care for newly diagnosed advanced ovarian cancer currently
includes cytoreductive surgery, followed by combination chemotherapy with platinum
and paclitaxel. Optimal tumor debulking is critical in the management of ovarian
carcinoma and residual disease has been shown to be one of the most important factors
influencing survival in patients with advanced ovarian carcinoma (Makar et al. 1995,
Eisenkop et al. 1998). Patients in stage IIIc and IV ovarian carcinoma have a
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Table 1: Histologic classification of common epithelial tumors of the ovary
SEROUS TUMORS
Benign: Cystadenoma and papillary cystadenoma
Surface papilloma
Adenofibroma and cystadenofibroma
Borderline:* Cystadenoma and papillary cystadenoma
Surface papilloma
Adenofibroma and cystadenofibroma
Malignant: Papillary adenocarcinoma and papillary cystadenocarcinoma
Surface papillary carcinoma






Malignant: Adenocarcinoma and cystadenofibroma
Malignant adenofibroma and cystadenofibroma
ENDOMETRIOID TUMORS
Benign: Adenoma and cystadenoma
Adenofibroma and cystadenofibroma









Mesodermal (müllerian) mixed tumors, homologous and
heterologous






Borderline: Proliferating Brenner Tumor








*Tumors of borderline malignancy / Carcinoma of low malignant potential (LMP)
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significantly better survival if postoperatively no residual tumor remains as compared
to those who have a residual tumor of 10 mm or more (Eisenkop et al. 1998).
As a standard surgical approach a midline incision extending from the
symphysis to above the umbilicus or to the xiphoid is performed. After obtaining
histological confirmation by frozen section, bilateral salpingo-oophorectomy,
hysterectomy, infragastric omentectomy, and pelvic and paraaortic lymphadenectomy
are performed. Appendectomy is optional. Resection of the small intestine, colon,
peritoneal surfaces, partial gastrectomy, partial liver resection, and urinary tract
surgery are performed as necessary, depending on the extent of metastasis. Diffuse
peritoneal spread of the carcinoma is treated by infrared light thermocoagulation. The
incidence of lymph node metastasis has been reported to be as high as 64%-75% in
advanced stage carcinomas, but even in stage I carcinomas, lymph node metastasis
have been found in up to 24% of the cases (Burghardt et al. 1991, Petru et al. 1994).
Pelvic and paraaortic lymphadenectomy is therefore routinely performed at the
Department of Gynecology, Charité Campus Virchow-Klinikum as part of the primary
surgery. The aim of surgery is optimal debulking with resection of all visible tumor.
Surgery is followed by adjuvant combination chemotherapy in all cases of
FIGO-stage Ic-IV. In stage Ia and Ib disease, the decision depends on the histologic
grading of the tumor. Stage Ia/Ib ovarian carcinomas with grade I do not need to
receive adjuvant chemotherapy while patients with G3 tumors would be treated with
chemotherapy. In stage Ia/Ib, grade II tumors, decision should be made individually.
The standard combination chemotherapy for adjuvant treatment of primary
tumors is Carboplatin and Paclitaxel. Application of Cisplatin (75 mg/m²) and
Paclitaxel (135 mg/m², 24h infusion) has been shown to be superior to Cisplatin in
combination with Cyclophosphamide (750 mg/m²) (McGuire et al. 1996). Because of
the toxicity profile of Cisplatin, especially nephro- and neurotoxicity, and similar
reponse rates of Cisplatin and Carboplatin, the present regimen for most hospitals as
first line treatment of ovarian cancer is Carboplatin AUC 6 and Paclitaxel 175 mg/m²
(3-h-infusion). However, resistance to chemotherapy remains a complex problem.
Despite high overall clinical response rates of up to 80% including a high proportion
of complete reponses achieved with platinum-based therapy, most patients
subsequently relapse and require additional treatment (McGuire and Ozols, 1998).
A consensus for the treatment of recurrent ovarian cancer has not been
established so far. Patients with late recurrency (>12 months after completion of
primary chemotherapy) benefit from surgical tumor debulking in terms of median
survival and response to a second line chemotherapy. In a multidisciplinary approach
in a team of gynecologists, surgeons and urologists we try to achieve optimal tumor
debulking by surgery for recurrent disease followed by second line chemotherapy.
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Patients who were initially sensitive to platinum-based chemotherapy have demon-
strated relatively high response rates (40%-50%) to second-line platinum-based
therapy (Markman et al. 1991).
Promising results have been found for Topotecan, a topoisomerase I inhibitor
(Hycamtin, SmithKline Beecham Pharmaceuticals, Philadelphia, PA) with response
rates of up to 31% in recurrent ovarian cancer, depending on initial response to
platinum-based chemotherapy (ten Bokkel Huinink et al. 1997). Another substance
that may play an important role for second line chemotherapy in the future is
Gemcitabine, a novel nucleoside analog, which has been shown to have response rates
as high as 19% in patients with recurrent ovarian cancer who had been resistant to
previous first line Cisplatin chemotherapy (Lund et al. 1994).
Other substances for chemotherapy of recurrent ovarian cancer include
Etoposide, Treosulfan, pegylated liposomal Doxorubicin, and Docetaxel. The primary
goal of therapy in relapsed ovarian cancer is to extend survival time by maximizing all
available therapies while minimizing side effects and preserving quality of life.
1.1.4 Clinical course and prognosis
Although relative 5-year survival is 83%- 88% in stage FIGO I, and 59-64% in
FIGO II, the more advanced stages III and IV have a survival of approximately only
30% and 18% respectively (Kosary, 1994). Overall, earlier diagnosis by vaginal
ultrasound, radical debulking surgery and chemotherapy have contributed to a
significant improvement in the 5-year survival rate from 36% in 1974-1976 to 47% in
the years 1986-1993 (Landis et al. 1998).
Established prognostic factors of ovarian cancer are FIGO stage, residual tumor
after surgery, histological grading, lymph node status, age, and amount of ascites in
primary surgery (Kosary, 1994, Makar et al. 1995, Eisenkop et al. 1998, Reles et al.
2001, as reviewed by Holschneider and Berek, 2000). The role of the histological type
as a prognostic factor remains controversial (Kosary, 1994, Makar et al. 1995). Other
factors such as DNA-ploidy, decline of CA125 level after surgery, expression of
oncogenes and growth factor receptors (Her-2/neu, EGFR), and alterations of tumor
suppressor genes (p53, Rb) are currently under investigation.
Within FIGO-stages, grade and lymph node status have a large impact on
survival. Survival declines from 94.6% for well differentiated FIGO stage I tumors to
69.7% for poorly differentiated. For FIGO stage II, this decline is from 78.3% to
48.2%, for FIGO stage III from 76.2% to 23.9%, and for FIGO stage IV from 50.2% to
13.8% (Kosary, 1994). For patients diagnosed with stage I ovarian tumors, 5-year
survival is 85.1% without lymph node metastasis, but survival drops to 51.9%, if
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lymph node metastasis are present. Age also has a strong impact on survival. A women
at age 40 with stage IV ovarian cancer has a 50% 5-year survival probability, while
this declines to 7.7% in stage IV for a patient >70 years of age (Kosary, 1994).
Multivariate analysis usually reveals stage as well as residual tumor after
surgery, and in some studies histological grade of differentiation and age as
independent prognostic factors in epithelial ovarian cancer (Eisenkop et al. 1998,
Reles et al. 2001).
1.2 Molecular genetic alterations in ovarian tumors
1.2.1 Hereditary ovarian tumors
Approximately 10% of ovarian cancers are thought to be due to autosomal
dominant hereditary syndromes (Lynch et al. 1978). The risk of ovarian cancer in first
and second degree relatives of women with ovarian cancer is increased 3.6- and 2.9-
fold respectively, compared to women who have no family history of ovarian cancer
(as reviewed by Berchuck et al. 1999). Three syndromes have been recognized so far
(Table 2):
Table 2: Genetic alterations in hereditary ovarian cancer syndromes
Hereditary ovarian cancer syndrome Gene affected by mutation
Site specific ovarian cancer BRCA1, BRCA2
Hereditary breast and ovarian cancer (HBOC) BRCA1, BRCA2
Hereditary Non-Polyposis Colon Carcinoma
(HNPCC)
MSH2, MLH1, PMS1, PMS2
(DNA mismatch repair genes)
(1) site-specific ovarian cancer syndrome (familial predisposition to ovarian
cancer only), (2) hereditary breast and ovarian cancer (HBOC) (predisposition to both
breast and ovarian cancers), and (3) hereditary non-polyposis colorectal cancer
syndrome (HNPCC), also known as Lynch II syndrome (predisposition in men for
colorectal, cancer and in women for breast, colorectal, endometrial and ovarian cancer)
(as reviewed by Berchuck et al. 1999).
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It has been estimated that the breast-ovarian cancer syndrome accounts for the
majority of hereditary ovarian cancer cases (65-75%), out of which, approximately 10-
15% are site specific. Site-specific and breast-ovarian cancer syndromes have been
linked to mutations in the BRCA1 and BRCA2 gene.
The BRCA1 gene is located on chromosome 17q21-12 and it is thought to act as
a tumor suppressor gene (Hall et al. 1990, Miki et al. 1994). Initial studies in families
selected on the basis of strong family history and early age of onset, suggested that
germline mutations in BRCA1 were responsible for about 50% of hereditary breast
cancers and 90% of hereditary ovarian cancers (Ford et al. 1995). Constitutional
mutations in BRCA1 were found in 34-58% of hereditary ovarian cancer families from
North American and European origin (as reviewed by Aunouble et al. 2000). In
families with BRCA1 mutations, the lifetime risk of developing ovarian cancer was
estimated to be as high as 60% (Easton et al. 1995). More recently it has been
suggested that initial estimates of BRCA1 penetrance may have been too high because
of selection bias. Population-based case-control studies estimated a cumulative risk of
14.6% respectively, 32.2% for BRCA1 mutation carriers to develop ovarian cancer at
the age of 60 years (Laplace-Marieze et al. 1999, Whittemore et al. 1997).
The second major breast/ovarian cancer susceptibility gene, BRCA2, was
identified on chromosome 13q12 (Wooster et al. 1995), and may account for 10% to
35% of hereditary ovarian cancer. BRCA2 mutations were found in 7-14.5 % high risk
families (as reviewed by Aunoble et al. 2000), and the penetrance of the gene was
estimated to be 27% by age 70 (Ford et al. 1998). Approximately 80-90% of BRCA1
and BRCA2 mutations result in truncated protein products, while missense mutations
are rare (as reviewed by Berchuck et al. 1999).
The HNPCC syndrome (Hereditary Non-Polyposis Colon Cancer) is suspected
to account for 10-15% of the hereditary ovarian cancer cases. Affected families
typically present with colon and endometrial carcinomas, but some ovarian cancers
occur too. HNPCC is associated with germline mutations in a family of genes involved
in DNA repair (MSH2, MLH1, PMS1, PMS2) (as reviewed by Berchuck et al. 1999).
At present, testing for BRCA1 and BRCA2 mutations is recommended, if two
individuals in a family either had ovarian cancer at any age, or breast cancer before
age 50, and are first or second degree relatives. When these conditions are met, there is
a 10% to 20% probability of finding a mutation. The most notable founder mutations
described thus far are the BRCA1 185delAG, the BRCA1 5382insC and the BRCA2
6174delT mutations (as reviewed by Berchuck et al. 1999).
Besides genetic testing, ultrasound and Doppler screening as well as serum
CA125 marker testing are prevention tools for high risk families. Prophylactic
oophorectomy followed by hormonal replacement therapy in women in their late 30s
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or 40s is believed to be a reasonable intervention to consider in BRCA1 and BRCA2
mutation carriers. However, it has been noted that approximately 2% of these women
develop primary peritoneal papillary serous carcinoma after oophorectomy (Piver et al.
1993). Oral contraceptive use (six years or more) by women out of families with
hereditary ovarian cancer decreases the risk by as much as 60% and therefore seems an
attractive alternative for cancer prevention (Narod et al. 1998).
In general, genetic counseling and testing, as well as the decision about the best
strategy for prevention or early detection of ovarian cancer in high risk families,
requires a multidisciplinary approach by geneticists, gynecologists, and psychologists.
Health care, family planning, psychological aspects, and potential health insurance
problems are important considerations for these patients.
1.2.2 Sporadic ovarian tumors
Molecular genetic alterations are frequent in sporadic ovarian cancers and these
alterations include chromosomal deletion, oncogene amplification and overexpression,
mutation of tumor suppressor genes, and alternative and aberrant RNA splicing. Some
alterations have been found to correlate with tumor histopathological criteria and
clinical outcome.
Loss of heterozygosity (LOH) is defined as a deletion of a portion of a
chromosome that contains a putative tumor suppressor gene. LOH implies loss of the
normal polymorphism present at a given locus. Tumor DNA has a propensity to loose
one of its two alleles of various genes, compared with DNA from normal cells of the
same patient. LOH has been frequently identified in ovarian carcinomas. Several
investigators reported that chromosomes 17p, 17q, and 6q show high frequencies of
LOH, as high as 31%-83%, 39%-74%, and 39%-74% respectively, in ovarian
carcinomas (as reviewed by Chuaqui et al. 1997). Other loci potentially important in
ovarian carcinogenesis are chromosomes 4p, 7p, 12p, 12q, 18q, and 19p (as reviewed
by Chuaqui et al. 1997).
Several oncogenes have been found to be altered in ovarian cancer, including
HER-2/neu, k-ras, fms, c-myc, and c-fos. Most important among these are HER-2/neu,
k-ras, and c-myc. The HER-2/neu gene maps to 17q21-22 and encodes a 185-kd
transmembrane glycoprotein receptor (p185 HER2), which has partial homology with
the epidermal growth factor receptor. It has tyrosine kinase activity and promotes cell
proliferation and differentiation. The p185 HER2 protein is a member of the family of
growth factor receptors, which include also EGF-R, HER-3, and HER-4.
In an early study by Slamon et al. 1989, HER-2/neu was found to be amplified
and overexpressed in 26% of ovarian carcinomas. The number of gene copies
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significantly correlated with clinical outcome, >5 gene copies giving the poorest
outcome. The prognostic value of HER-2/neu overexpression still remains contro-
versial though. Only one author has reported an independent correlation with survival
in 275 cases (Meden et al. 1994), while others found correlations only in univariate
analysis or no correlation at all, including 174 cases analyzed at the Department of
Gynecology, Charité-Campus Virchow-Klinikum (as reviewed by Aunoble et al. 2000,
Schmider, 1999).
Table 3: Molecular genetic alterations in sporadic ovarian cancer
Structure Type of Alteration Affected Chromosomes
or Genes
Chromosomes Loss of heterozygosity (LOH) 17p, 17q, 6q
4p, 7p, 12p, 12q, 18q, 19p


















More important than the prognostic value is the fact that this protein is used as
a therapeutic target for a recombinant humanized anti-HER2 monoclonal antibody
(rhuMAb HER2 [trastuzumab] ). RhuMAb HER2 has achieved an objective response
rate of 15% as a single agent in patients with HER-2/neu overexpressing metastatic
breast cancer who had received extensive prior therapy (Cobleigh et al. 1999). The
therapy was well tolerated and the most common adverse effects were infusion-
associated fever and chills. Several protocols of a combination therapy of trastuzumab
with chemotherapeutic agents are currently under investigation. The results of the
rhuMAb HER2 clinical trials demonstrate that a better understanding of genetic
alterations in cancer can lead to new targeted approaches to cancer treatment.
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The c-myc oncogene is located on chromosome 8q24 and is involved in cell
cycle regulation by activation or inhibition of several genes including cyclins (A,D or
E) and p53 (Dang, 1999). Amplification and/or overexpression of the wild-type
sequence has been demonstrated in 26-37% of ovarian cancer, but a correlation to
survival has only been demonstrated in one study in co-expression with HER-2/neu
and p21ras (as reviewed by Aunoble et al. 2000).
K-ras was localized to 12p12.1 and is a member of the family of ras genes
which code for serine/threonine protein kinases. Mutated K-ras protein looses the
ability to become inactivated and thus stimulates growth and differentiation
autonomously (as reviewed by Aunoble et al. 2000). In ovarian cancer, mutations of
the K-ras oncogene have been detected in 11-75% in mucinous and 5-36% in
nonmucinous tumors (as reviewed by Aunoble 2000 et al.). These results suggest that
K-ras mutational activation is an early event of mucinous ovarian tumorigenesis.
Little is known about the prognostic value of K-ras. While most studies find no
correlation, only one study showed a significant relationship between K-ras alterations
and poor clinical outcome (Scambia et al. 1997).
Among the tumor suppressor genes which are altered in sporadic ovarian
cancer, p53 plays the most important role, while BRCA1 and BRCA2 are only rarely
mutated. p53, located at 17p13.1, codes for a 53 kilodalton transcription factor which
regulates cell cycle control and apoptosis. It has been found to be mutated in
approximately 40-80% and overexpressed in 32%-84% of epithelial ovarian cancers
(as reviewed in chapter 1.3.7). The value of p53 mutations and protein overexpression
as prognostic markers are controversial (as reviewed in chapter 1.3.7). Since efficacy
of platinum-based chemo-therapy is believed to depend on p53-induced apoptosis (re-
viewed in chapters 1.3.8 and 5.1.7), restoration of p53 function has become an
attractive target for gene therapy (as reviewed in chapter 1.2.3).
Further genes that are frequently altered in ovarian cancer are the mdm2 gene, which
tightly regulates p53 function (as reviewed in chapter 1.4.3), and the CIP1/WAF1
gene, which mediates p53 induced G1 cell cycle arrest. (see chapter 1.3.3). The
CIP1/WAF1 gene was shown to have no mutations but an AGC→AGA (serine→
arginine) polymor-phism at codon 31 was detected in 15% of ovarian cancer cases
(Lukas et al. 1997). We found overexpression of the p21 protein in 61% of ovarian
carcinomas, and high overexpression (>50% of the nuclei) was correlated significantly
with early stage and favourable prognosis of ovarian cancer (Schmider et al. 2000).
The Rb/cyclin D1/p16 pathway may also be involved in ovarian carcinogenesis,
but the mechanisms remain to be further analyzed. Sequence alterations of the
retinoblastoma gene are rare, but pRb expression was found in 71% of ovarian
carcino-mas as opposed to 41% of benign tissues (Dong et al. 1997). Mutations of the
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p16ink4A tumor suppressor gene which encodes a cyclin-dependent kinase inhibitor
are infrequent in ovarian cancers, but methylation of the gene has been noted in 4% of
ovarian cancers (Wong et al. 1999). Recently aberrant RNA splicing of the p16ink4A
gene has been described in ovarian cancer (Suh et al. 2000).
As opposed to hereditary ovarian cancer, alterations of the BRCA1 and BRCA2
tumor suppressor gene are rare in sporadic ovarian cancer. Although LOH at the
BRCA1 and BRCA2 locus is seen in 80% respectively more than 50% of sporadic
ovarian carcinomas, mutations of BRCA1 have been found in only 5%, and mutations
of BRCA2 in only 4.6% respectively 8% of these tumors (as reviewed by Aunoble et
al. 2000).
1.2.3 Gene therapy
Because p53 is a central regulator in cell cycle control and mutations of the p53
gene are the most frequent abnormalities identified in human tumors, restoration of
p53 function has become a major focus of research for gene replacement therapy. Re-
introduction of wild-type p53 gene into cells that have lost normal p53 function can
induce either growth arrest or apoptosis (El-Deiry et al. 1993, Yonish-Rouach et al.
1991, Wills et al. 1994, Nielsen and Maneval, 1998).
For the delivery of tumor suppressor genes into cancer cells, adenovirus vectors
(Ad) have been shown to be most efficient. Adenoviruses can be produced in high
titers and can infect both dividing and non-dividing cells at high efficiencies, thus
resulting in high levels of transgene expression. Adenovirus vectors do not normally
integrate into the host genome, so transgene expression is transient (as reviewed by
Pützer 2000).
In vitro studies of cell cultures derived from various human malignancies have
shown that delivery of wild-type p53 in cells previously mutant or null for p53 results
in a dose-dependent inhibition of cell proliferation, usually associated with cell death
via apoptosis (Wills et al. 1994, Yonish-Rouach et al. 1991, Nielsen and Maneval,
1998, Hirai et al. 1999). p53 tumor suppressor gene therapy, applied to an
intraperitoneal model of ovarian cancer in mice, demonstrated an increase in survival
in the treated compared to the control group (Mujoo et al. 1996, Kim et al. 1999).
Considering the short half-life of wild-type p53 and the fact that only a small
percentage of tumor cells can be transduced, some of the growth suppressing effect of
adenovirus mediated p53 gene therapy is thought to be due to the so-called bystander
effects. These effects possibly include transfer of metabolic products through gap
junctions, phagocytosis of apoptotic vesicles containing dead tumor cells that mediate
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apoptosis, induction of an immune reponse against the tumor, and inhibition of
angiogenesis (as reviewed by Pützer 2000).
Cell culture experiments have shown that the sensitivity of tumor cells to
various chemotherapeutic agents such as adriamycin, etoposide, doxorubicin, cisplatin
and others depends on the efficient induction of apoptosis mediated by a functional
p53 protein. Therefore, loss of p53 can enhance resistance to chemotherapy (Lowe et
al. 1993, Vasey et al. 1996, Vikhanskaya et al. 1997). In addition to the anti-tumor
effect of p53 tumor suppressor gene transduction, sensitization to chemotherapy by re-
introduction of wt p53 may play an important role for gene therapy. Other potential
targets for gene therapy include the WAF1/CIP1, a universal inhibitor of the cyclin
dependent kinases, the mdm2 gene and other genes which are involved in cell cycle
regulation.
A synergistic efficacy of adenovirus-mediated p53 gene therapy and
chemotherapy, both for Cisplatin and Paclitaxel, have been demonstrated in xenograft
models of colon, ovarian, prostate and breast cancer (Ogawa et al. 1997, Nielsen et al.
1998, Gurnani et al. 1999).
Promising results have been found in the first clinical p53 gene therapy study
(Schering Plough Research Institute/ Essex Pharma) for ovarian carcinomas with p53
mutations. In a phase I clinical trial, re-introduction of wild-type p53 via a
recombinant adenovirus was investigated in recurrent ovarian cancer. Intraperitoneal
administration of Ad p53 resulted in successful p53 gene transfer and expression as
well as objective tumor response in part of the cases (I.B. Runnebaum, personal
comunication).
Currently, the Department of Gynecology of the Charité-Campus Virchow-
Klinikum participates in a multinational, multicenter, randomized phase II/III trial of
chemotherapy alone (Taxol/Carboplatin) versus chemotherapy plus p53 gene therapy
in newly diagnosed stage III ovarian cancer and primary peritoneal cancer with ≤ 2cm
residual disease following surgery, which is conducted by the Schering-Plough
Research Institute (Project Director: Jo Ann Horowitz, M.D., USA).
The present data suggests that gene replacement therapy provides a potentially
effective anti-tumor strategy. The increasing knowledge about regulation of cell
division and apoptosis opens new perspectives for treatment strategies. By means of
molecular genetic techniques such as the chip technology for analyzing mutations and
gene expression patterns, a precise genetic characterization of tumor cells and an
individual choice of the most efficient therapy may be possible in the future.
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1.3 The p53 tumor suppressor gene
1.3.1 p53 domains: structure and function
The p53 gene is a tumor suppressor gene and has been named "the guardian of
the genome„ (Lane, 1992) or the "cellular gatekeeper of growth and division„ (Levine,
1997). The p53 protein is a transcription factor which plays a central role in the
regulation of cell cycle arrest and apoptosis following DNA damage.
The p53 gene contains eleven exons which encode for a 2.8 kb mRNA,
translated into a 53kD protein (Matlashewski et al. 1984, Harlow et al. 1985). Exon 1
is always non-coding. In human p53, a very large intron of 10 kb with unknown
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Fig. 1: Structural and functional regions of the p53 protein (redrawn from May and
May, 1999)  Functional regions and corresponding amino acid residues are shown on
top. In the middle, evolutionary highly conserved domains I-V are shown. The bottom
represents the tertiary structure of the site-specific DNA-binding. L1, L2, L3 indicate
loops, and LSH indicates a loop-sheet-helix structure. The tertiary structure is shown
in more detail in Fig. 2.
The human p53 protein contains 393 amino acids and can be divided into three
regions: 1) the amino-terminal region, which contains the transcriptional trans-
activation domain, 2) the carboxy-terminal region, which contains the functional
regions for nuclear localization, tetramerization, and both non-specific DNA-binding
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and recognition of primary DNA damage, and 3) the central region of the protein
(amino acid residues 102 to 292), which contains most of the sequence specific DNA












































Fig. 2: Topological diagram of the secondary structure elements of the core
domain of the p53 protein (redrawn from Cho et al. 1994). The residues at the start
and the end of each secondary structure element are indicated. The DNA-binding
regions of the protein (L1-S2-S’, L2, L3, S10-H2) correspond to the conserved regions
of the p53 gene and are colored yellow for region II (residue 117-142), red for region
III (residue 171-181), blue for region IV (residue 234-258) and green for region V
(residue 270-286). The boundaries of the two ß-sheets that make up the ß-sandwich are
shaded. The scaffolding regions are white.
The functional form of the p53 protein is a tetramer, which is assembled by the
amino acid residues 323-356 of the carboxy-terminal region of the protein (Wang et al.
1994). It has been shown that some p53 mutants exhibit a dominant negative
phenotype and are able to associate with the wild-type p53 protein, which is expressed
by the remaining wild-type allele, to induce the formation of an inactive
heterooligomer (Soussi and May, 1996).
15
Within the p53 sequence five regions have been identified, which have been
highly conserved throughout evolution (Soussi et al. 1990). The conserved domain I
(amino acid residues 12-23) is located within the aminoterminal region and
corresponds to the binding site of the MDM2 protein. The conserved domains II
(residues 117-142), III (residues 171-181), IV (residues 234- 258) and V (residues
270-286) are located in the central region of the protein and are almost identical to the
DNA interactive regions of the protein as described in the crystallographic structure of
the p53 protein by Cho et al. (1994) (Fig 2).
The crystallographic analysis of the p53 protein has revealed the following
motifs in the central region of the gene: 1) two antiparallel β-sheets composed of four
and five β-strands that hold the other elements, 2) a loop-sheet-helix-motif (LSH)
containing three β-strands, an α-helix, and the L1 loop (residues 112-141), 3) an L2
loop containing a small helix (residues 163-195), and 4) an L3 loop composed mainly
of turns (residues 236-251) (Cho et al. 1994) (Fig 2).  The LSH motif and the L3 helix
are involved in direct DNA interaction (Cho et al. 1994).
There is remarkable correspondence between these structural elements and the
conserved domains II-V of the gene. More than 90% of the missense mutations in the
p53 gene have been found clustered in so-called "hotspots„ in the highly conserved
regions of the II-IV of the gene, which have also been identified as the DNA binding
regions (Greenblatt and Harris, 1994). It has been suggested to distinguish between
class I mutations, which affect amino acid residues directly involved in the protein-
DNA interaction (residues in LSH and L3), and class II mutations, which affect amino
acids involved in the stabilization of the tertiary structure of the protein (residues in
L2) (Soussi and May, 1996). While class I mutations result in defective contacts with
the DNA and loss of the ability of p53 to act as a transcription factor, class II
mutations disrupt the structural basis of the p53 core domain and may, therefore,
indirectly affect its function.
1.3.2 p53 response to cellular stress: upstream events
Under normal conditions, the p53 protein is present in extremely small
quantities in most cells and displays a rapid turnover rate which is on the order of
minutes. Rapid degradation of p53 in normal cells is critical to efficiently dampen p53
activity and is regulated in large part by MDM2 via ubiquitin-mediated proteolysis
(Maki and Howley, 1997, Haupt et al. 1997, Kubbutat and Vousden, 1998).
In its role as a tumor suppressor gene, p53 serves as a "guardian of the
genome„ (Lane, 1992). The amount of p53 protein increases in response to a variety of
signals mediated by cellular stresses, such as DNA damage produced by γ-irradiation
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or ultraviolet radiation (Guidos et al. 1996), oncogene activation, hypoxia (Graeber et
al. 1996), nucleotide depletion (Linke et al. 1996), and metabolic and pH changes (Fig.
3). The p53 protein level increases proportionally to the extent of DNA damage
through a prolonged half-life of the protein (Levine, 1997). Furthermore, the DNA-
binding activity of p53 is increased. p53 stabilization and enhanced activity are
regulated by several mechanisms.
1) p53 protein stabilization can occur through N-terminal phosphorylation and
decreased MDM2-binding, for example after exposure to DNA-damaging ionizing
radiation or the topoisomerase inhibitor etoposide (Siliciano et al. 1997). Two
candidate kinases for p53 phosphorylation have been identified. The ATM gene which
recognizes DNA damage phosphorylates p53 on serine 15, and DNA-PKs (DNA-
activated protein kinase) which phosphorylates p53 at both serine 15 and serine 37
(Woo et al. 1998, Siliciano et al. 1997, Canman et al. 1998, Shieh et al. 1997).
Phosphorylation of p53 at serines 15 and 37 impairs the ability of MDM2 to inhibit
p53-dependent transactivation, most likely due to a conformational change of p53
(Shieh et al. 1997).
Shieh et al. (1999) have also shown that in addition to serine 15, serine 20 is
phosphorylated in response to DNA damage. Recently it has been shown that mutation
of serine-20 renders p53 less stable and more prone to MDM2 mediated degradation.
p53 peptides phosphorylated at serine-20 are less efficient competitors of the
p53/MDM2 interaction than non-phosphorylated peptides (Unger et al. 1999). These
observations are particularly interesting, given that serine-20 resides in the region of
p53 which binds to MDM2 (Kussie et al. 1996, Picksley et al. 1994). p53 protein that
has been phosphorylated at the N-terminus binds poorly to MDM2 and is, therefore,
stabilized through a decrease in its degradation rate.
2) Acetylation of the C-terminal domain of p53 which occurs on lysine 382 by
p300 or lysine 320 by PCAF causes a conformational change at the C-terminus and
activates p53-dependent DNA-binding (Sakaguchi et al. 1998).
3) C-terminal dephosphorylation of p53 at serine 376 creates a consensus
binding site for interaction with 14-3-3σ, which enhances the ability of p53 to bind to
DNA (Waterman et al. 1998). A phosphorylation-acetylation cascade model has been
discussed. It suggests that following DNA damage, N-terminal phosphorylation directs
C-terminal acetylation to activate p53 (Sakaguchi et al. 1998). This would result in









































Fig. 3: p53 pathways. Upstream activators are shown above in red. Multiple downstream effectors of p53 which play a role for cell cycle
arrest and apoptosis are shown. Arrows indicate a positive effect, while a flat line indicates inhibition. Quadrangles indicate specific functions
in p53/MDM2 interaction.
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1.3.3 Downstream mediators of p53-dependent cell cycle arrest
The downstream events mediated by p53 play a major role for cell cycle arrest,
apoptosis, and genomic stability. The growth controlling functions of p53 include cell
cycle arrest, apoptosis, senescence and antiangiogenesis (Fig. 4). The transcriptional
activating function of p53 is a major component of its biological effects and a
substantial number of target genes have been identified. These include WAF1/CIP1,
GADD45, 14-3-3σ, bax, FAS/APO1, KILLER/DR5, PIG3, Tsp1, IGF-BP3 and others
(as reviewed by El-Deiry 1998). It has been suggested, that there may be as many as


































Fig. 4: Response to cellular stresses in cells with wildtype p53 versus cells with
mutated p53
The G1 checkpoint
p53 directly regulates the expression of p21WAF1/Cip1, a universal inhibitor of the
cyclin dependent kinases (Cdk) (Fig.3) (El-Deiry et al. 1993). This 21 kilodalton
protein forms a quaternary complex found in normal cells with cyclin/Cdks and the
DNA polymerase processivity factor PCNA (Xiong et al. 1993). It binds to the cyclin-
Cdk complexes cyclin D1-Cdk4, cyclin E-Cdk2, cyclin A-Cdk2 and cyclin A-Cdc2
and inhibits their kinase activity (Fig. 3). One molecule of p21 per complex appears to
permit Cdk activity, while two molecules inhibit its activity and block cell cycle
progression (Zhang et al. 1994). The available evidence suggests that p21 acts on
cyclin-Cdk complexes and PCNA such that it blocks DNA replication. p21 binds with
its greatest affinity to G1 cyclin-CDK complexes, and binds poorly to cyclin B/cdc2.




While it is clear that p53-deficiency leads to defective cell cycle arrest in G1,
the role of p53 in G2 arrest is less clear. Deregulation of the G2 checkpoint is one of
the hallmarks of malignant transformation. The G2 checkpoint is the last barrier before
the perpetuation of mutations and therefore, very important for the maintanance of
genomic stability. Overexpression of wildtype p53 protein has been found to arrest
cells in G2 and inhibit entry into mitosis (Stewart et al. 1994). This property of p53 is
important in a novel cell cycle checkpoint that controls entry into mitosis when DNA
synthesis is blocked. p53-/- cells do not arrest in response to spindle inhibitors, but
undergo multiple rounds of DNA synthesis without DNA segregation. This results in
the formation of tetraploid and octaploid cells (Cross et al. 1995).
The GADD45 (growth arrest and DNA-damage inducible gene #45) was
initially discussed to play a role in G1 arrest. The gene is induced when cells are
subjected to DNA damage, leading to arrest in the G1 phase of the cell cycle (Kastan
et al. 1992). The GADD45 protein was found to interact with the replication and repair
factor PCNA and to inhibit the entry of cells into the S-phase (Smith et al. 1994). More
recent evidence has suggested that cyclin B/cdc2 may be bound and inhibited by
GADD45, thereby leading to G2 arrest (Zhan et al. 1999). The cdc2 kinase-cyclin B1
complex, termed Mitosis Promoting Factor (MPF), serves as the primary mediator of
the signal for G2-mitosis transition (Zhan et al. 1999).
The 14-3-3σ proteins have also been suggested to be involved as mediators of
p53-dependent G2-arrest. These 14-3-3σ proteins have been shown to bind to the non-
functional phosphorylated form of the cdc25c phosphatase, which in turn, prevents the
dephosphorylation of the cdc2 kinase, thus resulting in non-functional MPF and
inducing G2 arrest (Conklin et al. 1995). The 14-3-3σ gene has been shown to be
upregulated by p53 (Hermeking et al. 1997).
Another gene which may play a role as a mediator of cell cycle arrest is B99. It
is a p53 target gene, which is induced by DNA damage and is specifically upregulated
in the G2-phase, during which its protein is localized in the microtubule network.
Ectopic overexpression of B99 in p53-null fibroblasts leads to G2 arrest (Utrera et al.
1998).
The present knowledge about p53 suggests, that even though p53 can cause an
arrest or prolongation of G2 to enable sufficient repair of DNA defects before the
onset of mitosis, p53 also contributes to the efficiency of DNA repair and therefore
reduces the G2 delay (as reviewed by Schwartz and Rotter 1998).
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The spindle checkpoint
p53 is associated with centrosomes and thus may affect centrosome duplication
directly (Brown et al. 1994). Embryo fibroblasts from p53-null mice acquire more than
two centrosomes, leading to mitosis with more than two spindle poles and frequent
mitotic failure (Fukasawa et al. 1996). p53(-/-) cells have also been found to show
aberrant DNA replication, termed endoreduplication. Polyploid giant cells were the
result. Therefore, this checkpoint prevents the formation of aneuploid cells that are
destined to harbor an unstable genome (Cross et al. 1995).
1.3.4 Mechanisms of p53-dependent apoptosis
Overexpression of wild-type p53 can result in a rapid loss of cell viability by a
manner characteristic of apoptosis (Yonish-Rouach et al. 1991). Apoptosis is defined
as a programmed form of cell death in which the cell "commits suicide„ by
disintegrating into membrane vesicles. The determinants of whether a cell undergoes a
viable cell cycle arrest or apoptosis in response to p53 activation are not fully
understood. The extent of the DNA damage and the levels of p53 have been shown to
affect the choice between cell cycle arrest and apoptosis (Chen X. et al. 1996).
Other factors of influence include expression of the retinoblastoma gene (Rb),
the transcription factor E2F1, viral protein expression and growth factor availability.
The Rb/E2F1 pathway may play a central role in determining the balance between cell
cycle arrest and apoptosis. Loss of Rb function by expression of viral proteins or by
homozygous gene disruption has been correlated with loss of G1 arrest after DNA
damage and apoptosis (Slebos et al. 1994, Howes et al. 1994, Morgenbesser et al.
1994). Inactivation of pRb by either E2F-1 overexpression (Qin et al. 1994) or by
caspase-mediated cleavage of p21WAF1 has also been shown to induce apoptosis
(Levkau et al. 1998). Furthermore, overexpression of Rb blocks p53-mediated
apoptosis (Haupt et al. 1995).
p53-mediated apoptosis is thought to occur through a combination of sequence-
specific transactivation-dependent and independent mechanisms acting in concert.
Several target genes, such as bax, Fas/APO1, KILLER/DR5, PIG genes, PAG608, and
Pidd are induced by p53 through sequence specific transactivation (SST) and have
been identified to participate in the induction of apoptosis.
The bax gene encodes a 21-kD protein of the Bcl-2 family and has been found
to possess potent pro-apoptotic properties (Oltvai et al. 1993, Miyashita and Reed
1995). The ratio of p21 Bax: Bcl-2 has been suggested as a criteria to determine
whether cells live or die (Oltvai et al. 1993). Furthermore, the downregulation of Bcl-
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2, which normally enhances cell survival, further promotes apoptosis (Miyashita et al.
1994). Thus p21 Bax may be an important target mediator of p53-dependent apoptosis.
The cell surface death receptor gene CD95/Fas/Apo-1 is a potent inducer of
apoptosis (as reviewed by Nagata 1997). Once cell surface death receptors bind death
ligands, they transmit rapid apoptotic signals. However, the role of CD95/FAS/APO1
seems to be cell-type and signal-dependent (as reviewed by Gottlieb and Oren 1998).
p53 stimulates the expression of another death-receptor, KILLER/DR5, which is
activated by the death ligand TRAIL (as reviewed by Gottlieb and Oren 1998).
PIGs (p53-induced genes) cause disruption of mitochondrial integrity and
subsequent apoptosis through stimulating reactive oxygen species formation (Polyak et
al. 1997). Other putative pro-apoptotic target genes of p53 are PAG608 (Israeli et al.
1997), the genes which encode IGF-BP3 (Buckbinder et al. 1995) and p85 (Yin et al.
1998). Recently, Pidd, a new gene regulated by p53, was identified and found to
induce apoptosis (Lin et al. 2000).
Inactivation of p53 function may provide a selective advantage for clonal
expansion of preneoplastic and neoplastic cells. Of particular interest is the fact that
hypoxia can activate p53 and promote p53-dependent apoptosis. A hypoxic environ-
ment occurs frequently within the central portion of tumors, particularly prior to
sufficient neoangiogenesis. This would explain the hypoxia-driven selection for cells
with diminished apoptotic potential within solid tumors and would provide an
attractive explanation for the loss of p53 function in tumors (Graeber et al. 1996).
The p53-dependent apoptotic pathway has not only been demonstrated to be
critical to the development of tumors but also to their treatment, since the effectiveness
of various chemotherapeutic agents depends on the ability of p53 to induce apoptosis
(as reviewed in chapter 1.3.8).
1.3.5 p53 and genomic stability
Inactivation of p53 can lead to an increase of mutation frequency resulting
from inefficient nucleotide excision repair (NER). Poor NER causes genomic
instability. The instability is manifested as gene amplification, aneuploidy, and
chromosomal aberrations, associated with malignant progression. p53 can bind to
several DNA helicases, which are part of the basal transcription factor TFIIH (Wang et
al. 1995). One functional outcome of such interaction may be modulation of nucleotide
excision repair (NER) by p53 (Wang et al. 1995).
A model has been proposed in which p53 binds the damaged DNA and
stimulates DNA repair (Wang et al. 1996). Upon successful completion of DNA
repair, it has been proposed that p53 would be phosphorylated and then released from
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the DNA (Lu et al. 1997). If repair is not carried out successfully, it is assumed that
p53 fails to be released and its extended interaction with DNA helicases triggers
apoptosis (Wang et al. 1996).
Furthermore, p53 can recognize several forms of damaged DNA including the
mismatched DNA (Lee et al. 1995) and the single-stranded DNA ends (Oberosler et al.
1993, Bakalkin et al. 1994). p53 may act as a sensor that binds to damaged DNA
regions and recruits the NER machinery by trapping TFIIH, a major component of the
repair complex, at sites where it is needed. This p53-TFIIH complex in turn may
facilitate the formation of a functional „repairosome„ (Wang and Harris, 1997).
p53’s function is frequently lost during the process of tumorigenesis and in the
spontaneous immortalization of primary cells. This indicates that loss of p53’s
function promotes genomic instability.
1.3.6 The role of p53 in tumorigenesis
The p53 gene plays a crucial role for cell cycle control, induction of apoptosis,
DNA repair, and genomic stability, all of which are central to the prevention of human
carcinogenesis. Inactivation of the wild-type p53 function is thought to be a common
event during the development of cancer. Several mechanisms of functional inactivation
of p53 such as mutation, inhibition, nuclear export, degradation through the MDM2
protein, or aberrant transcription are known.
Mutations which inactivate some or all of p53’s functions as a tumor
suppressor gene have been found in over 50% of all human tumors (Hollstein et al.
1994). Over 85% of these mutations are missense mutations that encode altered forms
of the protein with a prolonged half-life. Missense mutations are predominantly
located in the DNA-binding regions of the protein and therefore affect the DNA-
binding ability of the p53 protein (Cho et al. 1994). As a consequence, p53 can not
activate the target genes that regulate cell cycle arrest. p53 protein alterations due to
mutations therefore provide a selective advantage for clonal expansion of neoplastic
cells (Vogelstein 1994).
In addition to failure to elicit a tumor suppressor response, these mutant p53s
are also unable to activate expression of MDM2. As a result, these mutant p53 proteins
are unusually stable and accumulate to high levels in the tumor cells (Kubbutat and
Vousden, 1998). However, wildtype p53 may also be inactivated through amplification
of the mdm2 gene in some tumors, especially sarcomas, since the MDM2 protein
rapidly degrades and inhibits p53 by binding to the protein (Oliner et al. 1992,
Kubbutat et al. 1997, Haupt et al. 1997).
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The function of p53 may also be abolished through mechanisms that prevent its
entry into the nucleus, or promote nuclear exclusion, and keep it localized in the
cytoplasm, as has been described for some breast tumors and neuroblastomas (Moll et
al. 1995, Roth et al. 1998, Stommel et al. 1999).
Furthermore in a number of human tumors transcription of p53 has been shown
to be reduced or absent. This could result from cis-acting mutations in the regulatory
regions of the gene or hypermethylation of the promoter as has been shown for other
tumor suppressor genes (Counts and Goodman, 1995, Baylin, 1997).
More common than loss of expression, is elevated expression of p53 due to
mutation. The myc-oncogene may play an important role for high p53 expression. C-
myc has been found to be elevated as an early event in oncogenesis and is thought to
subsequently induce p53 expression, which then leads to cell cycle arrest. A cell
population with mutant p53 would not undergo growth suppression as expected but
would have a growth advantage under these conditions. Clonal selection of these cells
would therefore be favored (as reviewed by Reisman and Loging 1998).
Humans with germline mutations, who are heterozygotes for the wild-type
allele of p53, have a very high frequency of developing cancer (90-95%) at an early
age (Li-Fraumeni-Syndrom). The tissue distribution of these cancers is, however, not
random (sarcomas, breast, adrenal carinomas) and it is not clear what this means for
the p53 function (Li and Fraumeni, 1969).
1.3.7 Clinical implications
Ovarian cancer, like most other adult malignancies, is thought to result from
accumulation of mutations in multiple genes, which are important for normal function.
The p53 tumor suppressor gene is the most frequently mutated gene in human cancers
(Greenblatt and Harris, 1994) and plays a critical role in the regulation of cell cycle
and apoptosis. It has been found to be mutated in approximately 40-80% of epithelial
ovarian cancers (Mazars et al. 1991, Kihana et al. 1992, Milner et al. 1993, Kohler et
al. 1993b, Kupryjanczyk et al. 1993, Wertheim et al. 1994, Zheng et al. 1995, Kappes
et al. 1995, Casey et al. 1996, Righetti et al. 1996, Skilling et al. 1996, Schuyer et al.
1998). In a previous study of 105 ovarian cancer patients we found mutations in 57%
of the cases (Wen et al. 1999). It is thought that p53 protein alterations due to missense
mutations, nonsense or frameshift mutations, provide a selective advantage for clonal
expansion of neoplastic cells (Vogelstein, 1994).
Only few studies have analyzed the entire open reading frame of the gene
(Kihana et al. 1992, Kupryjanzcik et al. 1993, 1995, Casey et al. 1996, Skilling et al.
1996, Sood et al. 1997, Angelopoulou et al. 1998, Wen et al. 1999) and have found
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mutations in 50% - 79% of the cases. 5%-20% of these mutations were outside exon 5-
8 (Kupryjanzcik et al. 1993, Skilling et al. 1996, Casey et al. 1996, Wen et al. 1999).
Therefore a study which is limited to exons 5-8 will miss a substantial number of
mutations.
Though p53 protein expression has been studied extensively by immuno-
histochemistry in ovarian cancer. In those studies which used frozen ovarian
carcinoma specimens for immunohistochemical analysis of p53, the percentage of
cases with p53 overexpression was 32%-84% with an overall average of 51% (Marks
et al. 1991, Kihana et al. 1992, Eccles et al. 1992, Kohler et al. 1993a, Kiyokawa et al.
1994, Henriksen and Oberg 1994, Sheridan et al. 1994, Lee et al. 1995, Casey et al.
1996, Skilling et al. 1996, Buttitta et al. 1997, Geisler et al. 1997, Schuyer et al. 1998,
Wen et al. 1999).
The role of p53 alterations as a prognostic factor remains controversial. Several
studies have identified p53 overexpression as a prognostic factor (Bosari et al. 1993,
Henriksen et al. 1994, Hartmann et al. 1994, van der Zee et al. 1995, Klemi et al. 1995,
Levesque et al. 1995, Herod et al. 1996, Viale et al. 1997, Eltabakkah et al. 1997,
Geisler et al. 1997, Röhlke et al. 1997, Werness et al. 1999, Anttila et al. 1999), and
few studies as an independent prognostic factor of overall survival in multivariate
analysis (Klemi et al. 1995, Herod et al. 1996, Geisler et al. 1997, Röhlke et al. 1997,
Anttila et al. 1999). p53 mutations have been found to be associated with a
significantly shorter overall survival compared to the wildtype p53 sequence in only
one study (Wen et al. 1999).
1.3.8 p53 and efficacy of chemotherapeutic agents
Cell culture experiments have shown that the sensitivity of tumor cells to
various chemotherapeutic agents depends on the efficient induction of apoptosis
mediated by a functional p53 protein. Therefore loss of p53 can enhance resistance to
chemotherapy (Lowe et al. 1993, Vasey et al. 1996, Vikhanskaya et al. 1997). It is well
documented that drugs such as Adriamycin, Etoposide, Doxorubicin, Cisplatin, and
others induce DNA damage and p53-dependent apoptosis.
The wildtype p53-expressing A2780 human ovarian cancer cell line acquired
cross resistance to Cisplatin and Doxorubicin by transfection with a dominant negative
mutant p53 gene, while it retained sensitivity to Taxol (Vasey et al. 1996). In another
study Cisplatin caused strong induction of p53, WAF1, and Bax in the Cisplatin
sensitive A2780 cell line, while there was no such effect in a Cisplatin resistant cell
line A2780-DX3, which furthermore showed a significant proportion of potentially
inactive p53 protein located in the cytoplasm instead of the nucleus (Vikhanskaya et
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al. 1997).  Other studies suggest that Cisplatin-resistance in the 2780CP ovarian cancer
cell line is caused by a defect in the signal transduction pathway for p53 induction
following cisplatin-induced DNA damage (Siddik et al. 1998).
Further strong evidence for the importance of a functional p53 protein for the
efficacy of Cisplatin and Carboplatin is given by a database of the National Cancer
Institute on drug activity in cell lines which shows a strong correlation between p53
wildtype sequence respectively p53 function and efficacy of Cisplatin and Carboplatin
(Weinstein et al. 1997). In contrast to this, antimitotic tubulin-active agents such as
Taxol show a strong negative correlation between p53 wildtype as well as p53 function
and activity of the drug (Weinstein et al. 1997). Sensitivity to Taxol has been found
enhanced through the absence of functional p53 protein because of increased G2M
arrest and p53 independent apoptosis (Wahl et al. 1996, Vikhanskaya et al. 1998).
Since dysfunctional p53 can not mediate the apoptotic process, tumors with
p53 mutations or altered p53 protein may become resistant to platinum-based
chemotherapy (Lowe et al. 1994). This has been initially demonstrated in two clinical
studies which showed that patients with FIGO III/IV ovarian cancer had a poor
response to platinum-based chemotherapy if their tumors had p53 overexpression
(Buttitta et al. 1997) or p53 missense mutations (Righetti et al. 1996). In a further
study which analyzed 168 primary stage III-IV ovarian carcinomas, p53
overexpression was significantly correlated with resistance to a platinum based
chemotherapy (Ferrandina et al. 1999).
The hypothesis that ovarian cancer cells with functional p53 are more sensitive
to Cisplatin is further supported by the findings of gene therapy studies. Introduction
of wildtype p53 protein via adenovirus gene transfer into A2780/CP Cisplatinum
resistent cells significantly sensitized these cells to platinum cytotoxicity, indicating
that p53 was involved in resistance to cisplatin (Song et al. 1997). Similar results were
reported for p53-deleted SK-OV-3 ovarian cancer cells (Kanamori et al. 1998).
Since the efficacy of a platinum-based chemotherapy may depend in part on a
functional p53 gene, the introduction of a p53 wildtype sequence into ovarian cancer
cells via an adenovirus has become a major focus of research (see chapter 1.2.3).
Furthermore, molecular genetic analysis of ovarian tumors might in the future identify
those patients who are most likely to respond to a chemotherapy.
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1.4 The mdm2 (murine double minute 2) gene
1.4.1 Molecular structure of the mdm2 gene
The mdm2 (murine double minute) gene was initially described as a proto-
oncogene and is amplified and overexpressed in human soft tissue sarcomas and glio-
mas. It was originally identified in a spontaneously transformed Balb/cT3 fibroblast
murine cell line (Cahilly-Snyder et al. 1987). In these cells mdm2 is localized on
double minute chromosomes and is amplified approximately 50-fold (Fakharzadeh et
al. 1991).
In humans, the gene is located on chromosome 12q13-14 (Oliner et al. 1992).
The full length mRNA encodes for a 90 kD protein of 491 amino acids. The mouse
mdm2 gene contains 12 exons, of which exon 3-12 comprise the coding region
(Montes de Oca Luna et al. 1996). Comparison of the gene in different species reveals
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Fig. 5: Structure and functional regions of the MDM2 protein. Above functional
domains with corresponding amino acid residues are shown (see Freedman et al.
1999). DNA-PK sites comprise aa 388/389, 395/396 and 407/408. The p53 binding
domain and conserved region I are almost identical. Since the human mdm2 exon
boundaries are not fully known yet, mouse exons 1-12 are shown with the first codon
of each exon indicated. Exon 1 and 2 are noncoding (Montes de Oca Luna et al. 1996).
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Region I contains 90 aa of the N-terminus and corresponds closely to the p53
binding site (aa 19-102) (Chen et al. 1993). In a crystal structure analysis of the 109-
residue amino-terminal domain of MDM2 bound to a 15-residue transactivation
domain peptide of p53, it was shown that MDM2 has a deep hydrophobic cleft, on
which the p53 peptide binds as an amphiphatic α helix (Kussie et al. 1996).
The region II of MDM2 protein contains a central acidic domain, which was
shown to interact with the ribosomal L5 protein and its associated 5S rRNA (Marechal
et al. 1994, Elenbaas et al. 1996). This suggests a possible function in ribosome
biosynthesis or in translational regulation.
Between region I and II, a putative nuclear localization signal has been
suggested to be located at amino acid 181 (Fakharzadeh et al. 1991). Recently, a
conserved nuclear export signal (NES) sequence has been localized to amino-acid
residues 191-199 and mediates the ability of MDM2 to shuttle between the nucleus
and the cytoplasm and back (Roth et al. 1998). Region III contains a central zinc-
fingerlike sequence of unknown function.
Region IV, which is highly conserved between species, contains a c-terminal
RING finger domain, which has been shown to specifically bind to RNA. This
suggests a role for MDM2 in translational regulation in a cell (Elenbaas et al. 1996).
Sequence analysis defined the RING finger domain as the most conserved region of
MDM2. Recently it was shown that the RING finger domain is essential for MDM2
targeted degradation of p53 (Kubbutat et al. 1999). The C-terminal region may also
play an important role for the suppression of MDM2 function since it has recently
been shown that ARF binds to MDM2 at the C-terminus and degrades the MDM2
protein. Thereby, MDM2’s inhibition of p53 is indirectly neutralized (Zhang et al.
1998, Pomerantz et al. 1998).
RING finger domains have been hypothesized to participate in protein-protein
interactions or DNA-binding, but for MDM2 it has been shown that the RING finger
interacts specifically with RNA in vitro (Elenbaas et al. 1996). This means that the
RNA-binding activity of MDM2 is likely to be an important function of MDM2.
Recently the RING finger of MDM2 was shown to play a role in cell cycle regulation
which was independent of p53 degradation (Argentini et al. 2000).
1.4.2 mdm2 expression in tumors
The mdm2 gene has been found amplified and overexpressed mainly in tumor
cells of non-epithelial origin, especially in those derived from the mesenchyme. mdm2
amplification has been found in approximately 20% of soft tissue tumors including
osteosarcomas, liposarcomas, and malignant fibrous histiocytomas, and furthermore, in
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about 9% of gliomas, 12% of testicular germ cell tumors (as reviewed by Momand and
Zambetti 1997). In carcinomas, except for esophageal tumors, amplification is rare (as
reviewed by Momand and Zambetti 1997) and has not been found in any case of
ovarian cancer (Foulkes et al. 1995). In primary sarcomas and cell lines that were
characterized in more detail, amplification of the mdm2 gene correlated with
overexpression of the MDM2 protein (Oliner et al. 1992).
Overexpression has been found in some tumors independently of amplification.
In human leukemia samples, mdm2 mRNA was dramatically upregulated while a
normal DNA copy number was maintained (Momand and Zambetti, 1997). MDM2
protein overexpression has been found despite normal levels of mdm2 mRNA, most
likely due to enhanced translation efficiency (Landers et al. 1994).
Evidence of different sizes of mRNA transcripts in tumors was noted when
mdm2 was initially cloned (Oliner et al. 1992) and, later, altered mRNAs resulting
from alternative splicing were described in bladder and ovarian carcinomas (Sigalas et
al. 1996). These alternatively spliced mdm2 mRNAs were correlated with advanced
stage and poor differentiation in ovarian carcinomas and transfection of NIH 3T3 cells
with the splice variants showed transforming ability of the RNA transcripts (Sigalas et
al. 1996). Smaller protein variants of sizes between 78 kD and 12kD have been noted
in non-small cell lung cancer, and are also thought to be derived by differential
splicing (Maxwell, 1994).
The finding of these alterations in human tumors indicates that mdm2 acts as a
proto-oncogene that promotes the tumorigenicity of a cell through inactivation of the
p53 tumor suppression function and possibly by other, as yet unidentified,
mechanisms.
1.4.3 The MDM2/p53 autoregulatory feedback-loop
mdm2 has several characteristics of a cellular proto-oncogene and the
mechanism by which it promotes the tumorigenicity of a cell became clearer when
MDM2 was discovered to bind to the p53 protein and inhibit p53 mediated
transactivation (Momand et al. 1992). MDM2 is a potent inhibitor of p53. It binds to
the transcriptional activation domain of p53 and blocks its ability to regulate target
genes (Picksley et al. 1994, Chen J. et al. 1996) and to exert antiproliferative effects
(Chen, C.-Y. et al. 1994, Haupt and Oren, 1996, Chen, J. et al. 1996). Mdm2
expression is upregulated by p53 in an autoregulatory feedback loop (Gottlieb and
Oren, 1998).
Several mechanisms of MDM2/p53 interaction are presently known: 1)
counteracting the induction of cell cycle inhibitory genes 2) a protective role of
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MDM2 against apoptosis 3) nuclear export and 4) rapid degradation of the p53 protein
by MDM2 (Fig. 6).
1) MDM2 was shown to inhibit p53-transcriptional activation by „concealing„
the acidic activation domain of p53 from the transcriptional machinery (Oliner et al.
1993). Other experiments suggested that p53 protein, if it is bound in a complex with
MDM2, no longer binds to p53 target DNA (Zauberman et al. 1993). The binding site
of MDM2 to p53 has been located to amino-acid 18-23 at the N-terminus of the p53
protein by mapping studies (Chen et al. 1993). Only the amino-terminal end of MDM2
is necessary to bind and inhibit p53, suggesting that the full-length protein may carry


































Fig. 6: Autoregulatory feedback loop of the p53 tumor suppressor gene and the
mdm2 gene. p53 at basal and at increased levels activates the mdm2 gene. The
MDM2 protein binds to p53, inhibits its DNA binding ability, and promotes nuclear
export and protein degradation.
the mdm2 gene (Chen et al. 1993). MDM2 residues G58, D68, V75 and C77 have been
shown to be critical for MDM2 interaction with p53. Mutation of these residues
prevents MDM2 interaction with p53 in vitro and MDM2’s regulation of p53’s
transcriptional activity in vivo (Freedman et al. 1997).
Recent reports also indicate that MDM2 may have a second mechanism to
inhibit p53-dependent transcriptional activation at a promoter. In these experiments,
deletion mutants of MDM2 defective in p53 binding are able to repress both p53-
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activated and basal transcription when brought to a promoter by fusion to a DNA-
binding domain (Thut et al. 1997).
MDM2 is upregulated in response to p53 activation and has been shown to
inhibit p53-dependent G1 arrest in response to irradiation (Chen et al. 1994, Chen J. et
al. 1996). Control of p53 activity by MDM2 also plays an important role during
embryonic development. The expression of the xenopus laevis homolog xdm2 of
mdm2 increases during early embryogenesis from oocyte stage I/II to reach its
maximum in oocyte stage V/VI in unfertilized eggs and then becomes undetectable
(Marechal et al. 1997). Earlier studies had already demonstrated that the mdm2-null
genotype leads to embryonic lethality while mice deficient for both mdm2 and p53
develop normally and are viable (Montes de Oca Luna et al. 1996, Jones et al. 1995).
These results strongly suggest a primary developmental role for MDM2 in negative
regulation of p53 function.
2) The role of MDM2 in protecting against apoptosis is less clear, but several
studies have shown evidence for this function of MDM2. p53 dependent apoptosis
induced by c-myc overexpression was inhibited by MDM2 (Chen et al. 1996) and
protection from apoptosis required formation of a p53- MDM2 complex in human
H1299 cells (Haupt et al. 1997). Rb can overcome the antiapoptotic effect of MDM2
on p53-induced apoptosis by preventing MDM2 from targeting p53 for degradation.
Rb-MDM2 interaction, though, does not prevent inhibition of p53-mediated
transcription (Hsieh et al. 1999). Recently, experiments with fibroblasts from
p53/mdm2 null mice, which were transfected with a retroviral vector carrying
temperature-sensitive p53, have shown that loss of mdm2 can induce the p53-
dependent aopoptotic pathway in vivo (de Rozieres et al. 2000).
3) MDM2 has been shown to contain a nuclear export signal (NES) and to be
able to shuttle across the nuclear membrane in both directions (Fig. 6) (Roth et al.
1998). The findings suggest that MDM2 binds to p53 in the nucleus and transports it to
the cytoplasm for degradation (Roth et al. 1998, Tao and Levine, 1999). Cytoplasmic
distribution of p53 is thought to result from efficient export of nuclear p53 in
combination with MDM2-mediated degradation (Lu et al. 2000).
4) MDM2 was shown to promote rapid degradation of the p53 protein (Haupt
et al. 1997, Kubbutat et al. 1997, Kubbutat and Vousden, 1998). MDM2
downregulates the amount of p53 protein but does not reduce p53 mRNA levels
(Haupt et al. 1997, Kubbutat et al. 1997). These results indicate that p53 levels are
regulated by MDM2 through a post-transcriptional mechanism. Once shuttled out of
the nucleus, p53 is thought to be transported to a cytoplasmic proteasome for ubiquitin
mediated degradation (Roth et al. 1998, Tao and Levine, 1999). Amino-acids 92-112
of p53 have been identified to function as a degradation signal (Gu et al. 2000).
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Degradation of p53 by MDM2 depends directly on the ability of MDM2 to shuttle
from the nucleus to the cytoplasm (Tao and Levine, 1999). Expression of p19ARF was
shown to block the nucleo-cytoplasmic shuttling of MDM2 and could therefore





















Fig. 7: Hypothetic model about the effects of impaired MDM2 function on p53
protein accumulation in the cell. Cellular stresses cause p53 activation, which is
downregulated by functional MDM2 in an autoregulatory feedback loop. In case of
nonfunctional MDM2, wildtype p53 accumulates in the nucleus.
The MDM2/p53 autoregulatory feedback loop, as described above, can be
abolished by p53 as well as MDM2 alterations (Fig. 7). Firstly, p53 mutations have
been shown to cause accumulation of p53 protein which is frequently seen in tumors
due to a lack of p53-mediated MDM2 induction (Haupt et al. 1997, Kubbutat et al.
1997). Secondly, a dysfunctional MDM2, as it is seen in some forms of alternative
splicing, can cause p53 accumulation due to the loss of p53 binding ability (Kubbutat
et al. 1997, Kraus et al. 1999).
Physiologically, the MDM2 protein itself is degraded by ARF, which means
that p53 cell cycle regulatory functions can be restored by ARF/ MDM2 binding
(Zhang et al. 1998, Pomerantz et al. 1998). Despite other, as yet not fully understood,
functions of MDM2 the MDM2/p53 interaction seems to play a crucial role in cell
cycle regulation. MDM2 ensures effective reduction and termination of the p53 signal
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after DNA damage induced p53 activation to reverse cell cycle arrest and allow the re-
entry of the cell into the cell cycle.
1.4.4 Clinical implications of mdm2 alterations
mdm2 amplification has been frequently noted in tumors of mesenchymal
origin, and overexpression, which is present in approximately 20% of soft tissue
sarcomas, has been found associated with poor prognosis (Cordon-Cardo et al. 1994).
mdm2 alternative mRNA splicing has been found to be associated with poor
differentiation and advanced stage in ovarian carcinomas (Sigalas et al. 1996). Since
MDM2 controls p53 function in an autoregulatory feedback loop, it plays a major role
in tumorigenesis.
It was hypothesized that tumors expressing abnormally high levels of mdm2
could be treated by means of peptides derived from the p53 interaction domain. By
binding to MDM2 and preventing its interaction with p53, such peptides could restore
p53 function to the tumor cells, presumably preventing further growth (Oliner et al.
1993). Microinjection of a monoclonal antibody against the p53-binding domain of
MDM2, 3G5, (Chen et al. 1993) blocks the p53/MDM2 interaction and leads to p53-
dependent activation of reporter genes in cell lines that have wild-type p53 (as
reviewed by Freedman et al. 1999).
Since MDM2 is assumed to counteract the induction of apoptosis by p53, it
may also play a role for the response of tumors to DNA-damaging chemotherapeutic
agents. Overexpression of mdm2 was found to decrease the susceptibility of human
glioblastoma cells to apoptosis induced by Cisplatin, while expression of antisense
mdm2 increased their susceptibility (Kondo et al. 1995). Lowering the levels of mdm2
in cell lines that overexpress p53 also appears to activate the wild-type p53 protein
present in such cells. By using antisense oligonucleotides to the mdm2 message in a
choriocarcinoma cell line which has wild-type p53 and mdm2 gene amplification, p53
reporter genes can be activated and the cells induced to undergo apoptosis (Chen et al.
1998). Following intraperitoneal administration of anti-mdm2 antisense oligonucleo-
tides, in vivo antitumor activity was observed in nude mice bearing osteosarcoma and
choriocarcinoma xenografts (Wang et al. 1999). An mdm2 antisense phosphorothioate
oligodeoxynucleotide was identified that effectively inhibits mdm2 expression in
tumor cells containing mdm2 gene amplification. Antisense inhibition of mdm2 was
asso-ciated with a decrease in MDM2/p53 complex formation, increase in p53-
inducible gene expression, increase in p53 transcriptional activity and apoptosis (Chen
et al. 1998). Recently a novel mechanism of MDM2 degradation by the protein ARF
has been identified, which can neutralize the inhibition of p53 by MDM2 and restore
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the p53 function for cell cycle control and apoptosis (Zhang et al. 1998, Pomerantz et
al. 1998).
Further understanding of the functions and regulatory mechanisms in which
mdm2 is involved will give important new insights in tumorigenesis and resistance to
chemotherapy. Disruption of the MDM2/p53 wildtype interaction and perhaps Rb,
E2F1, and DP1 might be important goals for cancer therapy.
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2. OBJECTIVES
The p53 gene is a tumor suppressor gene which has been named the "guardian
of the genome„ (Lane 1992). It is activated in response to cellular stresses and DNA
damage and regulates cell cycle arrest and apoptosis. It has been found to be mutated
in more than 50% of human carcinomas and the loss of its function through mutation is
thought to be one of the major steps in carcinogenesis (Hollstein et al. 1994). The
mdm2 (murine double minute 2) gene was initially described as a proto-oncogene and
is amplified and overexpressed in human soft tissue sarcomas and gliomas (Oliner et
al. 1992). Most importantly though, MDM2 was found to be activated by p53 and
subsequently inhibit p53 in an autoregulatory feedback-loop and promote its nuclear
export and rapid degradation (Momand et al. 1992, Haupt et al. 1997, Kubbutat et al.
1997, Roth et al. 1998). Thereby it allows the cell to re-enter the cell cycle after repair
of DNA damage.
In this investigation we analyzed frozen tumor tissue of a series of 178 ovarian
carcinoma patients with long term follow-up data for alterations of the p53 and mdm2
gene and their impact on response to chemotherapy and survival. p53 mutations and
polymorphisms were characterized by screening the entire coding region of the gene
(exon 2-11) with PCR/SSCP (Single Strand Conformation Polymorphism) and DNA
sequence analysis. Overexpression of p53 was analyzed by immunohistochemistry in
frozen tissue.
Since MDM2 promotes the rapid degradation of p53 protein, alterations of
MDM2 are expected to cause p53 stabilization and accumulation, as it is seen in a
number of ovarian carcinomas with wildtype p53 sequence. We therefore analyzed
mdm2 for amplification and overexpression by Southern and Northern hybridization
and for RNA alternative splicing by RT-PCR and cDNA sequencing. The frequency
and the type of alternative mdm2 RNA splice variants were also analyzed in ovarian
tumors of borderline malignancy, benign cystadenomas, and normal ovarian tissue to
identify patterns of splicing which may be involved in carcinogenesis.
Results of p53 and mdm2 alterations were statistically evaluated for
correlations to clinical and histopathological parameters, response to platinum-based
chemotherapy, time to relapse or progression of disease, and overall survival.
Furthermore p53 mutation and overexpression were analyzed in correlation to mdm2
alterations to clarify whether loss of the p53 binding domain in mdm2 splice variants
would cause stabilization and accumulation of p53 protein in the absence of mutations.
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3. PATIENTS, MATERIALS, AND METHODS
3.1 Patients and clinical data
3.1.1 Asservation and storage of tissue
During exploratory laparotomy both ovaries were examined for tumor involvement and
salpingo-oophorectomy was performed in a typical manner. The ovary which was suspected of
being tumorous or, if both were involved, the ovary which had the greater tumor mass was sent
to the Pathology Department for frozen section diagnosis, where a tissue block of at least 1
cm³ was excised and immediately snap frozen in liquid nitrogen. The tissue was stored in
plastic containers (Althor Products, Bethel, Connecticut, USA) at -80° C. Ninety-eight cases
were collected at the Department of Gynecology of the Charité, Campus Virchow-Klinikum,
Humboldt-University in Berlin. Eighty cases were available from the USC frozen tissue
resource of the Principal Investigator Michael F. Press MD, PhD and had mainly been
collected at the M.D. Anderson Cancer Center in Houston, Texas, USA.
3.1.2 Study population and surgical therapy
The study population consisted of a total of 178 patients with invasive epithelial ovarian
carcinoma who had undergone surgery between 1972 and 1995 at the Department of
Gynecology of the Charité, Campus Virchow-Klinikum, Humboldt-University in Berlin
(n=98) or at the M.D. Anderson Cancer Center in Houston, Texas, USA (n=80). The clinical
and histopathological characteristics of the patients are demonstrated in Table 12. Patient age
ranged from 23 to 84 years with a median age of 57 years. The racial-ethnic groups
represented were: White 92%, African-American 5%, Hispanic 3% and Asian 1%.
Each patient underwent exploratory laparotomy with bilateral salpingo-oophorectomy,
hysterectomy, and infracolic omentectomy as part of her treatment for ovarian cancer. In 61 of
the patients pelvic lymphadenectomy and in 29 patients additional paraaortic
lymphadenectomy was performed as part of the primary surgery.
3.1.3 FIGO-stage, histology and grade of differentiation
All patients were staged according to the 1986 guidelines of the International Federation of
Gynecologists and Obstetricians (FIGO) (Pettersson 1991). For purposes of statistical analysis,
patients who had undergone surgery before 1986 were restaged according to the 1986
guidelines. At the time of diagnosis, 21% of the patients were diagnosed as FIGO stage I, 5%
as stage II, 61% as stage III and 13% as stage IV (Table 12). Complete surgical resection of the
tumor was possible in 71 cases (46%) and optimal debulking with a residual tumor mass of
less than 2 cm was achieved in 48 cases (31%), but a residual tumor mass of more than 2 cm
was left in situ in 34 cases (22%).
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All tumors were classified and graded according to the criteria defined by the World Health
Organization. The 178 epithelial ovarian carcinomas studied for p53 alterations included 111
(62%) serous, 30 (17%) endometrioid, 8 (5%) mucinous, 6 (3%) clear cell, 1 (0.6%) malignant
Brenner tumor, 10 (6%) undifferentiated, 10 (6%) mixed epithelial and 2 (1%) unclassified
epithelial tumor.
The tumors were graded as well differentiated in 28 (16%) cases, moderately differentiated in
52 (29%) and poorly differentiated in 98 (55%) cases. The evaluation of differentiation was
based on the degree of histologic differentiation with the formation of papillary, tubular,
glandular or cystic structures versus solid structures.
One hundred and three cases included in this study had been previously characterized for DNA
ploidy and S-phase fraction with a Cell Analysis System Image Analyzer (CAS 200, Becton-
Dickinson). Fifty-four percent of the ovarian carcinomas were found to be diploid, 38%
aneuploid and 8% tetraploid. The S-phase-fraction was low (< 5%) in 27%, intermediate (5% -
14.5%) in 47% and high (≥ 14.5) in 26% of the patients (Reles et al. 1998).
3.1.4 Adjuvant  chemotherapy
Adjuvant chemotherapy was given to 115 (76%) of the patients with tumor stages Ib-IV.
Among these, 54 (47%) of the patients were treated with Cisplatinum / Cyclophosphamide, 20
patients (17%) with Carboplatinum / Cyclophosphamide and 41 (36%) of the patients with
other chemotherapy-regimens. 36 patients (24%) were not treated with adjuvant chemotherapy
because of early stage disease, old age, or because they refused treatment. In 27 patients,
information about chemotherapy treatment was insufficient (Table 12).
The response to chemotherapy was defined 1) as platinum refractory, if there was no change or
progressive disease during therapy, 2) as platinum resistant, if the patient responded initially
but relapsed or progressed within 6 months after the last cycle of chemotherapy and 3) as
platinum sensitive, if no relapse or progression was noted within six months after the last cycle
of chemotherapy.
3.1.5 Clinical follow-up information
Clinical follow-up and overall survival information was available for all 178 patients and
information about progression of the disease was available for 138 (78%) patients. The
majority of patients were seen at the outpatient clinics of the Charité, Campus Virchow-
Klinikum, Berlin and the MD Anderson Cancer Center, Houston, respectively for follow-up.
Additional information was available from physicians in private practice. Follow-up ranged
from 1 month to 12 years with a median follow-up of 31 months in the total cohort and 52
months for the survivors.
During the time of follow-up 117 (66%) deaths occured. 104 patients died from ovarian
cancer, 6 patients by intercurrent disease or accident, and one patient died from a complication
of surgery. Sixty (34%) patients were alive and in 7 cases, no information about the cause of
death was available. At the time of last contact, 48 patients (27%) showed no evidence of
disease. 76 patients (43%) had been documented to have recurrent disease, three patients had
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known residual disease with steady state, 11 patients (6%) had primarily progressive disease
and in 29 (16%) patients, who died from the tumor, the date of relapse was not available from
the patient charts. In 11 patients, the disease status was not sufficiently documented.
3.2 Materials
3.2.1 Plastic ware, chemicals, and consumables
If not otherwise specified, sterile disposable plastic ware for molecular biology experiments
was purchased from CLP (Continental Lab Products) and Falcon Labware (Oxnard, CA,
USA). PCR tubes were purchased from CLP (Continental Lab Products). Chemicals were
obtained from Sigma (St. Louis, MO, USA) and Amersham Life Science(Arlington Heights, Il,
USA). Restriction enzymes were ordered from Gibco BRL (Gaitherburg, MD, USA) or NEB
(Beverly, CA, USA). Length standards for DNA and RNA were purchased from Gibco BRL
(Gaitherburg, MD, USA). Molecular biology products were obtained from Pharmacia
(Uppsala, Sweden), Stratagene (La Jolla, CA, USA) or NEB (Beverly, CA, USA). Tissue
culture plastic ware was purchased from Falcon Labware (Oxnard, CA, USA) and additives for
tissue culture and media from Gibco BRL (Gaitherburg, MD, USA) or Difco (Detroit, MI,
USA).
3.2.2 Standard buffers and solutions
TE 10 mM Tris/Cl, pH 7.4
1 mM EDTA
TAE 40 mM Tris / acetate, pH 8,0
1mM EDTA
TBE 89 mM Tris
89 mM boric acid
2 mM EDTA
pH 8.3






GTB 20x 250 ml ready mix Tris base 54g
Taurine 18 g
Na2-EDTA 1g
MOPS 200 mM MOPS
50 mM Na Acetate 3.H2O
10 mM Na2-EDTA
SSC 150 mM NaCl
15 mM Na-citrate
DEPC-H2O 0.1% v/v DEPC in H2O
(Diethyl-pyrocarbonat)
Stop Solution for SSCP 95% v/v Formamide
20 mM EDTA
0.25% w/v Bromophenol Blue
0.25% w/v Xylene Cyanol
Dye for RNA/DNA 1 mM EDTA, pH 8.0
gel electrophoresis 50% v/v Glycerol
0.25% w/v Bromophenol blue
0.25% w/v Xylene cyanole
Loading buffer RNA gels (1ml) 10x MOPS 100 µl
Formamide 500 µl
Formaldehyde 174 µl
10 x dye 100 µl
EtBr (10mg/ml) 10 µl
0.1 M sodium acetate buffer pH 4.0 0.2 M acetic acid 82 ml
0.2 M sodium acetate 18 ml
deionized H2O 100 ml
200 ml
Ethyl Green solution Ethyl Green 0.5g
0.1 M sodium acetate buffer 100 ml
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3.2.3 Standard gel electrophoresis components
1.2% Agarose Gel (100 ml) 0.5x TBE 100 ml
Agarose 1.2g
EtBr (10mg/ml) 2 µl
0.5 x MDE Gel for SSCP (100 ml) MDE Gel Solution 25 ml
10 x TBE 6 ml
Glycerol 10% 5 ml
deionized H2O 64 ml
TEMED 40 µl
10 % APS 400 µl
6% Acrylamide Gel for Sequencing SequagelTM Concentrate 24 ml
(100 ml) SequagelTM Diluent 66 ml
10 x GTB buffer 10 ml
TEMED 40 µl
10% APS 800 µl
1% Agarose gel for Northern Agarose 5g
(500 ml) DEPC H2O 365 ml
10 x MOPS 50 ml
Formaldehyde 85 ml
3.2.4 Chemicals
Table 4: List of all chemicals used in the experiments
Chemical Company Catalog #
Acetic Acid Sigma A 5640
Acetone Sigma A 4206
Acrylamide Sigma A 8887
Ammonium Persulfate Sigma A-3678
Ampicillin Sigma A 9393
Aprotinin Sigma A 1153
Bisacrylamide Sigma M 7256
Bromophenol Blue Sigma B 0126
Chloroform Sigma C 5312
DAB Abbott (ER Kit) 2A08-18
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Deoxycholate Sigma D 5670
dNTP (Ultrapure dNTP Set) Pharmacia Biotech 27-2035-01
dNTP mix 10mM Gibco 18427
DNA ladder 1Kb Gibco 15615-016
DTT (Dithiotreitol) Gibco 15508-013
ECL Western blotting detection reagent Amersham RPN 2109
E. coli pulser cuvettes 0.1 cm BIO-RAD 165-2089
EDTA Sigma E 7889






Ethyl Green Sigma M 8884
Exonuclease I Amersham Life Sciences US 72050
Fetal calf serum Omega FB 01
Gene Clean Kit Bio 101 1001-600
L-Glutamine (cell culture) Gibco 21051-016
Glycerol Amersham Life Sciences US 16374
Glycine Sigma G 7403
GTB Glycerol Tolerant Buffer Amersham Life Sciences US 71949
Hepes Gibco 11344-033
Hybridization membrane Hybond ECL Amersham Life Sciences RPN 68D
Hybridization membrane Hybond XL Amersham Life Sciences RPN 82S
Isopropanol Sigma 405-7
Kanamycin Sigma K 4000
Kcl (Potassium Chloride) Sigma P 9333
Kodak X-OMAT AR Eastman Kodak Company 1651454
Kodak Biomax MS film Eastman Kodak Company 1435726
Kodak Biomax MR film Eastman Kodak Company 8715187
Kodak Biomax MR2 film Eastman Kodak Company IB8952855
LB Agar tablets Sigma L 7025
LB Broth Sigma L 3022
Leupeptin Sigma L 2023
LipofectamineTM Reagent Gibco BRL 18324-020
MDETM Mutation Detection Gel Solution AT Biochem 1-500-00
MegaprimeTM DNA labelling system Amersham Life Science RPN1604/5/6/7
Methanol Sigma M 1775
MicroSpin Columns S-400 HR Pharmacia 27-5140-01
Mineral oil (PCR) Sigma M 8662
M-MLV Reverse Transcriptase Gibco BRL 28025-013
NaCl (Sodium Chloride) Sigma S 7653
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NaF (Sodium Fluoride) Sigma S 7920
Nonidet P40 (Octylphenoxy Polyethoxy Ethanol)
(Igepal CA 630)
Sigma I 3021
oligo (dT)15 primer Promega C 1101
pcDNA3.1 Expression vector Invitrogen V 790-20
Penicillin/Streptomycin Gibco 043-05140
Pepstatin A Sigma P 5318
Permount Fisher SP15-500
Phenol/chloroform/isoamyl alcohol (25:24:1) Boehringer Mannheim 101 001
Plasmid Maxi Protocol kit Qiagen 12162
PMSF (PhenylmethylsulfonylFluoride) Sigma P 7626
Protein G sepharose beads Pharmacia 17-0618-01
Proteinase K Sigma P 6556
Pwo DNA Polymerase Boehringer Mannheim 1644947
Qiagen Plasmid Midi Protocol Kit Qiagen 12143
Qiagen Plasmid Purification Kit (Mini-Prep) Qiagen 12123
Qiaquick Gel Extraction Kit Qiagen 28704
Qiaquick PCR Purification Kit Qiagen 28104
Quick SpinTM Columns Boehringer Mannheim 1273 922
Rapid-hyb buffer Amersham Life Science RPN 1635
Restriction enzyme
AscI NEB 558S
Bam HI NEB 136S
BglI NEB 143S




Sal I Gibco 15217-011
RNAguard Pharmacia 27-0816-01
RNA ladder 0.24-9.5 Kb Gibco 15620-016
RPMI medium 1640 Gibco 21870-092
Salmon sperm DNA Gibco 15632-011
SDS (Sodium Dodecyl Sulfate) Pharmacia US75832
SDS-PAGE Standards, broad range, prestained BIO-RAD 161-0318
Sequagel TM  Sequencing System, Concentrate National Diagnostics EC 830
Sequagel TM  Sequencing System, Diluent National Diagnostics EC 840
Shrimp Alkaline Phosphatase Amersham Life Sciences US 70173
Sodiumacetate (NaOAc) Sigma S 7670
SEA Spray CLP 5455
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TA Cloning kit (INVαF’ One Shot Kit) Invitrogen K2000-01
Taq DNA Polymerase 500 units Promega M 1865
TEMED (N,N,N,N’-Tetramethyl-Ethylendiamine) Sigma T 8133
T4 DNA Ligase 500 units Boehringer Mannheim 481220
Tris base Sigma T 6791
Trizol Reagent Gibco 15596-026
Tween-20 Sigma P 7949
Whatman 3 MM Chromatography paper Fisher 057163W
X-Gal Gibco 15520-034
Xylene cyanole Fisher X3P-IGAL
3.2.5 Radio-chemicals
[α-32P]dCTP (10 mCi/ml - 3000 Ci/mmol) Amersham # AA 0005
[α-33P]dATP (10 mCi/mmol - 2000 Ci/mmol) Dupont # NEG/613 H
[α-33P]dCTP (10 mCi/mmol - 2000 Ci/mmol) Dupont # NEG/612 H
[α-33P]ddATP (450 µCi/ml - 1500 Ci/mmol) Amersham Kit # 188403
[α-33P]ddATP (450 µCi/ml - 1500 Ci/mmol) Amersham Kit # 188403
[α-33P]ddATP (450 µCi/ml - 1500 Ci/mmol) Amersham Kit # 188403
[α-33P]ddATP (450 µCi/ml - 1500 Ci/mmol) Amersham Kit # 188403
3.2.6 Standard kits
The Qiaquick PCR Purification Kit (Qiagen, Hilden, Germany) was used for purification of
PCR products for cloning and the Qiaquick Gel Extraction Kit (Qiagen, Hilden, Germany) and
the Geneclean kit (BIO 101) were used for extraction of DNA from agarose gels. DNA
sequencing was performed with the Thermo Sequenase radiolabeled terminator cycle
sequencing kit (Amersham Life Science). Purification of plasmid DNA was performed with
the Qiagen Plasmid Purification Kit (Qiagen, Hilden, Germany) for mini- and midi-preps. The
TA cloning kit (Invitrogen, INVαF’One Shot Kit) was used for cloning cDNA into a TA
vector. For detection of proteins in Western blotting we used the ECL Kit (Amersham).
3.2.7 Monoclonal and polyclonal antibodies
Monoclonal Antibodies
Clone origin Company Catalog #
DO7 mouse anti-human p53 protein DAKO Inc. M7001
3F10 rat anti human influenza virus HA Boehringer Mannheim 1867423
9E10 mouse IgG1 anti human c-myc Boehringer Mannheim 1667149
12CA5 mouse IgG1 anti HA Boehringer Mannheim 15833816
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Polyclonal Antibodies
normal mouse IgG Zymed Laboratories 08-6599
rabbit anti-mouse IgG Zymed Laboratories 61-6500
mouse peroxidase anti-peroxidase antibody Sternberger Meyer 405
goat anti-mouse IgG-HRPO BIO-RAD 172-1011
rabbit anti-rat IgG-HRPO DAKO P0162
3.2.8 Laboratory equipment and other materials
For DNA and RNA extraction a tissue homogenizer (VWR) was used and centrifugation steps
were carried out in an Eppendorf 5415 table centrifuge. The optical density of DNA and RNA
were measured with a Beckman DU-600 spectrophotometer. PCR reactions were performed in
either a Perkin Elmer Cetus DNA Thermal Cycler 480 or an MJ Research PC 100/96V
Thermal Cycler.
For SSCP and sequencing, gel electrophoresis was carried out in a 38x50 cm Sequi-Gen GT
Sequencing Cell (Biorad), using a Power Pac 3000 Power Supply (Biorad). For sequencing a
Vinyl Sharkstooth Comb of 0.4 mm thickness and 30 cm length with 97 wells was used to
separate lanes. Gels were dried in a Savant gel drier (GDS 100 - SGD 2000 - GP 110).
Tissue sections for immunohistochemistry were cut with a Tissue Tek II Cryostat, mounted on
Fisher slides and encircled with a PAP pen (Kiyota International Inc.). Staining results were
evaluated with an Olympus BH2 microscope.
For Southern and Northern hybridization radioactivity of the probe was measured in a
Scintillation Counter Tri-Carb 2100TR (Packard Instruments) and hybridization was carried
out in a Micro Hybridization Incubator Model 2000 (Robbins Scientific).
For DNA cloning into the pcDNA3 expression vector a Biorad E. coli pulser apparatus 120 V
was used for transformation of bacteria. Western blotting of expressed proteins was carried out
with a Transblot Electrophoretic Transfer Cell (BIO-RAD Laboratories, Hercules, CA, USA).
3.3 Methods
3.3.1 Immunohistochemistry
3.3.2.1 Sections of tissues and control cell lines
Frozen tissue samples were embedded in OCT compound, sectioned at 4 µm in a TissueTek II
cryostat, thaw-mounted on glass slides and fixed immediately in acetone for 10 minutes. The
initial tissue section, stained with hematoxylin and eosin, was used to confirm that an ovarian
tumor of the appropriate histopathologic type was present in the frozen specimen. Subsequent
tissue sections were immunostained for p53 or used as a negative control section.
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Frozen cell pellets of human breast cancer cell lines known to have mutant p53 (SK-BR-3 and
T47D, American Type Culture Collection) were used as positive control specimens for the
immunohistochemistry. After fixation in acetone, sections were transferred to PBS buffer and
subsequently, endogenous peroxidase was bleached off by incubation with 0.5% H2O2 in PBS
for 15 minutes.
3.3.1.2 Incubation with primary and secondary antibodies
After rinsing in PBS for 2 x 5 minutes, unspecific antigen activity was blocked by incubation
with 10% normal rabbit serum for 20 minutes. Tissue sections were encircled with a PAP pen.
p53 immunostaining was performed by successive incubation in a primary mouse monoclonal
p53 antibody (DO-7, 0.95 microgm/ml [1:100 dilution], DAKO Corp.) for 1 hour and after
rinsing in PBS a bridging secondary rabbit antimouse IgG antibody (Zymed Laboratories) for
30 minutes.
A negative control was prepared for each unknown tissue by substituting normal mouse IgG
(2.5 microg/ml [1:1000 dilution], Zymed Laboratories, Inc. Cat# 08-6599) for the primary p53
antibody.
3.3.1.3 Peroxidase-antiperoxidase reaction
After rinsing in PBS, the peroxidase anti-peroxidase antibody (Sternberger Meyer #405) was
applied in a 1:50 dilution for 30 minutes at room temperature and slides were subsequently
rinsed in PBS again for 3 x 5minutes. A DAB solution (Abbott Kit #2A08) was prepared,
filtered through a 0.22 µm millipore filter and applied to the slides for 7 minutes at room
temperature after blotting off excess saline.
Slides were counterstained by rinsing in 0.1 M sodium acetate buffer for 10 minutes, staining
in ethyl green solution for 10 minutes, rinsing in deionized H2O for 2x 10 dips and 1x 30
seconds, and dehydrating in butanol with 2x 10 dips, 1x 3 minutes and xylene 3x for 2 minutes
each.  Slides were subsequently mounted with Permount (Fisher).
3.3.1.4 Microscopic evaluation
Nuclear immunostaining patterns were evaluated by three observers (Angela Reles, Wen H.
Wen, Michael F. Press). The immunoreactivity for p53 antibody was scored as the percentage
of positively stained nuclei by counting 100-200 (minimum 100) tumor cells. Tumors with
10% or more nuclei showing immunostaining were considered to have p53 overexpression.
3.3.2 Molecular biology techniques
3.3.2.1 Isolation of genomic DNA from frozen tumor tissue
Frozen tissue sections stained with hematoxylin and eosin were used to confirm that the
majority of the tissue selected for analysis was composed of tumor cells.  To isolate genomic
DNA, 10-20 serial frozen tissue sections (10 microns thick) of the tumor were collected in
Eppendorf tubes and incubated in 300 µl extraction solution consisting of 10mM Tris Hcl pH
7.5, 25mM EDTA, 100mM NaCl, 0.5% SDS and Proteinase K (0.1 mg/ml) overnight at 50°C.
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After complete digestion 300 µl of phenol:chloroform:isoamyl alcohol (50:49:1) were added
and DNA was purified by centrifugation following deproteination at 14.000 rpm for 5 min.
The DNA containing supernatant was placed in a new tube and DNA was precipitated with 2.5
volumes of 100% ethanol and 0.1 volume 3M Na-Acetate pH 6.0 overnight at -20° C. After
centrifugation at 14.000 rpm for 30 min and removing the supernatant the pellet was washed
with 75% ethanol, airdried and resuspended in 20 µl  TE buffer. The DNA yield was measured
by spectrophotometry at OD 260 and the concentration was determined according to the
formula: DNA concentration (µg/ µl) = (OD 260 x 50 x dilution factor) : 1000
3.3.2.2 Isolation of genomic DNA from paraffin embedded tissue
Formalin-fixed, paraffin-embedded tissue stained with hematoxylin and eosin was used to
confirm that the majority of the tissue selected for analysis was composed of tumor cells.
Three serial sections of 8-10 microns were collected into Eppendorf tubes and deparaffinized
by subsequent treatment with Xylene for 5 min, 100% ethanol for 3 min and 95% ethanol for 3
min, each step followed by 5 min centrifugation at 14.000 rpm and removal of the supernatant.
The tissue was airdried for 1 hour and then placed in 400 µl of an extraction solution at pH 8.0
containing:
• 100 mM Tris/Cl
• 4mM EDTA
• 500 µg/ml proteinase K
for 3 to 4 days at 50°C. After complete digestion 400 µl of phenol:chloroform:isoamyl alcohol
(50:49:1) were added and DNA was purified by centrifugation following deproteination at
14.000 rpm for 5 min. The DNA containing supernatant was placed in a new tube and DNA
was precipitated with 2.5 volumes of 100% ethanol and 0.1 volume 3M Na-Acetate pH 6.0
overnight at -20° C.  After centrifugation at 14.000 rpm for 30 min and removing the
supernatant the pellet was washed with 75% ethanol, airdried and resuspended in 20 µl TE
buffer. The DNA yield was measured by spectrophotometry at OD 260 and the concentration
was determined according to the formula: DNA concentration (µg/ µl) = (OD 260 x 50 x
dilution factor) : 1000
3.3.2.3 Polymerase Chain Reaction (PCR) for p53
The PCR was used 1) to amplify each of the exons contributing to the open reading frame of
the p53 gene (exon 2-11) of all ovarian cancer cases for the mutation screening by SSCP
(Single Strand Conformation Polymorphism) and 2) to reamplify those exons which had
shown abnormal band patterns in SSCP to detect mutations by DNA sequencing. Sense and
antisense primers for exon 2-11 of the p53 gene were designed and analyzed for sequence
homologies by using the DNAsis software package on a Macintosh computer and the NCBI
(National Center of Biotechnology Information, website: www.ncbi.nlm.nih.gov) sequence
data base available through the internet. Primers were usually of 20-21 bases length with a
G/C-content ranging between 40-60%.
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Table 5: Primers and PCR conditions for amplification of p53 exon 2-11









ex 2 Sn 5' CAGGGTTGGAAGCGTCTCAT 3' 11642-11661 224 bp 1.6 63°C
ex 2 Asn 5' CTTCCCACAGGTCTCTGCTA 3' 11865-11846
ex 3 Sn 5' TAGCAGAGACCTGTGGGAAGC 3' 11846-11866 159 bp 0.6 63°C
ex 3 Asn 5' AGAGCAGTCAGAGGACCAGGT 3' 12004-11984
ex 4 Sn 5' CGTTCTGGTAAGGACAAGGG 3' 11921-11940 445 bp 0.8 63°C
ex 4 Asn 5' AAGAAATGCAGGGGGATACGG 3' 12366-12346
ex 5 Sn 5' CTGTTCACTTGTGCCCTGAC 3' 13004-13023 271 bp 0.7 60°C
ex 5 Asn 5' AACCAGCCCTGTCGTCTCTC 3' 13275-13256
ex 6 Sn 5' GCTGGAGAGACGACAGGGCT 3' 13252-13271 228 bp 0.7 60°C
ex 6 Asn 5' CAACCACCCTTAACCCCTCC 3' 13480-13461
ex 7 Sn 5' CTTGCCACAGGTCTCCCCAA 3' 13941-13960 237 bp 1.6 70°C
ex 7 Asn 5' AGGGGTCAGCGGCAAGCAGA 3' 14158-14177
ex 8 Sn 5' TTCCTTACTGCCTCTTGCTT 3' 14411-14430 231 bp 1.2 65°C
ex 8 Asn 5' AGGCATAACTGCACCCTTGG 3' 14622-14641
ex 9 Sn 5' AGCAAGCAGGACAAGAAGCG 3' 14592-14611 264 bp 1.4 66°C
ex 9 Asn 5' GCAAATGCCCCAATTGCAGG 3' 14836-14855
ex 10 Sn 5' CGATGTTGCTTTTGATCCGTCA 3' 17465-17486 257 bp 1.6 63°C
ex 10 Asn 5'ATCCTATGGCTTTCCAACCTAG3' 17722-17743
ex 11 Sn 5' TCCCGTTGTCCCAGCCTTAG 3' 18491-18510 383 bp 0.6 63°C
ex 11 Asn 5' GGTATGTCCTACTCCCCATC-3' 18874-18894
One pair of primers was used for each exon except exon 4 for which in part of the cases two
pairs of oligonucleotide primers were used as previously published (Wen et al. 1999). The
sequence of the primers for exon 7 and exon 8 was used as described by Kohler et al. (1993b).
Each of the oligonucleotide primer pairs were designed to span not only the exon of interest,
but also sufficient flanking intron sequence so that splice junction mutations would be
included for analysis. The 3' oligonucleotide primer of exon 11 was not outside of the splice
junction but was 196 nucleotides downstream of the translation termination-codon.
The annealing temperature was determined according to the NCBI information and the Mg++
concentration was optimized for each primer pair.  The sequence for each primer pair, the
nucleotides spanned by the primer, the expected PCR fragment size, the optimal Mg++
concentration and the annealing temperature were as shown in table 5.
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Primers were chemically synthesized by the University of Southern California core lab.  The
primers which were obtained in dried form were diluted in ddH2O. The concentration was
determined by measuring the absorbance at λ=260 nm (A260) and aliquots of 20 µl with a
concentration of 50 pmol were stored at -20°C. 2-5 µl of the tumor DNA samples were diluted
to a concentration of 100 ng/µl in TE buffer.
The PCR reaction with a total volume of 25µl was set up as follows:
• 1 µl DNA (100 ng)
• 1 µl dNTP mix (conc 100 µM)
• 0.6-1.6 µl Mg++ (conc 25 mM)
• 0.25 µl primer sense (conc 50 pmol)
• 0.25 µl primer antisense (conc 50 pmol)
• 2.5 µl Mg++ free buffer
• 0.2 µl Taq polymerase (1U) (Promega)
• 17.9-19.2 µl H2O to a total volume of 25 µl
• for SSCP 0.15 µl 33P-labeled-dATP and 0.15 µl 33P-labeled-dCTP were added
For each PCR run, a reaction mix with H2O instead of DNA was used as a negative control.
For SSCP specimens containing known mutations were processed as positive control samples
for exons 5-8 and normal ovarian tissue DNA was used as a normal control. The reactions
were set up on ice in 0.5 ml PCR tubes (CLP) and the mixtures were overlaid with one drop of
mineral oil to prevent evaporation during repeated heating and cooling during the PCR. After
short spinning at 12.000 rpm the PCR reaction was carried out in a DNA thermal Cycler
(Perkin-Elmer Cetus, Norwalk, CT, USA) at the following conditions:
1 cycle 94°C 2 min (initial denaturing of template DNA)
35 cycles 94°C 1 min (denaturing of template DNA)
60-70°C 1 min (annealing temperature, depending on primers)
72°C 2 min (elongation)
1 cycle 72°C 2 min (elongation)
After completion of the PCR reaction, samples were cooled to 4°C and, if not used
immediately, stored at -20°C.
3.3.2.4 Single Strand Conformation Polymorphism (SSCP)
The PCR products were checked on an agarose gel for the amount and correct size of DNA. 5 
µl of the PCR reaction were mixed with 5 µl dd H2O and 2 µl 10x DNA dye and run on a 1.2%
agarose gel (50 ml 0.5x TBE buffer, 0.6g Agarose and 1 µl EtBr) with 0.5x TBE as running
buffer at 70 volt for 1 hour.
Conformational differences in the PCR products were resolved on a non-denaturing, 0.5x
MDE (mutation detection enhancement) polyacrylamide gel with the addition of 5% glycerol
at room temperature (Spinardi et al. 1991). A total volume of 100 ml of the gel was mixed out
of the following components:
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• MDE Gel Solution 25 ml
• 10 x TBE 6 ml
• Glycerol 10% 5 ml
• dd H2O 64 ml
• TEMED 40 µl
• 10 % APS 400 µl
The gel mix was cast between two glasplates of a Biorad sequencing apparatus and allowed to
polymerize after insertion of a 0.4 mm thick 97 well comb for at least 1 hour at room
temperature. A 0.6x TBE solution was used as running buffer. 5 µl of the PCR product of each
sample were mixed with 7 µl of stop solution (as described above), and denatured at 94°C for
2 min, followed by immediate cooling on ice for 10 min, except for a normal DNA double-
stranded control. Fortyfive samples including the single-stranded normal DNA control, the
double-stranded normal DNA control and the positive control were loaded on the gel and run
at 21 W at room temperature for a time period between 8 hours (exon 3) and 20 hours (exon
4), on average 14-16 hours, depending on the expected size of the PCR product.  After the
DNA had migrated far enough through the gel to allow separation of the DNA strands, the gel
was dried on Whatman 3 MM paper and subsequently exposed to a Kodak Biomax MR film
for 12-48 hours.
3.3.2.5 DNA sequence analysis
DNA segments identified as having altered mobility by SSCP were evaluated by conventional
DNA sequence analysis methods (Sanger et al. 1977, Slatko, 1996). Both the sense and anti-
sense strands were analyzed by the dideoxynucleotide chain termination technique with PCR
sense and anti-sense primers using the ThermoSequenase radiolabeled terminator cycle
sequencing kit (Amersham Life Science, Arlington Heights, Il, USA).
a) Preparation of the sequencing gel:
• two big glas plates of a Biorad sequencing apparatus were cleaned twice with ddH2O, once
with 100% ethanol, once with acetone and subsequently prepared with SEA spray
• both plates were mounted with 0.4 mm spacers shortly before the gel was cast
• a 6% acrylamide gel was prepared with
- 24 ml SequagelTM Concentrate
- 66 ml SequagelTM Diluent
- 10 ml 10x GTB buffer
• 40 µl TEMED and 800 µl 10% APS were added to start polymerization
• the gel was immediately cast with a syringe into the mounted glas plates and a comb with 0.4
mm width was inserted upside down to create a gel free space. Polymerization was allowed at
4°C for 2 hours or overnight
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b) Sequencing reaction
• the ThermoSequenase kit included the following solutions:
• Thermo Sequenase DNA polymerase 4U/µl, Thermoplasma acidophilum inorganic
pyrophosphatase, 50mM Tris⋅HCl, pH 8.0, 1mM dithiothreitol (DTT), 0.1mM
ethylenediamine tetraacetic acid (EDTA), 0.5% Tween-20, 0.5% Nonidet P-40, 50%
glycerol
• Reaction buffer (concentrate): 260mM Tris⋅HCl, pH 9.5, 65mM MgCl2
• dGTP termination master mix: 7.5µM dATP, dCTP, dGTP, dTTP
• Stop solution: 95% formamide, 20mM EDTA, 0.05% bromophenol blue, 0.05% xylene
cyanol FF
• Glycerol tolerant gel buffer: powdermix 54g Tris base, 18gm Taurine, 1gm Na2EDTA⋅2H2O,
H2O to 250ml for a 20x buffer concentrate
• 33P labeled terminators:
ddATP, 0.3µM [α-33P]ddATP (1500Ci/mmol, 450µCi/ml) 11.25 µCi
ddCTP, 0.3µM [α-33P]ddCTP (1500Ci/mmol, 450µCi/ml) 11.25 µCi
ddGTP, 0.3µM [α-33P]ddGTP (1500Ci/mmol, 450µCi/ml) 11.25 µCi
ddTTP, 0.3µM [α-33P]ddTTP (1500Ci/mmol, 450µCi/ml) 11.25 µCi
The sequencing reaction was set up according to the following protocol (Mok et al.1993):
Ovarian carcinoma template DNA was reamplified with the appropriate PCR primer pair as
described previously. 5 µl of the amplified PCR product were pretreated with 1 µl (2U) of
shrimp alkaline phosphatase (Amersham) and 1 µl (10U) of exonuclease I (Amersham) at
37°C for 15 min in a thermal cycler followed by inactivation of the enzyme at 80°C for 15
min.
For each case two sets of PCR tubes (for the sense and the antisense primer) were labelled as
A,C,G,T and a termination mix was set up on ice as follows:
• A 2 µl dGTP termination master mix + 0.5 µl [α-33P]ddATP
• C 2 µl dGTP termination master mix + 0.5 µl [α-33P]ddCTP
• G 2 µl dGTP termination master mix + 0.5 µl [α-33P]ddGTP
• T 2 µl dGTP termination master mix + 0.5 µl [α-33P]ddTTP
Subsequently a reaction mix of 20 µl volume was set up on ice for each case as follows:
• pretreated PCR product 3 µl
• reaction buffer 2 µl
• ddH2O 12 µl
• primer 2.5 pmol/µl 1 µl
• Thermosequenase 2 µl
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4.5 µl of this reaction mix were added to each A,C,G,T termination mix tube (total volume 7 µ
l) on ice. The sequencing reaction was carried out in a thermal cycler (MJ research) which was
preheated to 95°C under the following conditions for 30 cycles:
• 95°C 30 sec
• 55°C 30 sec
• 72°C 90 sec
followed by cooling to 0°C. Subsequently 4 µl of stop solution were added to each of the
reactions and the samples were stored at -20°C overnight.
c) Gel electrophoresis:
• the glasplates containing the gel were fixed into a sequencing gel apparatus (Biorad) and the
upper and lower chambers were filled with 1x glycerol tolerant buffer. The comb was removed
and inserted for lane separation. The gel spaces were carefully cleaned from gel residues and
urea.
• pre-electrophoresis was carried out with 2 µl of stop solution in each lane at a power of 120
watts until the gel warmed up to a temperature of 50-55°C.
• the stopped sequencing reactions were denatured at 80°C for 3 min and placed on ice for
loading
• 2 µl of the samples were loaded per lane in the order of A,C,G,T for each case and
electrophoresis was carried out at 120 watts until either the BPB or the XC marker had
migrated far enough through the gel (depending on the region of interest), assuming that BPB
migrates at a length of 26 bases and XC at a length of 106 bases of the DNA sequence in a 6%
acrylamide gel
• after electrophoresis the glasplates were separated after cooling to room temperature
• the gel was removed from the glasplate by application of 3 MM Whatman paper and dried at
80°C for 60 min in a vacuum gel drier
• the DNA sequence was revealed by autoradiography by exposure of the dried gel to a
Biomax MR film at RT for 12-48 hrs
3.3.2.6 Automated DNA sequencing
Automated DNA sequencing was used 1) to identify p53 mutations in ovarian cancer cases
which had not shown SSCP alterations and 2) to compare the normal tissue DNA sequence of
tumor cases with suspected p53 polymorphisms.
Fourty-two ovarian carcinoma cases which had no mobility shift identified by SSCP screening
were subjected to complete DNA sequence analysis of exon 2-11 by automated DNA sequence
analysis, to identify those mutations which SSCP failed to identify, as described elsewhere
(Wang-Gohrke et al.1998, Wen et al. 1999). The automated sequencing was performed in the
Molecular Biology Laboratory of Prof. Dr. R. Kreienberg at the Department of Gynecology
and Obstetrics at the University of Ulm, Germany, using an A.L.F. Express Sequencer
(Pharmacia Biotech, Uppsala, Sweden) (Wang-Gohrke et al. 1998).
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For automated sequencing of normal tissue controls for p53 polymorphisms a PCR reaction of
50 µl volume was set up with 400 ng of DNA, 40 µmoles dNTP, 25pmol of each of the
appropriate primers, Mg++ concentration as described in table 5 and 2U of Taq DNA
polymerase. The PCR product was analyzed by gel electrophoresis on a 1.2% agarose gel
(Seakem) made up with 0.5x TAE buffer and 160 µg/l ethidium bromide. The PCR product of
the expected size was extracted from the gel with a DNA gel extraction kit (Qiagen,
Chatsworth, CA).
150 ng of each purified PCR product and 5 pmol of each of the appropriate primers as used for
the PCR reaction were submitted to automated sequencing on a Perkin Elmer 377 ABI prism
automated sequencer. DNA sequencing was performed with a dye-based (Big Dye) Applied
Biosystems procedure incorporating 3’ fluorescent-labeled dideoxynucleotide triphosphates
(dye terminators) into the extension of the PCR products (asymmetric PCR). The specific
emissions were detected and analyzed by a PC program which counts the fluorescence label
excitements produced by laser lights.
3.3.2.7 Isolation of total RNA from tumor tissue
Total RNA was extracted from frozen tissue by using the TRIzol reagent and extraction
protocol (Gibco BRL). Frozen tissue sections stained with hematoxylin and eosin were used to
confirm that the majority of the tissue selected for analysis was composed of tumor cells. To
isolate total RNA an adjacent piece of frozen tissue (50 mg) of the tumor was collected in an
Eppendorf tube placed on dry ice. Subsequently 1 ml of TRIzol reagent was added to the tube,
immediately followed by homogenization with a tissue homogenizer (VWR) at maximum
speed. The homogenized samples were incubated 5 min at room temperature to permit
complete dissociation of nucleoprotein complexes. After adding 0.2 ml of chloroform, tubes
were vigorously shaken by hand for 15 sec and then incubated at room temperature for 3 min,
followed by centrifugation at 12.000 rpm for 15 min at 4°C. The RNA-containing upper
aqueous phase was transferred to a fresh tube and precipitated with 0.5 ml isopropyl alcohol,
incubated for 10 min at room temperature and then centrifuged at 12.000 rpm for 10 min at
4°C. After centrifugation the supernate was removed and the RNA pellet was washed with 1
ml of -20°C cold 75% ethanol, mixed by vortexing and centrifuged at 10.000 rpm for 5 min at
4°C. Subsequently the RNA pellet was airdried and redissolved in DEPC-H2O. The RNA yield
was measured by spectrophotometry at OD 260 and the concentration was determined
according to the formula: RNA conc. (µg/ µl)  =  (OD 260 x 40 x dilution factor) : 1000
RNA preparations were stored at -70°C.
3.3.2.8 Northern hybridization
Total RNA from tumor tissue and a control cell line (SA1 osteosarcoma cell line) was
fractionated, blotted on nylon membranes and hybridized according to the following protocol:
a)  RNA fractionation:
• 15 µg of total RNA dissolved in DEPC-H2O were added to DEPC- H2O to a total volume of
15 µl; 10 µg of an RNA ladder (Gibco) were used as a length standard
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• a 1% agarose gel containing 1% MOPS and 17% formaldehyde was cast
• 45 µl of a denaturing buffer containing 5 µl MOPS (10x), 25.8 µl formamide, 8.7 µl
formaldehyde (37% solution), 5 µl 10x dye (1mM EDTA, 0.25% bromophenol blue, 0.25%
xylene cyanol, 50% glycerol) and 0.5 µl EtBr was added to the RNA
• the samples were denatured at 65°C and afterwards kept on ice
• the samples were loaded on the gel and electrophoresis was carried out at 40 volt for
approximately 16 hours, until the bromophenol-blue marker had reached the end of the gel
b) Immobilization of the fractionated RNA on nylon filters:
• after completion of electrophoresis, the gel was photographed with a fluorescent scale next to
the RNA ladder under UV-illumination
• the gel was then washed in DEPC-H2O for 2x 30 minutes and in 10x SSC for 2x 30 minutes
• a nylon membrane (BioRad) was cut to the exact size of the gel and soaked in DEPC-H2O
• a glasplate was placed on top of a 35 mm dish in a tray which was filled with 10x SSC
• a long sheet of 3MM Whatman paper was laid on top of the glasplate in such a way, that
both ends reached into the buffer tank
• the gel was laid on top of the Whatman paper, the nylon membrane was placed on the gel
and covered with two sheets of Whatman paper of the same size, soaked in DEPC-H20
• a pile of paper towels was placed on top of the gel-nylon-membrane stack and weightened
down with a book; the Whatman paper surrounding the gel stack was covered with plastic foil
• the transfer was carried out for 14 hours overnight
• after the transfer the RNA was crosslinked at 1200 in a stratalinker.
c.) Hybridization
• the blot was transferred into a hybridization tube and was pre-hybridized for 2 hours at 65°C
in 10 ml rapid hyb buffer (Amersham)
• 25 ng of a 1.7 kb mdm2 cDNA probe (kindly provided by B. Vogelstein, John Hopkins
Oncology Center, Baltimore, USA) were radioactively labeled (Megaprime labeling kit,
Amersham) with p32 dCTP (Amersham) at an activity of 1-3 x 106 cpm/ml
• the probe was purified from unincorporated p32 in a quick spin column (Boehringer
Mannheim 100400)
• for hybridization, the probe was mixed with 100 µl salmon sperm DNA, boiled for 10 min,
iced for 10 min, mixed with 10 ml rapid hyb buffer and added to the blot; hybridization was
then carried out under the same conditions as prehybridization
• after hybridization, the blot was washed 1) in 2x SSC, 0.1% SDS for 15 min at rt, 2) in 0.5x
SSC, 0.1% SDS for 15 min at rt and 3) in 0.1x SSC, 0.1% SDS for 10 to 20 min at 65°C
• blots were wrapped into plastic foil and x-ray autoradiography was carried out at -70°C on
Biomax MS film overnight
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3.3.2.9 Southern hybridization
Genomic DNA from tumor tissue and cell lines was fractionated, blotted on nylon membranes
and hybridized according to the following protocol:
a)  DNA fractionation:
• 15 µg of genomic DNA were diluted in TE buffer to a total volume of 40 µl; 15 µl (1.5 µg)
of a 1 kb DNA ladder (Gibco) were used as a length standard
• DNA samples were digested with EcoRI (3 units/ µg DNA) for 4 hrs at 37°C
• 500 ml of a 1% agarose gel (prepared with 0.5x TBE buffer) were cast
• after completion of digestion, 5.5 µl 10x dye (1mM EDTA, 0.25% bromophenol blue, 0.25%
xylene cyanol, 50% glycerol) was added to the DNA samples
• the samples were loaded on the gel and electrophoresis was carried out at 40 volt for
approximately 16 hours, until the bromophenol-blue marker had migrated 10 cm through the
gel
b) Immobilization of the fractionated DNA on nylon filters:
• after completion of electrophoresis, the gel was photographed with a fluorescent scale next to
the DNA ladder under UV-illumination
• the gel was then washed 1) in 0.25 M HCl until the dye turned yellowish 2) washed in 0.5M
NaOH, 1.5M NaCl until the dye changed back to blue, 3) rinsed in ddH2O 4) neutralized by 2x
30 min washing in 0.5 M Tris, 3M NaCl, pH 7.4
• a nylon membrane (BioRad) was cut to the exact size of the gel and transfer was carried out
as described for Northern blotting
c.) Hybridization
• 25 ng of a DNA probe were radioactively labeled (Megaprime labeling kit, Amersham) and
hybridization was carried out as described for Northern hybridization
• after hybridization, the blot was washed twice in 2x SSC for 5 min at rt and twice in 0.1x
SSC, 0.1% SDS for 30 min at 65°C
• blots were wrapped into plastic foil and x-ray autoradiography was carried out at -70°C on
Biomax MS film overnight
3.3.2.10 cDNA synthesis
cDNA synthesis was performed with the following reaction mix:
• 2 µg total RNA
• add H2O to a volume of 7 µl
• 0.5 µl oligo dT primer
were heated to 70°C for 10 min and then immediately cooled to 0°C in ice water for 5 min; the
following reagents were mixed on ice:
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• 1 µl M-MLVRT (200U/µl)
• 5 µl RT buffer
• 2 µl dNTP mix (containing 10mM of each dNTP)
• 1 µl MgCl (25mM)
• 1 µl DTT
• 1µl RNA guard
• 2 µl H2O
and the total volume of 13 µl was added to each tube. The cDNA synthesis was carried out at
39°C for 1 hour and stopped by heating to 95°C for 5 min, followed immediately by cooling
the samples in ice water; 2 µl of the cDNA were used for RT-PCR; the cDNA was stored at -
70°C.
3.3.2.11 Polymerase Chain Reaction (PCR) for mdm2 with nested primers
a) Nested PCR for amplification of mdm2 cDNA
cDNA which had been synthesized by reverse transcription from total RNA was used as a
template for a nested PCR protocol. cDNA was amplified by a set of external mdm2 primers
spanning the entire coding region of the mdm2 gene spanning exon 3 to exon 12. Since mdm2
is expressed at low levels the PCR product was then subjected to a second run of PCR with
internal primers. The primer sequence we used had been previously published (Sigalas et al.
1996). The internal sense primer has a gap of eight nucleotides.
The annealing temperature was determined to be 58° C according to a formula based on the
nucleotide content. The Mg++ concentration was chosen as 1.4 mMol according to previous
protocols (Sigalas et al. 1996).
Table 6: mdm2 external and internal primers for nested PCR
Primer Primer sequence spans nucleotides
of coding region
ext Sn 5' CTGGGGAGTCTTGAGGGACC 3' 248-267
ext Asn 5' CAGGTTGTCTAAATTCCTAG 3' 1831-1851
int Sn 5' CGCGAAAACCCCGGGCAGGCAAATGTGCA 3' 280-293, 302-318
int Asn 5' CTCTTATAGACAGGTCAACTAG 3' 1784-1805
Primers were obtained from the University of Southern California core lab. The
concentration of the primers dissolved in ddH2O was determined by measuring the absorbance
at λ=260 nm (A260). Primers were diluted to a concentration of 50 pmol. 2 µl of the cDNA,
which had been reverse transcribed from total RNA, were used as a template for the external
PCR run and 2 µl of the resulting product were used for the internal primer PCR run.
The PCR reaction was set up for the external primer run to a total volume of 25 µl as follows.
For the internal primer run a volume of 50 µl was set up to have a greater DNA yield for
sequencing analysis.
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• 2 µl cDNA / 4 µl PCR product
• 1 µl / 2 µl dNTP mix (conc 400 µM)
• 1.4 µl / 2.8 µl Mg++ (conc 25 mM)
• 0.25 µl / 0.5 µl primer sense (conc 50 pmol)
• 0.25 µl / 0.5 µl primer antisense (conc 50 pmol)
• 2.5 µl / 5 µl Mg++ free buffer
• 0.2 µl (1U) / 0.4 µl (2U) Taq polymerase (Promega)
• 17.4 µl H2O to a total volume of 25 µl / 34.8 µl to a total volume of 50 µl
For each PCR run, a reaction mix with H2O instead of DNA was used as a negative control.
The reactions were set up on ice in 0.5 ml PCR tubes (CLP) and the mixtures were overlaid
with one drop of mineral oil to prevent evaporation during repeated heating and cooling during
the PCR. After short spinning at 12.000 rpm the PCR reaction was carried out in a DNA
thermal Cycler (Perkin-Elmer Cetus, Norwalk, CT, USA) at the following conditions for both
external and internal primers:
1 cycle 94°C 2 min (initial denaturing of template DNA)
30 cycles 94°C 1 min (denaturing of template DNA)
58°C 1 min (annealing temperature)
72°C 2 min (elongation)
1 cycle 72°C 2 min (elongation)
After completion of the PCR reaction, samples were cooled to 4°C and, if not used
immediately, stored at -20°C.
b) PCR of the ß2 microglobulin gene as a control
PCR amplification of the ß2 microglobulin gene was used as an internal control to confirm that
the RNA used for reverse transcription was intact and that sufficient and equal amounts of
cDNA had been synthesized. The β2-microglobulin gene is approximately 8Kb in size and
consists of four exons and three introns. The complete mRNA comprises 945 nucleotides and
codes for a polypeptide of 99 amino acids, which are mostly represented by the exon 2
sequence (93 amino acids). We designed a pair of primers which span 898 bp of cDNA. The
sense primer was located close to the 5’ end of exon 1 and the antisense primer close to the 3’
end of exon 4. The sequence of the primers was:
sense: 5’ TCCTGAAGCTGACAGCATTC 3’ (nucleotides 855-874) and
antisense: 5’ CCGTACCAACACCAATTAGA 3’ (nucleotides 3983-4002).
Primers were obtained from the University of Southern California core lab. Primer
concentration was determined by measuring the absorbance at λ=260 nm (A260) and primers
were diluted to 50 pmol/µl. 1 µl of the cDNA template was used for the reaction which was
carried out at an annealing temperature of 62° and a Mg++ concentration of 0.8 mmol. The
PCR reaction with a total volume of 25 µl was set up as follows:
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• 1 µl cDNA
• 1 µl dNTP mix (conc 400 µM)
• 0.8 µl Mg++ (conc 25 mM)
• 0.25 µl primer sense (conc 50 pmol)
• 0.25 µl primer antisense (conc 50 pmol)
• 2.5 µl Mg++ free buffer
• 0.2 µl Taq polymerase (1U) (Promega)
• 19 µl H2O to a total volume of 25 µl
For each PCR run, a reaction mix with H2O instead of DNA was used as a negative control.
The reactions were set up on ice in 0.5 ml PCR tubes (CLP) and the mixtures were overlaid
with one drop of mineral oil to prevent evaporation during repeated heating and cooling during
the PCR.  After short spinning at 12.000 rpm the PCR reaction was carried out in a DNA
thermal Cycler (Perkin-Elmer Cetus, Norwalk, CT, USA) at the following conditions:
1 cycle 94°C 2 min (initial denaturing of template DNA)
35 cycles 94°C 1 min (denaturing of template DNA)
62°C 1 min (annealing temperature)
72°C 2 min (elongation)
1 cycle 72°C 2 min (elongation)
After the PCR reaction was completed, samples were cooled to 4°C and 10 µl of the reaction
product was run on a 1% agarose gel. A single PCR product of approximately 900 bp size was
detected for all cDNA samples.
3.3.2.12 Subcloning of cDNA into a TA cloning vector
For optimal ligation efficiencies, a fresh PCR reaction was run with the internal mdm2 primers
using the external primer PCR product as a template to provide sufficient single 3’ A-
overhangs. Ligation and transformation were performed by using the Original TA Cloning
Kit (Invitrogen), which contains the pCRTM 2.1 vector.
a) Ligation
• the amount of PCR product was estimated by the following formula to ligate with 50 ng (20
fmoles) of pCRTM 2.1 vector for a 1:1 vector:insert ratio
x ng PCR product = (y bp PCR product)(50 ng pCRTM 2.1 vector)
(size in bp of the pCRTM 2.1 vector ≈ 3900)
• the PCR product was purified with the QIAquick PCR Purification Kit (Quiagen) according
to the manufacturers instructions
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• the ligation reaction was set up as follows:
fresh PCR product 6 µl
10x ligation buffer 1 µl
pCRTM 2.1 vector (25ng/µl) (Invitrogen) 2 µl
T4 DNA ligase (5U/µl ) ( Boehringer Mannheim) 1 µl
Total volume 10 µl
• the ligation reaction was carried out at 14°C overnight in a waterbath
b) Transformation
• the chemically competent E. coli bacteria (One ShotTM competent cells, strand DH 5α) were
used for transformation
• the vials containing the ligation reactions were centrifuged briefly and placed on ice
• one 50 µl vial of frozen One ShotTM competent cells for each ligation was thawed and kept
on ice
• 0.5 M ß-mercaptoethanol was thawed and 2 µl were pipetted into each vial of the competent
cells, mixed gently by stirring
• 2 µl of the ligation reaction were pipetted into each vial containing the competent cells,
mixed gently by stirring and incubated for 30 minutes on ice
• the vials were heat shocked for exactly 30 seconds in a 42°C waterbath and placed on ice for
2 minutes
• 450 µl of SOC medium from the kit (at room temperature) were added to each tube
• the vials were then shaken horizontally at 37°C for 1 hour at 225 rpm in a rotary shaking
incubator; the vials with the transformed cells were placed on ice.
• 50 µl of x-gal were spread on LB agar plates containing 50 µg/ml kanamycin
• 100 µl of each transformation were spread out evenly on the agar plates
• plates were then inverted and incubated at 37°C for at least 18 hours; plates were then shifted
to 4°C for 2-3 hours to allow for proper color development
• 8-10 white or blue-white colonies were picked from each transformation and placed into 3 ml
of LB-medium containing 50 µg/ml kanamycin
• to check the size of the insert, the following PCR reaction was set up:
ddH20 13.64 µl
Mg free buffer 2 µl
dNTP 400µM 1 µl
primer PR 126 1 µl
primer PR 127 1 µl
MgCl++ 0.96 µl
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Taq polymerase 0.4 µl
Total 20 µl
• the PCR reaction was run at 1 cycle 94°C 5 min, 30 cycles  94°C 1 min, 57°C 1 min, 72°C 1
min, 1 cycle 72°C 5 min
• to check the size of the insert, 10 µl of the PCR product were run on a 1% agarose gel.
• all clones which contained an insert were selected for sequencing
3.3.2.13 Growth and storage of bacteria
• bacteria from a single colony from a LB agar plate were used to inoculate 5 ml or 100 ml of
LB broth for small scale or large scale preparation of plasmid DNA, respectively. The LB
broth contained the appropriate antibiotic (concentration 50 µg/ml for kanamycin, 50 µg/ml for
ampicillin). Bacteria were grown overnight at 37°C in a horizontally rotating shaker at 230
rpm.
• E.coli strains were stored as glycerol stocks at -70°C. Therefore 0.5 ml of an overnight
culture of E. coli was vigorously mixed with 0.5 ml of a solution containing 50% LB broth
with kanamycin at a concentration of 50 µg/ml and 50% glycerol. The mixture was shock
frozen in liquid nitrogen and the stocks were transferred to -70°C. To recover bacteria from
frozen stocks, an inoculation loop was used to scrape off some bacteria which were
subsequently streaked out on a LB agar plate containing the appropriate antibiotic.
3.3.2.14 Generation of electro-competent bacteria
Electro-competent bacteria of the strain DH10B were generated and tested according to the
following protocol:
a) Growth of electro-competent bacteria
• 25ml of LB medium were inoculated with bacteria scraped off from a frozen stock and
incubated at 37°C for 12-16 hrs, with vigorous shaking at 300 rpm
• 1 ml of the overnight culture was inoculated into 500 ml of LB supplemented with 20 mM of
glucose
• the bacteria were grown at 37°C with vigorous shaking at 300 rpm, while taking OD
measurements every 20 minutes until an OD600 of 0.6-0.7 was reached
• the cultures were chilled on ice for 30 min and for the following steps kept ice cold
• the bacteria were transferred to four 400 ml centrifuge bottles and centrifuged at 3720 rpm
for 20 min at 4°C
• the supernatant was poured off and the bacteria were resuspended in 8 ml of ddH2O
• 250 ml of ddH2O were added to each bottle, and the centrifugation and washing steps were
repeated; the pellets of two bottles were collected in one
• after centrifugation, the pellet was resuspended in 50 ml of a H2O/10% glycerol 1:1 solution
and centrifuged at 3600 rpm at 4°C for 20 min
• the pellet was then resuspended in an equal volume of the H2O/ 10% glycerol mix and
frozen in 300 µl aliquots in 1.5 ml screw cap tubes on dry ice and stored at -80°C
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b) Transformation of electro-competent bacteria
• 1 µl of plasmid DNA was added to 30 µl of the E.coli and incubated 30-60 sec on ice
• the suspension was transferred into a 0.1 cm gap Gene pulse cuvette (Bio-Rad, Hercules, CA,
USA)
• the bacteria were pulsed in a Bio-Rad gene pulser at 1.66 kV, usually resulting in a time
constant of 4.5 -5 msec
• the bacteria were mixed with 1 ml of LB medium and incubated for 1h at 37°C with vigorous
shaking
• 100 µl and 10 µl of the bacterial suspension were plated on agar plates containing 50 µl/ml
ampicillin; the plates were incubated at 37°C for 12-16 hours
• colonies were counted on the 10 µl plate and efficiency was expressed in bacterial colonies
per one µg of plasmid used
3.3.2.15 Small scale (mini-prep) and medium scale preparation (midi-prep) of plasmid DNA
Mini- and midi-preps of plasmid DNA were carried out with a Quiagen plasmid purification
kit (Quiagen Inc, Chatsworth, CA, USA) according to the protocol supplied by the
manufacturer:
• bacteria of a 5 ml (midi-prep: 50 ml) overnight culture were centrifuged at 10.000 g for 1-2
minutes, the supernatant was blotted off
• the bacterial pellet was resuspended in 0.3 ml (midi-prep 5 ml) of buffer P1
• 0.3 ml (midi-prep 5 ml) of buffer P2 lysis buffer was added, the sample was gently mixed
and the bacteria were allowed to lyse for 5 min at room temperature
• 0.3 ml (midi-prep 5 ml) of ice-cold buffer P3 neutralization solution was added, the sample
was gently mixed and incubated on ice for 10 min (midi-prep 20 min)
• bacterial debris was removed from the lysate by centrifugation in an Eppendorf Microfuge,
15 min, 12.000 rpm, 4°C (midi-prep: 20 min, 12000 rpm, 4°C in a Sorvall RC2-B centrifuge
equipped with a SS34 rotor, Sorvall, Newton, CT, USA)
• a Quiagen-tip 20 (midi-prep: Quiagen-tip 100) ion-exchange resin was equilibrated with 1 ml
(midi-prep: 5 ml) buffer QBT and the clear supernatant was applied to the Quiagen column
• to remove contaminating DNA from the ion-exchange resin, the quiagen column was washed
4x with 1 ml (midi-prep: 2x 12 ml) medium salt-buffer QC
• plasmid  DNA was eluted from the column with 0.8 ml (midi-prep: 5 ml) high-salt buffer QF
• the plasmid DNA was precipitated with 0.7 volumes isopropanol kept at room temperature
• centrifugation 20 min, 12000 rpm, 4°C in an Eppendorf microfuge (midi-prep 30 min,
12.000 rpm, 4°C in a Sorvall-centrifuge with SS34-rotor)
• the DNA pellets were washed once with -20°C cold 70% ethanol, air-dried and dissolved in
10-20 µl TE (midi-prep: 150 µl, 300 µl for big pellets)
• the concentration of the sample was determined by measuring the absorbance at λ=260 nm (1
OD corresponds to 50 µg/ml plasmid DNA)
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• buffers used:
P1: 50 mM Tris/Cl, 10 mM EDTA, 100 µg/ml RNAseA, pH 8.0
P2: 200 mM NaOH, 1% SDS
P3: 3.0 M potassium-acetate, pH 5.5
QBT: 50 mM MOPS, 750 mM NaCl, 15% EtOH, 15% Triton X-100, pH 7.0
QC: 50 mM MOPS, 1000 mM NaCl, 15% EtOH, pH 7.0
QF: 50 mM Tris/Cl, 1250 mM NaCl, 15% EtOH, pH 8.5
3.3.2.16 Restriction enzyme digestion of plasmid DNA and PCR product
• Restriction enzyme digestion of DNA was carried out in 20 µl volumes at conditions
recommended by the manufacturer (NEB Biolabs) using the appropriate restriction enzyme
buffer supplied with the enzyme. Digestion of plasmid DNA was usually checked during the
reaction on a 0.8-1.5% agarose mini-gel containing 5 µg/ml ethidium bromide. Digestion was
usually stopped by incubation at 65°C for 10 to 15 min, before the digested DNA was used for
further experiments.
3.3.2.17 Sequencing of DNA fragments cloned into the pCRTM2.1 vector
• A PCR reaction of a total volume of 20 µl with the primers PR 126 and PR 127 (as supplied
by the manufacturer) was set up as follows:
• ddH20 13.6 µl
• Mgfree buffer 2 µl
• dNTP 400µM 1 µl
• PR 126 1 µl
• PR 127 1 µl
• 25 mM MgCl 0.96 µl
• Taq polymerase 0.4 µl
• the reaction was run under the following conditions: 1 cycle 94°C 5 min, 30 cycles 94°C 1
min, 57°C 1 min, 72°C 1 min, and 1 cycle 72°C 5 min. The PCR product was checked on a 1%
agarose mini-gel containing 5 µg/ml ethidium bromide.
• the PCR product was then pretreated and sequenced as described in chapter 3.2.5
3.3.2.18 Gel extraction of PCR products for sequencing
For further analysis of mdm2 splice products, the PCR product, amplified from the cDNA, was
extracted from a 1.2% agarose gel containing 5 µg ethidium bromide with a QIAquick Gel
Extraction Kit (Quiagen Inc, Chatsworth, CA, USA) with the buffers supplied in the kit
according to the manufacturers instructions:
• the DNA fragment was excised from the gel with a clean, sharp scalpel and weighed (100 mg 
≈ 100 ml)
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• buffer QX1 was added in a ratio of 3 volumes buffer: 1 volume gel
• the gel-buffer-mix was incubated at 50°C for 10 min with repeated flicking and inverting of
the tube
• one gel volume of isopropanol was added and mixed
• the sample was loaded into a QIAquick spin column, which was placed on a 2 ml collection
tube; the sample was centrifuged for 1 min at 12.000 g
• after discarding the flow-through, 0.5 ml of buffer QX1 was added to the column followed
by centrifugation for 1 min at 12.000 g
• for washing, 0.75 ml of buffer PE were added to the column and centrifuged for 1 min
• the flow-through was discarded and the column was centrifuged for an additional 1 min at
10.000 g
• the column was placed in a clean 1.5 ml microfuge tube and the DNA was eluted with 30 µl
TE buffer by centrifugation for 1 min at maximum speed
3.3.2.19 Sequencing of cDNA PCR products after gel purification
• the PCR product was enzymatically pretreated as described in chapter 3.2.5
• 3 µl of the gel-extracted DNA and 1 µl of the internal sense and the internal antisense mdm2
primers were used for the sequencing reaction, which was carried out with the Amersham
Thermosequenase kit as previously described (chapter 3.2.5)
• the sense and the antisense sequence were read and compared to homology with the mdm2
sequence by using the MacDNAsis software and the database of the NCBI (National Center of
Biotechnology) via the internet.
3.3.2.20 Primer design and PCR for in vitro protein expression using the pcDNA3-Vector
For in vitro protein expression of the mdm2 splice variants, MDM2 full length protein and p53
protein, cDNA was cloned into the pcDNA3.1 expression vector (Invitrogen) (Fig. 8a). A
variant of the pcDNA3 vector with a human myc epitope, respectively a human hemagglutinin
(HA) epitope was kindly provided by Ulf Grawunder PhD.
The following set of sense and antisense primers for p53 and MDM2 protein expression
containing restriction enzyme sites for BamHI and MluI was designed:
mdm2 sense: 5’ CG GGATCC ATGGGCAATACCAACATGTCTGTACCTAC 3’
BamHI mdm2 sequence (T exchanged to G)
mdm2 antisense: 5’ GCG ACGCGT GGGGGAAATAAGTTAGCACAATCATTTG 5’
MluI mdm2 sequence (G added for correct frame)
p53 sense: 5’ CG GGATCC ATGGAGGAGCCGCAGTCAGATCCTAGC 3’
BamHI p53 sequence
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p53 antisense: 5’ GCG ACGCGT GGTCTGAGTCAGGCCCTTCTGTCTTGAAC 5’
MluI p53 sequence (G added for correct frame)
CMV promotor: bases 209-863
T7 promotor: bases 864-882
Polylinker: bases 889-994
Sp6 promotor: bases 999-1016
BHG poly A: bases 1018-1249
SV40 promotor: bases 1790-2115
SV40 origin of replication: bases 1984-2069
NeoR ORF: bases 2151-2945
SV40 poly A: bases 3120-3250
pUC19 backbone: bases 3272-5446























































Fig. 8a: pcDNA3 expression vector (Invitrogen). cDNA of p53, full length mdm2 and mdm2
splice variants was ligated into the pcDNA3 expression vector.
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To generate the insert with the correct sequence for protein expression, a PCR reaction was run
with the pCRTM2.1 vector plasmid DNA containing the cDNAs of six different mdm2 splice
variants. The plasmid DNA was diluted 1:1000 in TE buffer. To obtain the PCR product
containing the full length mdm2 cDNA and the p53 sequence, undiluted cDNA generated by
reverse transcription from RNA of five different normal ovary tissues was used as a template.
The following reaction was set up:
• ddH2O 16.8 µl
• 10x  buffer 3 µl
• dNTP 1mM 6 µl
• primer sense 10pmol 1.5 µl
• primer antisense 10pmol 1.5 µl
• Pwo polymerase 0.2 µl
• plasmid DNA diluted 1:1000 1 µl
(respectively undiluted cDNA)
The PCR product was run on a 1.2% agarose gel to check the size of the DNA.
3.3.2.21 Purification and restriction enzyme digestion of PCR Product and pcDNA3 vector
a) Purification of the PCR-product
The PCR products generated with the primers designed for protein expression were purified by
using MicroSpin Columns S-400 HR, according to the manufacturers instructions:
• after vortexing and breaking off the tip, the columns were placed on Eppendorf tubes and
centrifuged for 2 min at 3000 rpm
• the flow-through was discarded, the columns were placed on fresh tubes and 40 µl of the
PCR product were loaded
• after centrifugation at 3000 rpm for 2 min, a yield of approximately 30 µl was obtained
b)  Restriction enzyme digestion of PCR product and vector
• 20 µl of the PCR product were enzyme digested overnight at 37°C in a 40 µl reaction volume
containing 4 µl BamHI buffer, 4 µl 10x BSA, 11 µl ddH2O, 0.5 µl BamHI (20.000 U/ml) and
0.5 µl MluI (10.000 U/ml)
• 5 µl of the pcDNA3 vector (concentration 1 µg/µl) were enzyme digested overnight at 37°C
in a 20 µl reaction volume containing 2 µl NEB buffer 4,2 µl 10x BSA, 10 µl ddH2O, 0.5 µl
BamHI (20.000 U/ml) and 0.5 µl AscI (10.000 U/ml)
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c)  Purification of PCR product and plasmid DNA
After enzyme digestion, the PCR products of the splice variants were run on a 1.5% agarose
gel and the plasmid DNA, the mdm2 full length, and p53 PCR product were run on a 0.8%
agarose gel. Both agarose gels were prepared with 1x TAE buffer and ethidiumbromide in a
concentration of 1.2 µl/100ml gel. The DNA was then excised from the gel and purified with
the Gene Clean kit (Bio 101), according to the manufacturers instructions:
• 3-3.5 volumes of sodium iodide were added to the gel slice (weight ≅ volume)
• the gel was solubilized by incubation at 55°C for 5-10 min with repeated mixing
• 10 µl of glassmilk beads (20 µl for the pcDNA3 vector) were added to the PCR products,
vortexed, incubated for 5-10 min at rt, repeatedly vortexed and centrifuged at 12.000 rpm for
20 sec
• the glassmilk bead pellet was washed 3x with 1.5 ml wash buffer; each washing step was
followed by vortexing and centrifugation; the supernatant fluid was removed.
• the pellet was dried for 5-10 min in a speed vacuum
• the pellet was resuspended with 25 µl TE buffer (50 µl for the pcDNA3 vector) and
incubated 5 min at rt
• the vials were centrifuged at 12.000 rpm for 20 sec to pellet the glassmilk beads
• the supernatant was transferred into fresh tubes
• a 1.2% agarose gel containing 1.2 µl EtBr/100ml gel was run with 2 µl of the purified DNA
to check the amount of DNA; the concentration of the vector was estimated to be 200 ng/µl
3.3.2.22 Ligation of mdm2 splice variant DNA into the pcDNA3 expression vector
To ligate the digested PCR products of the mdm2 splice variants, the full length mdm2 cDNA,
and the full length p53 cDNA into the pcDNA3 expression vector, the following reaction was
set up:
• pcDNA3 vector + myc epitope 0.5 µl
• 10x ligase buffer 2 µl
• H2O 6.5 µl
• T4 DNA ligase 1 µl
• mdm2 cDNA template 10 µl
• total 20 µl
• pcDNA3 vector + HA epitope 0.5 µl
• 10x ligase buffer 2  µl
• H2O 6.5 µl
• T4 DNA ligase 1 µl
• p53 cDNA template 10 µl
• total 20 µl
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Negative control I (no cDNA)
• pcDNA3 vector + myc epitope 0.5 µl
• pcDNA3 vector + HA epitope 0.5 µl
• 10x ligase buffer 2  µl
• H2O 16 µl
• T4 DNA ligase 1 µl
• total 20 µl
Negative control II (no cDNA, no ligase)
• pcDNA3 vector + myc epitope 0.5 µl
• pcDNA3 vector + HA epitope 0.5 µl
• 10x ligase buffer 2 µl
• H2O 17 µl
• total 20 µl
The ligation reaction was incubated for 30 min at room temperature.
3.3.2.23 Transformation of pcDNA3/cDNA constructs into electro-competent E. coli bacteria
• 40 µl of electro-competent E. coli bacteria (strain DH 10B) were thawed and pipetted into E.
coli pulser cuvettes 0.1 cm (BIO-RAD)
• electroporation was performed in a BioRad gene pulser at 1.66 kV with a time constant of
4.5-5 msec
• the bacteria were resuspended in 1 ml of LB medium and incubated at 37°C with vigorous
shaking for 30-45 min
• 100 µl of the bacterial suspension were plated on agar plates containing 50 µg/ml ampicillin
and incubated for 16 hours at 37°C
• six colonies per plate were picked and inoculated into 2 ml of LB medium containing 100 µ
g/ml ampicillin
• bacterial cultures were grown for 12-16 hrs at 37°C with vigorous shaking and plasmid DNA
was subsequently prepared by mini-preps as previously described (chapter 3.3.2.15)
3.3.2.24 Restriction enzyme digestion of the pcDNA3 vector containing the cDNA insert
The pcDNA3 plasmid DNA containing the mdm2 respectively p53 insert was digested with
the NcoI restriction enzyme in a reaction containing 2 µl template DNA, 1 µl 10x buffer, 1 µl
10x BSA, 5.8 µl H2O, and 0.2 µl NcoI (10 U/µl) at 37°C overnight. The pcDNA3 vector
contains three NcoI sites at positions 610, 1976 and 2711, which cut the plasmid into three
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Fig. 8b: mdm2 splice variant cDNA after NcoI restriction enzyme digestion of the
pcDNA3 expression vector. The expression vector has three NcoI restriction sites at
positions 610, 1976, and 2711 and the mdm2 cDNA (654 bp) has one NcoI restriction
site at position 533. The cDNA analyzed on the agarose gel shows three fragments of
the vector and two fragments of the cDNA insert, one with additional vector sequence.
All clones (lanes 1-6) contain the mdm2 splice variant cDNA.
The site of the polylinker is between position 889 and 994. The primer designed for the protein
expression contains a NcoI site. Therefore in cases with the expected insert, the plasmid was
cut 301 bases from the first restriction site 610. The mdm2 cDNA contains a NcoI site at
position 1664, which has been spliced out in clones 49, 66, 68, 83, and 84, but not in clone 20.
After restriction enzyme digestion, five bands of the correct size were seen in the mdm2 full
length clone and clone 20, while the other mdm2 clones contained four bands of the correct
size. The primer and the p53 cDNA also contain one NcoI site each, so that the p53 containing
plasmid was cut into five pieces of DNA (Fig. 8b). The plasmid DNA of the clones containing
the correct size inserts were phenol-chloroform extracted as previously described.
3.3.2.25 Transient transfection of Hela-cells with the cDNA containing plasmid
We used a transient cytoplasmic expression system that relies on the synthesis of the
bacteriophage T7 RNA polymerase in the cytoplasm of mammalian cells (Fig. 9) (Panicali and
Paoletti, 1982, Mackett et al. 1982, Moss and Flexner, 1987). The mdm2-cDNA of interest,
respectively the p53-cDNA, had been inserted into the pcDNA3 plasmid such that it came
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Fig. 9: Transient transfection of pcDNA constructs into vaccinia virus infected HeLa
cells.  The cDNA of interest was inserted into the pcDNA3 plasmid such that it came under the
control of the T7 RNA polymerase promoter (pT7). Using liposome-mediated transfection, this
recombinant plasmid is introduced into the cytoplasm of HeLa-cells infected with the vTF7-3
strain, a recombinant vaccinia virus encoding bacteriophage T7 RNA polymerase. During
incubation, the cDNA is transcribed with high efficiency by T7 RNA polymerase. Proteins
were detected by immunoprecipitation and Western blotting.
Using liposome-mediated transfection, this recombinant plasmid is introduced into the
cytoplasm of HeLa-cells infected with the vTF7-3, a recombinant vaccinia virus encoding
bacteriophage T7 RNA polymerase. During incubation, the cDNA is transcribed with high
efficiency by T7 RNA polymerase.
a) Infection of HeLa cells with the Vaccinia Virus vTF7-3
• HeLa cells (kindly provided by Ulf Grawunder PhD) were cultured in RPMI medium
supplemented with 10% fetal calf serum, 50 µM ß-mercaptoethanol, 1x glutamine and 1x
penicillin/streptomycin in a humidified incubator at 37°C, 10% CO2 until 50% confluence
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• cells were washed two times with serum free RPMI medium and after washing, 1 ml of
serum was added to the plates
• Vaccinia-virus of the strain vTF-3 had been cultured on monkey BSC 40 cells, which each
produced approximately 20-50 copies of the virus after infection; by shock freezing and
thawing, the cell membranes had been destroyed and the virus was contained in the
extracellular PBS supernatant; the virus stock was kindly provided by Ulf Grawunder PhD
• HeLa cells were infected with the virus by adding 20µl of the virus containing supernatant to
the RPMI medium and incubating the cells at 37°C for 30 min
b) Transient transfection of HeLa cells
• 1 µg of the plasmid DNA (1-5 µl) is dissolved in 100 µl of RPMI medium
• 20 µl of LipofectAMINE (Gibco BRL Life Technologies) were added to each vial and
incubated for 15 min at rt
• the plasmid-liposome complex was added to the HeLa cells and incubated in serum free
medium for six hours at 37°C
• after 6 hours, 5 ml of full medium were added to the cell culture; the cell culture was grown
overnight and harvested after 16 hours
3.3.3 Biochemical techniques
3.3.3.1 Preparation of cell lysates for SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
• the transfected HeLa cells were harvested in 1 ml medium after 16 hrs by scraping off the
cells from the cell culture plate and centrifugation at 12.000 rpm for 10 sec at room
temperature
• cells were resuspended in 100 µl lysis buffer (1% NP-40, 50 mM Tris/Cl, pH 8.0, 150 mM
NaCl, 0.5% deoxycholat, 0.1% SDS, 1 mM PMSF, 50 mM NaF, 0.02% Leupeptin, 0.02%
Pepstatin A, 0.02% Aprotinin) and were incubated on ice for 30 min
• nuclei were separated from the cytoplasmic lysate by centrifugation at 12.000 rpm, 4°C, 15
min in an Eppendorf Microfuge
3.3.3.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
Cellular proteins either for Western blot analysis or after immunoprecipitation were
electrophoretically fractionated by SDS-PAGE according to Laemmli (Laemmli, 1970).
Therefore,
• two glassplates (10 cm x 8 cm) were cleaned once with H2O, twice with 70% ethanol and
once with absolute ethanol, before the plates were mounted with 1.2 mm spacers
• a separating gel was cast using the appropriate acrylamide concentration to separate proteins
in the molecular-weight range of interest:
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final acrylamide concentration:
10% 12.5% 15% 17.5% 20%
MW-range (kd) 15-180 12-150 12-100 8-80 7-70
30% acrylamide 10 ml 12.5 ml 15ml 17.5 ml 20 ml
1% bis-acrylamide 3.9 ml 3.1 ml 2.6 ml 2.2 ml 2.0 ml
• 7.5 ml 1.5 M Tris/Cl pH 8.0, 150 µl 20% SDS, 10 µl TEMED and H2O to a total volume of
30 ml were added before polymerization was started by addition of 100 µl 10% ammonium-
persulfate
• the gel was cast immediately up to ¾ of the height of the glassplates and the acrylamide-
solution was overlaid with a few ml of H2O in order to prevent air-exposure of the acrylamide
solution
• the gel was allowed to polymerize for at least 1 hour at room temperature
• after polymerization, the H2O covering the gel was removed and the top-gel was prepared by
mixing 1 ml 30% acrylamide, 1 ml 1% bis-acrylamide, 2.5 ml 0.5M Tris/Cl (pH 6.8), 5.35 ml
H2O, 50 µl 20% SDS, 5 µl TEMED and 100 µl 10% ammonium persulfate
• the top gel was cast immediately, a comb was inserted, and the gel was allowed to
polymerize for an additional 2 hours at room temperature
• protein samples were mixed with 100 µl 2x reducing buffer containing




- 1.43 M 2-mercaptoethanol
• the samples were heated to 95°C for 10 min and 40 µl of each were loaded onto the gel
• the gel was subjected to electrophoresis for about 75 minutes at 120 volts using 0.025 M Tris
base, 0.192 M glycin, 0.1% SDS as electrophoresis buffer
3.3.3.3 Western blotting of p53 and MDM2 proteins fractionated by SDS-PAGE
The expression of the MDM2 full length and splice variant proteins and the p53 protein was
analyzed by Western blotting using antibodies directed against the myc- respectively HA-
epitope followed by the use of secondary horseradish peroxidase (HRPO) labelled antibodies,
which were detected by means of an ECL kit (Amersham Life Science, Arlington Heights, Il,
USA).
• after the bromophenol-blue marker had reached the bottom of the gel, fractionated proteins
were electro-blotted to a nitrocellulose membrane using a Bio-Rad Transblot-Cell (Bio-Rad
Laboratories, Hercules, CA, USA)
• the nitrocellulose membrane, 4 Whatman 3MM papers and two foam pads were soaked in
transfer buffer for 20 min
• the gel was laid on top of  2 Whatman 3MM papers, which had been placed on a foam pad
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• the membrane was laid over the gel and covered with 2 Whatman 3MM papers and the
second foam pad
• the assembly, as well as an ice-block for cooling, were put into the Transblot-Cell with the
nitrocellulose membrane oriented to the anode
• transfer was carried out for 1 hour at 15 Watts in a blotting buffer containing
- 0.025 M Tris-base
- 0.192 M glycine
- 20% methanol
• after electro-transfer the membrane was incubated in 100 ml blocking solution containing
PBS buffer, 0.05% Tween-20, 10% nonfat dry milk powder for 2 hours or overnight on a
shaker
• immunodetection of the proteins was performed by incubation of the membranes with anti-
myc mouse monoclonal antibody clone 9E10 (Boehringer Mannheim) in a concentration of 1 
µg/ml, respectively anti HA mouse monoclonal antibody clone 12CA5 (Boehringer
Mannheim) in a concentration of 0.2 µg/ml in 50 ml PBS, 0.05% Tween-20 for 1 hour at room
temperature
• the membranes were washed twice for 1 min and twice for 15 min in PBS, 0.05% Tween-20
at room temperature
• the membranes were then incubated with the polyclonal HRPO-labeled goat-anti-mouse
antibody (Bio-Rad) diluted 1:2000 in 50 ml PBS, 0.05% Tween-20 for one hour at room
temperature
• the membranes were washed twice for 1 min and twice for 15 min in PBS, 0.05% Tween-20
at room temperature
• specific binding of the HRPO-labeled antibodies was detected by incubation of the
membrane in a 1:1 mixture of solution A and B of the ECL-kit for 1 min at room temperature
• chemiluminesence was detected by exposing the membranes to a Biomax MR film for 10 sec
- 1 min at room temperature
3.4 Statistical tests
Statistical analyses were implemented using the SAS software packages. Overall
survival was defined as the time from initial surgery following the diagnosis of ovarian cancer
until death or the date of last follow-up, if the patient was still alive. All causes of death were
counted as failures. Time to progression was defined as the time from initial surgery until
documentation of disease progression. Patients who had not yet progressed were censored at
the date of last follow-up in which the disease status was assessed; no patients died prior to
progressing, unless they died from intercurrent disease. For 29 (16%) of the patients who died
of their ovarian cancer, the date of progression was not documented. For those patients (n=83)
who had progressed and whose date of progression was known, the median time from
progression to death was calculated using the Kaplan-Meier estimator, to estimate the date of
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progression (Kaplan and Meier 1958). This value, 273 days, was subtracted from the survival
time of the patients whose date of recurrence was not documented. In 5 patients this value was
greater than the time from surgery to death and in this situation, the time to progression was
taken as one-half of the interval between surgery and death. In 11 cases, no follow-up
regarding disease status was available; these patients were not included in the analysis of time
to progression but were included in the summary of baseline characteristics.
Medians, quartiles and percentages were used to summarize the patient characteristics
and to illustrate associations. Pearson´s chi-square test for association and the Mantel-Haenszel
test for trend (Mantel and Haenszel, 1959) were used to evaluate the strengths of the observed
associations. Kaplan-Meier plots, relative risks and p-values derived from the partial likelihood
ratio test based on Cox´s proportional hazards model (Cox, 1972) were used to summarize the
relationships; a stepwise forward selection algorithm was used to select a parsimonious subset
of variables to classify patients into better or worse prognosis subsets.
Finally to further explore the association between p53 overexpression and outcome, an
optimal cut-point for p53 nuclear staining was determined by adapting the maximally selected
chi-square methods of Miller and Halpern (Miller and Siegmund 1982, Halpern 1982, Lausen
and Schumacher 1992). To do this, we first applied the score function generated from the
stepwise proportional hazards model to each patient. The logrank test statistic, stratified by the
trichotomized scores, was used to compare overall survival for the two groups of patients
(below or equal to the percentage of p53 staining value vs above the value). The percentage of
p53 positive nuclei which yielded the largest stratified logrank test statistic (the maximal
logrank statistic) was selected as the optimal cutpoint.
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4. RESULTS
4.1 Alterations of the p53 tumor suppressor gene in ovarian cancer
4.1.1 p53 mutations
In a cohort of 178 ovarian carcinomas we found a total of 145 p53 sequence
alterations by PCR-SSCP and direct sequencing (66%) (Table 7). Among the sequence
alterations, 100 p53 mutations were identified in 99 cases, one of which had a
mutation in both exon 7 and exon 8. In addition, four silent mutations without
alteration of the amino acid sequence were identified and were considered
polymorphisms. Forty-five of the sequence alterations were polymorphisms or intron
alterations of undetermined significance.
Table 7: Summary of p53 sequence alterations in 178 ovarian carcinomas
Type of sequence alteration n % cases
Mutations with amino acid alterations in exon 2-11 92 51.1
(in 91 cases, double mutation in case #2341)
Splice site mutations 8 4.5
Polymorphisms in exon 2-11
exon 4, codon 36 1 0.6
exon 4, codon 72 9 5.1
exon 6, codon 213 1 0.6
exon 6, codon 224 1 0.6
exon 7, codon 231 1 0.6
Intron alterations (excluding splice site mutations)
intron 3 polymorphism (16 bp repeat) 24 13.5
intron 6 alteration (nt 13964) 2 1.1
intron 10 alteration (nt 17708) 2 1.1
intron 10 alteration (nt 18550) 4 2.3
Total number of sequence alterations (in 117 cases) 145 65.7
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Fig. 10 A-C: p53 mutation and overexpression
A: Single Strand Conformation Polymorphism (SSCP) analysis of the p53 gene, exon 5 in ovarian carcinomas.
Arrows in lanes 7 and 8 indicate band shifts suspicious for mutations.
B: DNA sequence analysis of exon 5 of the p53 gene in endometrioid ovarian carcinoma #2335.
Missense mutation in codon 141, TGC to TGG (amino acid exchange cystein to tryptophan).
C: Immunostaining shows overexpression of the p53 protein in the tumor nuclei (case #2335).
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Fig. 11 A-C: p53 mutation and overexpressio
A: Single Strand Conformation Polymorphism (SSCP) analysis of p53, exon 9 in ovarian carcinomas. Arrows in
lanes 3 and 10 (case #3402) indicate band shifts suspicious for mutations.
B: DNA sequence analysis of exon 9 of the p53 gene in endometrioid ovarian carcinoma #3402. A deletion
mutation of one basepair in codon 320 causes a frameshift.
C: Immunostaining shows overexpression of the p53 protein in the tumor nuclei (case #2335.)
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Thirteen of the p53 sequence alterations considered polymorphisms were exon
polymorphisms and 32 were intron alterations, some of which are known as
polymorphisms. Nine sequence alterations, which are known as a Codon 72 Arg→Pro
polymorphism, were found in exon 4.
One hundred p53 mutations were identified by PCR-SSCP and direct
sequencing in 99 ovarian cancer patients (56%) (Fig. 10-12, Table 8). 64 of these
alterations have been previously described in a study of 105 ovarian carcinoma
patients (Wen et al. 1999). One ovarian cancer patient had a mutation in exon 7 and
exon 8, both with alteration of the amino acid sequence. The majority of mutations
(86%) was found in exon 5 (22 mutations), exon 6 (12 mutations), exon 7 (26
mutations) and exon 8 (28 mutations) (Fig. 11, Table 8).  However, 14% of the
mutations were found outside codons 126-306 in exon 4 (3 mutations), exon 9 (3
mutations), intron 4 (3 splice junction mutations), intron 5 (1 splice junction mutation),
















Fig. 12: p53 mutations in ovarian cancer. Mutations of the p53 gene were identified
in 99/178 epithelial ovarian carcinomas. The majority of mutations were missense
mutations.
Out of 100 mutations, 72% were missense mutations (Fig. 12), 7% were single
base substitutions which resulted in the introduction of a premature stop codon, 3%
were insertions of one to six basepairs, 10% were deletions of one to seven basepairs
and 8% were splice junction mutations (Table 8). Four „silent„ DNA sequence
alterations, which did not result in an amino acid alteration, were considered
polymorphisms and were located in exon 4 (codon 36), exon 6 (codon 213 and 224),
and exon 7 (codon 231).
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Table 8: p53 mutations and protein overexpression in ovarian carcinomas
Case Histo- SSCP Exon Codon Amino DNA Amino Acid Mutation Im** TS/TV***
# patho- Result # Acids Sequence Sequence Type p53 CpG
logy Cons*
3379 Ser + 4 36 NC CCG to CCA Pro / Pro Polymorph + (TS)
2722 Ser + 4 42 NC GAT to TAT Asp to Tyr Missense + TV
3401 Ser + 4 49, 50 NC GAT ATT to GA..TT frameshift 2 bp Del - -
715 Ser - 4 73 NC GTG to TTG Val to Leu Missense + TV
3391 Endo + 4 nt 12301 Co CGgt to CGga intron 4 5' splice jun - TV
2658 Undiff + 5 nt 13053 Co agTA to ggTA intron 4 3' splice jun + TS
3355 Endo + 5 nt 13053 Co agTA to ggTA intron 4 3' splice jun + TS
1557 Ser + 5 130 Co CTC to GTC Leu to Val Missense + TV
3400 Ser + 5 132 Co AAG to AGG Lys to Arg Missense + TS
1282 Ser + 5 132 Co AAG to ACG Lys to Thr Missense + TV
ov 70 Ser + 5 135 Co TGC to TGG Cys to Trp Missense + TV
3367 Ser + 5 136 Co CAA to TAA Gln to Stop Nonsense - TS
687 Ser + 5 136 Co CAA to TAA Gln to Stop Nonsense - TS
2335 Endo + 5 141 Co TGC to TGG Cys to Trp Missense + TV
2745 Ser + 5 151 NC CCC to CAC Pro to His Missense + TV
3389 Mixed + 5 158 NC CGC to CCC Arg to Pro Missense + TV
824 Mixed + 5 159 NC GCC to GTC Ala to Val Missense + TS;CpG
704 Ser + 5 160 NC ATG to AAG Met to Lys Missense + TV
769 Ser + 5 163 NC TAC to TGC Tyr to Cys Missense + TS
2354 Brenner + 5 163 NC TAC to TGC Tyr to Cys Missense + TS
713 Ser + 5 166 NC TCA to TGA Ser to Stop Nonsense - TV
2650 Undiff + 5 175 Co CGC to CAC Arg to His Missense + TS;CpG
3371 Mixed + 5 175 Co CGC to CAC Arg to His Missense + TS;CpG
762 Ser + 5 175 Co CGC to CAC Arg to His Missense + TS;CpG
1270 Ser + 5 175 Co CGC to CAC Arg to His Missense + TS;CpG
3354 Ser + 5 179 Co CAT to GAT His to Asp Missense + TV
3529 Ser + 5 179 Co CAT to TAT His to Tyr Missense + TS
698 Adenoca + 5 179 Co CAT to CGT His to Arg Missense + TS
2716 Mixed + 5 179 Co CAT to CGT His to Arg Missense + TS
2721 Ser + 5 nt 13240 - TGgt to TGgc intron 5 5'-splice jun - TS
3353 undiff + 6 192 NC CAG to TAG Gln to Stop Nonsense - TS
ov 59 Ser + 6 193 NC CAT to CGT His to Arg Missense + TS
2719 Ser + 6 193-195 NC CATCTTATC to GCCCCT His,Leu,Ile to Ala,
Pro
Del / Ins + -
2309 Undiff + 6 195 NC ATC to AAC Ile to Asn Missense + TV
805 Ser + 6 201 NC TTG to TTT Leu to Phe Missense + TV
2352 Ser + 6 203 NC GTG to TTG Val to Leu Missense + TV
2733 Ser + 6 213 NC CGA to CTA Arg to Leu Missense - TV
2340 Ser + 6 213 NC CGA to CGG Arg / Arg Polymorph - (TS)
2737 Ser - 6 215 NC AGT to GT frameshift 1bp Del/Nonsense - -
2349 Ser + 6 216 NC GTG to TTG Val to Leu Missense + TV
241 Ser - 6 220 NC TAT to TGT Tyr to Cys Missense + TS
808 Clear - 6 224 NC GAG to GAA Glu / Glu Polymorph - (TS)
3373 Ser + 7 nt 13999 - agGT to aaGT intron 6 3' splice jun + TS
ov 49 Ser + 7 227 NC TCT to TCA Asp to Ser Missense + TV
2705 Mixed + 7 231 NC ACC to ACA Thr / Thr Polymorph + (TV)
3379 Ser + 7 234 Co TAC to TCC Tyr to Ser Missense + TV
2344 Clear + 7 234 Co TAC to TGC Tyr to Cys Missense - TS
2717 Ser + 7 234 Co TAC to TGC Tyr to Cys Missense + TS
2656 Endo + 7 237 Co ATG to ATT Met to Ile Missense + TV
3344 Endo + 7 239 / 240 Co AAC to AAC TTA Leu ins 3 bp Ins + -
2659 Endo + 7 242 Co TGC to TAC Cys to Tyr Missense + TS
790 Mixed + 7 242 Co TGC to TTC Cys to Phe Missense + TV
2338 Endo + 7 242 Co TGC to TTC Cys to Phe Missense + TV
2724 Endo + 7 242 Co TGC to AGC Cys to Ser Missense + TV
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2730 Ser + 7 243 Co ATG to GTG Met to Val Missense + TS
665 Ser + 7 244 Co GGC to AGC Gly to Ser Missense + TS
1752 Muc + 7 245 Co GGC to AGC Gly to Ser Missense + TS;CpG
1559 Ser + 7 245 Co GGC to GAC Gly to Asp Missense + TS;CpG
3540 Ser + 7 248 Co CGG to CAG Arg to Glu Missense + TS;CpG
802 Endo + 7 248 Co CGG to TGG Arg to Trp Missense + TS;CpG
249 Ser + 7 248 Co CGG to CAG Arg to Gln Missense + TS;CpG
3403 Undiff + 7 249, 250 Co AGG CCC to AGT TCC Arg,Pro to Ser,Ser Dble-Missense + TV,TS
2364 Ser + 7 251, 252 Co ATC CTC to ATC Leu del 3 bp Del + -
1589 Ser + 7 253 Co ACC to CCC Thr to Pro Missense + TV
2651 Undiff + 7 254 - 256 Co ATC ATC ACA  to A frameshift 7 bp Del - -
2001 Ser + 7 255 Co ATC to AGC Ile to Ser Missense - TV
2337 Endo + 7 258 Co GAA to TAA Glu to Stop Nonsense + TV
2341 Ser + 7 258 Co GAA to TAA Glu to Stop Nonsense - TV
3362 Undiff + 7 259 NC GAC to TAC Asp to Tyr Missense + TV
3347 Ser + 7 nt 14110 - AGgt to AGtt intron 7 5' splice jun - TV
2725 Ser + 8 nt 14449 - tagTG to aagTG intron 7 3' splice jun + TV
767 Ser + 8 264 NC CTA to TA frameshift 1 bp Del + -
696 Ser + 8 264, 265 NC CTA CTG to CTG Leu,Leu to Leu 3 bp Del + -
3364 Muc + 8 266 NC GGA to CGA Gly to Arg Missense + TV
ov45 Ser + 8 266 NC GGA to AGA Gly to Arg Missense + TS
2341 Ser + 8 267 NC CGG to CCG Arg to Pro Missense - TV
2332 Endo + 8 267 NC CGG to CCG Arg to Pro Missense + TV
2708 Mixed - 8 271 Co GAG to TAG Glu to Stop Nonsense - TV
2155 Ser - 8 272 Co GTG to ATG Val to Met Missense + TS
2732 Ser - 8 272 Co GTG to TTG Val to Leu Missense + TV
3346 Ser + 8 273 Co CGT to CAT Arg to His Missense + TS;CpG
3358 Undiff + 8 273 Co CGT to CAT Arg to His Missense + TS;CpG
3382 Endo + 8 273 Co CGT to CTT Arg to Leu Missense + TV
2715 Ser - 8 273 Co CGT to TGT Arg to Cys Missense + TS;CpG
693 Ser + 8 273 Co CGT to TGT Arg to Cys Missense + TS;CpG
700 Ser - 8 273 Co CGT to GGT Arg to Gly Missense + TV
2718 Ser + 8 275 Co TGT to TAT Cys to Tyr Missense + TS
ov 93 Ser + 8 275 Co TGT to GGT Cys to Gly Missense + TV
ov
164
Ser + 8 275 Co TGT to GGT Cys to Gly Missense + TV
2326 Mixed + 8 276 Co GCC to GTC Ala to Val Missense + TS
3385 Endo + 8 280 Co AGA to AGT Arg to Ser Missense + TV
2328 Ser + 8 280 Co AGA to ATA Arg to Ile Missense + TV
1751 Ser + 8 281 Co GAC to GAA Asp to Glu Missense + TV
2182 Endo + 8 281 Co GAC to GAG Asp to Glu Missense - TV
ov 72 Ser + 8 281 Co GAC to CAC Asp to His Missense + TV
3351 Ser + 8 282 Co CGG to TGG Arg to Trp Missense + TS;CpG
1756 Clear + 8 282 Co CGG to TGG Arg to Trp Missense + TS;CpG
1254 Ser + 8 286 Co GAA to GTA Glu to Val Missense + TV
3386 Ser + 8 300 NC CCC to ..CC frameshift 1 bp Del + -
3461 Endo + 8 301 NC CCA to CCC A frameshift 1 bp Ins - -
2339 Ser + 9 nt 14680 - agCA to aaCA intron 8 3' splice jun - TS
1749 Undiff + 9 311 NC AAC to AA.. frameshift 1 bp Del - -
3402 Endo + 9 320 NC AAG to A..G frameshift 1 bp Del + -
3394 Undiff + 9 324 NC GAT to G..T frameshift 1 bp Del + -
* according to Cho et al. 1994
** Im p53: Immunostaining for p53
*** TS / TV: Transition / Transversion
Histopathology: Ser: Serous, Endo: Endometrioid, Undiff: Undifferentiated
Muc: Mucinous, Clear: Clear Cell, Mixed: Mixed Epithelial
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Among the cases with insertions, one had a nine basepair deletion and a six
basepair insertion (case #2719). One case had a 3 bp insertion of TTA resulting in the
insertion of the amino acid residue Leucin between codon 239 and 240 in exon 7
(#3344). A one basepair insertion (case #3461) at codon 301, exon 8 caused a
frameshift with introduction of a premature stop at codon 305.
Eleven cases had deletions of 1-9 bp, four of which (cases # 2719, 2737, 767,
696) have been described previously (Wen et al. 1999). Of the newly identified
deletions, four were 1 bp deletions, one in exon 8 (case # 3386) and three in exon 9
(case # 1749, 3402, 3394), all resulting in the introduction of a premature stop codon
at codon 344. Three of these cases had p53 protein overexpression. One case had a 3
bp deletion in exon 7, resulting in the loss of a leucine residue (case #2364) and one
case had a 2 bp deletion in exon 4, causing the introduction of a stop codon at codon
50 (case #3401). This case was negative in immunohistochemistry. A seven bp
deletion in exon 7 (case #2651), affecting codons 254-256, resulted in a frameshift
affecting the entire sequence between codon 256 and a premature stop at codon 344.
Furthermore, we identified 5 splice junction mutations (cases # 3391, 2658,
3355, 3373, 3347) in addition to three cases described in our previous study (Wen et
al. 1999). Two of these affected the donor site at exon 4/intron 4 and exon 7/intron 7
respectively (Table 8). Both cases were negative for immunohistochemistry. Three
splice site mutations involved the consensus acceptor site at intron 4/exon5 (2 cases)
and intron 6/exon 7. These three cases had p53 protein overexpression (Table 8).
Four regions of the translated sequence of p53 have been highly conserved
throughout evolution and span codon 117-124 (II), 171-181 (III), 234-258 (IV) and
270-286 (V). These regions span a total of 79 codons. In 62% (62/100) of the cases,
mutations were located in these highly conserved regions (Fig. 13). Region II, which
spans part of exon 4 and exon 5, contained 10 mutations including 3 splice site
mutations in intron 4 (10%). Region III contained 8 mutations (8%), region IV 23
mutations (23%) and region V a total of 21 mutations (21%). Thirty-eight percent of
the mutations were found in non-conserved regions of the gene. The codons most
frequently mutated were codons 175, 179, 234, 242, 248, 273, 275 and 281 which were
each mutated in three or more different carcinomas (Fig. 13).
Fig. 13: p53 mutations in evolutionary highly conserved domains of the gene. The
upper part of the figure shows the number of mutations in codons 36 through 324 of
the p53 gene. Mutations in evolutionary highly conserved regions are marked in
yellow, mutations in non-conserved regions in dark blue and splice site mutations in
white. The lower part of the figure shows the corresponding DNA interacting regions
of the p53 protein.
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Fourty-two mutations (42%) were classified as transition mutations, 46 (45%)
as transversions, and 13% were deletions or insertions. We found 29 G:C to A:T
transitions and 13 A:T to G:C transitions. Among the G:C to A:T transitions 16 (55%)
were located in CpG sites, which are known to be potential sites of DNA methylation.
Out of 46 transversions, we found 20 G:C to T:A mutations, 12 G:C to C:G, 8 T:A to
A:T and 6 A:T to G:C mutations.
4.1.2 p53 polymorphisms and intron alterations
A total number of 45 p53 polymorphisms and intron alterations of unknown
significance were found in 33 cases (19%). In 15/33 cases (46%) with polymorphisms
or intron alterations additional p53 mutations with an amino acid exchange had been
identified. This accounted for 15% of the cases with mutations. Only 61/178 ovarian
cancer cases (34%) were found to have a completely normal p53 sequence with neither
mutations nor other sequence alterations in the DNA segments which were analyzed.
The most frequent exon polymorphism was located in exon 4 at codon 72 (Fig.
14), and was found in 9 cases (5.1%). This CGC→CCC polymorphism at codon 72
results in an arginine to proline amino acid exchange (Harris et al. 1986, Matlashewski
et al. 1987). In one case (#3379), an additional CCG to CCA (Pro/Pro) polymorphism
was identified at codon 36 of exon 4 (Table 9 and 10).
A further exon polymorphisms, CGA→CGG (Arg/Arg), was identified in exon
6 at codon 213. Another silent mutation which was considered a polymorphism,
occured at codon 224 of exon 6 as a GAG→GAA (Glu/Glu) polymorphism without
amino acid alteration. In exon 7 an ACC→ACA (Thr/Thr) polymorphism was
identified at codon 231 (Table 9 and 10).
An intron 3 polymorphism (Fig. 15), which is known as a 16 bp repeat (Lazar
et al. 1993) at nucleotide 11951, was found in 24 (14%) of the cases. Six (25%) of the
cases were identified by SSCP as homozygote and 18 (75%) were heterozygote for this
intron 3 alteration. Five cases were sequenced to confirm the polymorphism suspected
by the SSCP alteration.
Eight p53 sequence alterations were identified in intron sequences, flanking the
exons 7, 10 and 11 (Table 9 and 10). In all of these cases, a shift in the SSCP bands
was noticed without evidence of a mutation in the exon sequence. In intron 6 at
position 13964, a g→c base exchange was identified in two cases. No normal tissue
was available in these cases to verify the polymorphism.
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Fig. 14: CGC → CCC (Arg → Pro) polymorphism at codon 72 of the p53 gene
A: SSCP analysis of p53, exon 4 in ovarian carcinomas. DNA in lanes 2,4,5,6,and 8 shows
band shifts suspicious for sequence alterations and was analyzed by DNA sequencing.
B: DNA sequence analysis of p53, exon 4 shows a CGC to CCC poymorphism at codon 72,
resulting in an arginine to proline amino acid exchange.






















Fig. 15: Intron 3 polymorphism of the p53 gene
A: Single Strand Conformation Polymorphism (SSCP) of p53, exon 3 with the adjacent intron
sequence shows a band shift in lanes 2,4,8 and 9 indicating the intron 3 polymorphism.
B: Wild type (lanes 3 and 4) and the polymorphism sequence (lanes 1 and 2) of p53, intron 3
with a 16 bp insertion (lanes 1 and 2) and adjacent sequence are shown as
5’ to 3’: GCTggggacctggagggctGGGGGG
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In intron 10 at position 17708, an a→t base exchange was found in 2 out of five cases
which had shown SSCP alterations in exon 10.  In 4 out of 9 cases which had shown
an obvious band shift in the SSCP analysis for exon 11, a c→t base exchange at
position 18550 was identified.
Multiple polymorphisms were identified in 11/178 (6%) of all ovarian cancer
cases and 11/33 (33%) of the cases with polymorphisms. In case #3379, three
polymorphisms were identified, two in exon 4 (codon 36 and codon 72) and one in
intron 3. The other cases had two polymorphisms. Eight out of nine cases with exon 4
polymorphisms (89%) and 3/6 cases with intron 10 alterations (50%) had an additional
intron 3 polymorphism.
4.1.3 Confirmation of p53 polymorphisms in normal tissue DNA
In cases with exon 4, exon 6 or exon 7 polymorphisms, and in cases with intron
6 or intron 10 alterations, normal tissue of the ovarian cancer patients, which had been
formalin fixed and paraffin embedded at the time of surgery, was sequenced at the
same DNA site (Table 10). Normal tissue was available in 12/20 of these cases.  In
three cases with a codon 72 Arg→Pro polymorphism, the same sequence alteration
was found in normal tissue. In two heterozygote cases, in which the CGC sequence
was stronger than the CCC sequence and in one case with equally strong G and C band
only, the CGC (arginin) sequence was identified in normal tissue. In two cases with a
homozygote CGC→CCC polymorphism in the tumor, only CGC was identified in
normal tissue. In the cases with exon 6, intron 6 and exon 7 polymorphisms no normal
tissue was available
The intron 10 alteration at nucleotide 17708 was confirmed in one case, in
which normal tissue was available. We have identified this alteration in two ovarian
carcinoma cases, which had shown SSCP band shifts. We assume that this is an a→t
polymorphism at nucleotide 17708, which has not been described so far. Furthermore,
the intron 10 c→t sequence alteration at nucleotide 18550 was found in four ovarian
carcinoma cases and could be confirmed in all three cases, in which normal tissue had
been analyzed (Table 10). We therefore consider these intron alterations as two novel
intron 10 polymorphisms.
4.1.4 p53 protein overexpression
p53 protein overexpression, using a cut-point of  ≥10% positively stained
nuclei, was found in 62% (110/178) of the cases. The cut-off for p53 overexpression
was chosen as 10%, because we found frozen sections from proliferating normal
84












Fig. 16: Intron 10 polymorphism of the p53 gene
at nucleotide 17708
A novel polymorphism of  the p53 gene was identified
at nucleotide 17708 (a>t) of intron 10 by SSCP analysi














A C G T A C G T A C G T A C G T1   2   3   4   5   6   7   8   9  10 11 12
Fig. 17: Intron 10 polymorphism of the p53 gene at nucleotide 18550
A: SSCP analysis of p53 exon 11 and flanking intron sequence in ovarian carcinomas.
The band shift in lane 5 (case #3394) is suspicious for DNA sequence alterations.
B: DNA sequence analysis of p53 exon 11/ intron 10 reveals a novel c>t polymorphism
at nucleotide 18550 of intron 10 in the ovarian cancer cases #2660 and #3344.
The polymorphism was confirmed in normal tissue DNA.
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Table 9: p53 polymorphisms and overexpression in ovarian carcinomas
Case # Histo- SSCP p53 Exon/ Codon/ DNA Amino Acid Polymor- Immuno-
patho- Result Mut Intron Nucleotide Sequence Sequence phism Type staining
logy # p53
1749 Undiff + + Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat -
1751* Ser + + Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat +
1754 Ser + - Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat -
2341 Ser + + Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat -
2353 Ser + - Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat -
2364 Ser + + Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat +
2653* Undiff + - Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat +
2660* Ser + - Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat +
3348 Endo + - Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat -
3350* Ser + - Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat -
3351 Ser + + Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat +
3355 Endo + + Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat +
3357 Endo + - Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat -
3359 Endo + - Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat +
3362 Undiff + + Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat +
3365 Endo + - Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat +
3370* Muc + - Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat -
3376* Ser + - Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat -
3377* Ser + - Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat -
3379* Ser + + Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat +
3381* Endo + - Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat -
3385* Endo + + Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat +
3402* Endo + + Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat +
3403 Undiff + + Intron 3 nt 11951 gggtcgggaggtccag - 16 bp repeat +
3379* Ser + + Exon 4 36 CCG to CCA Pro / Pro known PM +
1751* Ser + + Exon 4 72 CGC to CCC Arg to Pro known PM +
3350* Ser + - Exon 4 72 CGC to CCC Arg to Pro known PM -
3354 Ser + + Exon 4 72 CGC to CCC Arg to Pro known PM +
3370* Muc + - Exon 4 72 CGC to CCC Arg to Pro known PM -
3376* Ser + - Exon 4 72 CGC to CCC Arg to Pro known PM -
3377* Ser + - Exon 4 72 CGC to CCC Arg to Pro known PM -
3379* Ser + + Exon 4 72 CGC to CCC Arg to Pro known PM +
3381* Endo + - Exon 4 72 CGC to CCC Arg to Pro known PM -
3385* Endo + + Exon 4 72 CGC to CCC Arg to Pro known PM +
2340 Ser + - Exon 6 213 CGA to CGG Arg / Arg known PM -
808 Clear - - Exon 6 224 GAG to GAA Glu / Glu possible PM -
3529 Ser + + Intron 6 nt 13964 gcgca to gccca - possible PM +
3390 Ser + - Intron 6 nt 13964 gcgca to gccca - possible PM -
2705 Mixed + - Exon 7 231 ACC to ACA Thr / Thr possible PM +
2653* Undiff + - Intron 10 nt 17708 ctact to cttct - possible PM +
3402* Endo + + Intron 10 nt 17708 ctact to cttct - possible PM +
2660* Ser + - Intron 10 nt 18550 ccctc to ccttc - possible PM +
3344 Endo + + Intron 10 nt 18550 ccctc to ccttc - possible PM +
3394 Undiff + + Intron 10 nt 18550 ccctc to ccttc - possible PM +
3464 Ser + - Intron 10 nt 18550 ccctc to ccttc - possible PM +
* multiple p53 polymorphisms
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Table 10: Normal tissue sequencing results for p53 polymorphisms
Case # Exon/ Codon/ Tumor Tumor Nl tissue Nl tissue Immuno-
Intron Nucleotide DNA Amino Acid DNA Amino
Acid
staining
# Sequence Sequence Sequence Sequence p53
3379 Exon 4 36 CCG to CCA Pro / Pro not available - +
1751 Exon 4 72 CGC to CCC Arg to Pro CGC Arg +
3350 Exon 4 72 CGC to CCC Arg to Pro CCC Pro -
3354 Exon 4 72 CGC to CCC Arg to Pro CGC Arg +
3370 Exon 4 72 CGC >> CCC* Arg >> Pro CGC Arg -
3376 Exon 4 72 CGC to CCC Arg to Pro not available - -
3377 Exon 4 72 CGC to CCC Arg to Pro CCC Pro -
3379 Exon 4 72 CGC / CCC Arg / Pro CGC Arg +
3381 Exon 4 72 CGC >> CCC Arg >> Pro CGC Arg -
3385 Exon 4 72 CGC to CCC Arg to Pro CCC Pro +
2340 Exon 6 213 CGA to CGG Arg / Arg not available - -
808 Exon 6 224 GAG to GAA Glu / Glu not available - -
3529 Intron 6 nt 13964 gcgca to gccca - not available - +
3390 Intron 6 nt 13964 gcgca to gccca - not available - -
2705 Exon 7 231 ACC to ACA Thr / Thr not available - +
2653 Intron 10 nt 17708 ctact to cttct - ctact to cttct - +
3402 Intron 10 nt 17708 ctact to cttct - not available - +
2660 Intron 10 nt 18550 ccctc to ccttc - ccctc to ccttc - +
3344 Intron 10 nt 18550 ccctc to ccttc - not available - +
3394 Intron 10 nt 18550 ccctc to ccttc - ccctc to ccttc - +
3464 Intron 10 nt 18550 ccctc to ccttc - ccctc to ccttc - +
* base G stronger than C
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tissues to show a small proportion of cells with p53 immunostaining, usually not more
than a few percent. This cut-off value of 10% had shown the best sensitivity and
specificity for p53 mutations in our previous study (Wen et al. 1999). 22 (12%) cases
had immunostaining <10% and 46 (26%) cases had no immunostaining of tumor cell
nuclei and, together were considered to have normal p53 expression. None of the
ovarian carcinomas had specific cytoplasmic staining. p53 immunostaining was not
observed in the benign tissue of ovarian carcinomas including fibrous connective
tissue, blood vessels and inflammatory cells. Seventy-five out of 178 (42%) cases were
found to have high overexpression with a percentage of positively stained nuclei of
more than 78%. This cut-point had been determined to be optimal as a predictor of
clinical outcome in the statistical analysis of survival.
4.1.5 Comparison of p53 overexpression with p53 mutations
p53 overexpression detected by immunohistochemical staining was signifi-
cantly correlated with p53 mutations (p<0.001) detected by DNA sequence analysis.
The percentage of cases with overexpression was 81% in ovarian carcinomas with p53
mutation and 38% in cases with wildtype p53. The percentage of cases with p53
immunostaining varied according to the type of mutation. The correlation between
protein overexpression and mutations was mainly due to the high proportion of
missense mutations. 67 out of 71 (94%) of the cases with missense mutations showed
p53 overexpression, while immunostaining ≥10% was only seen in 1/7 (14%) of the
cases with nonsense mutations, 8/13 (62%) of the cases with insertions or deletions
and 4/8 (50%) of the cases with splice site mutations (Fig. 18 a,b).
Overall only 46% (13/28) of the ovarian carcinomas with nonmissense
mutations had p53 overexpression, which is not significantly different from the
frequency of overexpression in 30/79 tumors with wildtype p53 sequence (38%)
(p=0.43). Nineteen percent (19/99) of the cases with p53 mutations failed to show
immunostaining, which is largely caused by nonmissense mutations.
4.1.6 p53 polymorphisms and p53 protein overexpression
Ovarian cancer cases with normal p53 expression respectively p53
overexpression were distributed approximately equally among cases with exon 4
polymorphism (p=0.27) and intron 3 polymorphisms (p=0.41) (Table 11).
Interestingly, though, out of eight cases with intron 6 or intron  10 sequence
alterations, seven cases had p53 overexpression which is close to reaching statistical
significance (p=0.086) (Table 11).
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p<0.001
Fig. 18a: p53 protein overexpression according to type of p53 mutation.
Overexpression is found in a high percentage of cases with missense mutations,
while the frequency of overexpression in nonmissense mutations is overall only 46%.













Fig. 18b: p53 protein overexpression according to p53 mutation or wildtype p53.
A high proportion of cases (38%) shows p53 protein accumulation (immunostaining in
≥10% of the nuclei) despite p53 wildtype sequence.
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Table 11: p53 protein overexpression in ovarian cancer cases with p53
polymorphisms










Exon 4 Codon 72
Polymorphism CGC Arg →CCC Pro 4 (44) 5(56) 9 (5)
Normal Sequence CGC Arg 106 (63) 63 (37) 169 (95) 0.27
Intron 3
16 bp repeat Polymorphism 14 (54) 12 (46) 26 (15)
Normal Intron 3 Sequence 96 (63) 56 (37) 152 (85) 0.37
Intron 6 / Intron 10
Polymorphism 8 (89) 1 (11) 9 (5)
Normal Sequence 102 (60) 67 (40) 169 (95) 0.086
Total 110 (62) 68 (38) 178 (100)
4.1.7 Correlation of p53 alterations with histopathological and clinical data
p53 mutations were significantly more frequent in ovarian carcinomas with
advanced FIGO stages III and IV (p<0.001), poor differentiation (p<0.001), residual
tumor burden after debulking surgery (p<0.04), DNA-aneuploidy (p=0.003) and high
S-phase-fraction as measured by image cytometry (p<0.001). Patients with p53
mutations also had a higher median age than patients with p53 wildtype (p=0.041).
Overexpression of the p53 protein was correlated only with low grade of
differentiation (p<0.001) and high S-phase-fraction (p<0.001) (Table 12).
4.1.8 p53 alterations and response to chemotherapy
Patients with p53 overexpressing tumors were significantly more often resistant
or refractory to a platinum based chemotherapy (61%) than patients with non-
overexpressing tumors (22%) (p=0.001) (Table 13, Fig. 19 A-D).
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Table 12. Clinico-pathologic characteristics of patients with epithelial ovarian cancer
p53 Mutation Analysis p53 Protein Expression p53 Alterations
Characteristic p53 p53 P Overex- normal P p53 normal P
Mutation Wildtype value* pression Expression value* Alteration p53 value*
Patients - no. (%) 99 (56) 79 (44) 110 (62) 68 (38) 132 (74) 46 (26)
Median age - yrs 57 53 0.041** 57 52 0.06** 57 52 0.056**
Histological Subtype - no. (%)
Serous 60 (61) 51 (65) 0.08 67 (61) 44 (65) 0.62 79 (60) 32 (70) 0.4
Mucinous 2 (2) 6 (8) 4 (4) 4 (6) 4 (3) 4 (9)
Endometriod 18 (18) 12 (15) 20 (18) 10 (15) 24 (18) 6 (13)
Clear Cell 1 (1) 5 (6) 2 (2) 4 (6) 4 (3) 2 (4)
Brenner 1 (1) 0 1 (1) 0 1 (1) 0
Undifferentiated 8 (8) 2 (3) 7 (6) 3 (4) 9 (7) 1 (2)
Mixed Epithelial 7 (7) 3 (4) 7 (6) 3 (4) 9 (7) 1 (2)
Unclassified 2 (2) 0 2 (2) 0 2 (2) 0
Clinical stage - no. (%)
FIGO I 11 (11) 25 (32) 0.001 18 (17) 18 (28) 0.11 21 (16) 15 (34) 0.005
FIGO II 3 (3) 5 (7) 4 (4) 4 (6) 5 (4) 2 (7)
FIGO III 67 (70) 39 (51) 72 (67) 34 (52) 83 (64) 23 (52)
FIGO IV 15 (16) 8 (10) 14 (13) 9 (14) 20 (16) 3 (7)
Grade of Differentiation - no. (%)
I (well) 7 (7) 21 (27) < 0.001 8 (7) 20 (29) < 0.001 11 (8) 17 (37) < 0.001
II (moderate) 25 (25) 27 (34) 32 (29) 20 (29) 36 (27) 16 (35)
III (poor) 67 (68) 31 (39) 70 (64) 28 (41) 85 (64) 13 (28)
Residual Tumor - no. (%)
No residual tumor 32 (39) 39 (56) 0.04 36 (40) 35 (56) 0.062 46 (41) 25 (60) 0.044
< 2 cm 29 (35) 19 (27) 32 (35) 16 (26) 37 (33) 11 (26)
> 2 cm 22 (27) 12 (17) 23 (25) 11 (18) 28 (25) 6 (14)
Lymph nodes - no. (%)
Negative 9 (11) 15 (22) 0.2 13 (15) 11 (17) 0.5 16 (15) 8 (19) 0.24
Positive 20 (25) 17 (25) 20 (24) 17 (27) 24 (23) 13 (30)
Not resected 50 (63) 37 (54) 52 (61) 35 (56) 65 (62) 22 (51)
DNA-ploidy - no. (%) (n=102)
Diploid 21 (39) 33 (69) 0.003 28 (48) 26 (59) 0.28 31 (44) 23 (74) 0.004
Aneuploid 33 (61) 15 (31) 30 (52) 18 (41) 40 (56) 8 (26)
S-Phase-Fraction - no. (%)
(n=102)
low ( < 5%) 4 (7) 22 (46) < 0.001 6 (10) 20 (45) < 0.001 9 (13) 17 (55) < 0.001
intermediate ( 5% - 14.4%) 26 (48) 21 (44) 29 (50) 18 (41) 35 (49) 12 (39)
high ( > 14.5%) 24 (44) 5 (10) 23 (40) 6 (14) 27 (38) 2 (6)
Treatment - no. (%)   ***
Cisplatin - Cyclophosphamide 27 (32) 27 (39) 0.43 34 (37) 20 (33) 0.55 39 (35) 15 (38) 0.98
Carboplatin -
Cyclophosphamide
13 (16) 7 (10) 13 (14) 7 (12) 15 (14) 5 (13)
Other regimens 25 (31) 16 (23) 26 (29) 15 (25) 31 (28) 10 (25)
No chemotherapy 17 (21) 19 (28) 18 (20) 18 (30) 26 (23) 10 (25)
No information - no. 17 10 19 8 21 6
* Chi-Square test for two categories, Mantel-Haenszel test for three or more categories
** Wilcoxon test
*** Chemotherapy regimens are described in the methods section
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Among patients with p53 mutations, 56% (22/39) as opposed to only 35%
(12/34) of the patients with wildtype p53 were resistant or refractory to platinum based
chemotherapy, but the result did not achieve statistical significance (p=0.071).
However the response to chemotherapy was correlated with the type of mutation. If
only patients with missense mutations were evaluated, only 10/29 (34%) were
platinum sensitive as compared to 29/44 (66%) of patients with p53 wildtype or
nonmissense mutations (p=0.008) (Table 13). Overall, time to progression since
chemotherapy was significantly shorter for patients with p53 alterations than patients
with normal p53 (p=0.037) (Fig. 19).
Table 13: Response to platinum-based chemotherapy in correlation to p53
alterations
















Sensitive 21 (78) 18 (39) 22 (65) 17 (44) 29 (66) 10 (34)
Resistant / Refractory 6 (22) 28 (61) 12 (35) 22 (56) 15 (34) 19 (66)
p-value 0.001 0.071 0.008
Total (100%) 27 46 34 39 44 29
Interestingly, out of 5 patients in our study who were treated with
Taxol/Carboplatin, the only patient (case #3400) who was sensitive to treatment and
had no evidence of disease 28 months after diagnosis of a poorly differentiated FIGO
III ovarian carcinoma, had high overexpression of p53 protein and a missense mutation
in exon 5.
4.1.9 p53 alterations as a predictor of time to progression and overall survival
Ovarian cancer patients with p53 mutations had a significantly shorter time to
progression (p=0.029) and overall survival (p=0.014) than patients with wildtype p53
(Fig. 20A, Table 14, 15). In 61/99 (62%) tumors, the p53 mutation was in an
evolutionary highly conserved domain. If the clinical outcome of these was
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Fig. 19 A-B: Estimated probability of not progressing in epithelial ovarian cancer
patients (n=74), who received platinum-based chemotherapy. (A) Ovarian
carcinomas with p53 mutations versus wildtype p53. (B) Ovarian carcinomas with p53
proteinoverexpression versus normal p53 expression.
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Fig. 19 C-D:: Estimated probability of (C) not progressing, and (D) overall
survival respectively in epithelial ovarian cancer patients (n=74), who received
platinum-based chemotherapy. Ovarian cancer with p53 alterations (mutation or
overexpression or both) versus normal p53 status.
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compared to patients with either wild-type p53 or a mutation in a nonconserved
domain, the difference in time to progression (p=0.010) and overall survival was even
more significant (p=0.007) (Fig. 20B). Similar results were seen for p53 mutations in
DNA interacting regions (Fig. 20C). Furthermore, time to progression and overall
survival were better in patients with normal p53 expression as opposed to p53
overexpression, but the results did not reach statistical significance (p=0.071, p=0.056
logrank) (Fig. 20D, Table 14, 15). In ovarian cancer cases with high p53
overexpression (>78%) though, time to progression and overall survival were
significantly shorter than in cases with low overexpression or normal p53 expression
(p=0.043, p=0.020 logrank). Overall, the most favourable prognosis in terms of overall
survival was seen in patients who had wildtype p53 sequence and normal p53
expression as opposed to those, who had either one or both alterations of the p53 gene
and p53 protein expression (p=0.007) (Fig. 20E,F).
4.1.10 Univariate and multivariable analysis of prognostic factors
Univariate analysis of time to progression identified p53 mutations, p53
alterations, residual disease, FIGO stage, histologic grade, age, lymph node status, and
S-phase-fraction as prognostic factors. Multivariable analysis of time to progression
identified only FIGO stage (p=0.001), residual disease (p=0.005) and age (p=0.032) as
independent prognostic factors (Table 14).
Univariate analysis of overall survival identified residual disease, FIGO stage,
age, grade, lymph node status and S-phase-fraction as prognostic factors besides p53
mutation and p53 alteration (Table 15). In multivariable analysis though, only residual
disease (p<0.001), FIGO stage (p=0.001), grade (p=0.009), and patient age (p=0.01)
were shown to be independent predictors of survival (Table 15).
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Fig. 20 A-B: Estimated probability of overall survival in patients with epithelial
ovarian cancer (n=178) according to p53 alterations. (A) p53 mutations versus
wildtype p53. (B) p53 mutations in evolutionary highly conserved domains versus
wildtype p53 or mutations in non-conserved domains.
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Fig. 20 C-D: Estimated probability of overall survival in epithelial ovarian
patients  (n=178) according to p53 alterations. (C) p53 mutations in DNA-
interacting regions versus wildtype p53 or mutations in scaffolding regions of the p53
protein. (D) p53 protein overexpression versus normal expression of the p53 protein.
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Fig. 20 E-F: Estimated probability of (E) not progressing, and (F) overall survival
respectively in epithelial ovarian cancer patients (n=178). Ovarian cancer with p53
alterations (p53 mutation or p53 overexpression or both) versus normal p53 status.
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Table 14: Multivariable proportional hazards Cox regression analysis for the identification of independent prognostic factors in time to
progression of patients with ovarian carcinoma.
Variables Univariate Analysis Multivariable Analysis
Variables in the Unadjusted Adjusted
Baseline Model * Relative Risk (95% CI) p-value[1] Relative Risk (95%CI) p-value[2]
FIGO < 0.001 0,001
I + II 1,00 1,00
III + IV 6,08 (3.16, 11.71) 3,76 (1.70, 8.32)
Residual Disease < 0.001 0,005
None 1,00 1,00
Any 3,89 (2.50, 6.06) 1,98 (1.19, 3.27)
Histologic Grade < 0.001 0,44
Well Differentiated 1,00 1,00
Moderately 1,95 (0.99, 3.85) 1,23 (0.54, 2.81)
Poorly 3,00 (1.58, 5.68) 1,52 (0.70, 3.34)
The p53 Variables Unadjusted Adjusted
Relative Risk (95% CI) p-value[1] Relative Risk (95%CI) p-value[2]
Immunostaining 0,071 0,67
No 1,00 1,00
Yes 1,42 (0.96, 2.08) 1,10 (0.71, 1.69)
Mutation 0,029 0,82
No 1,00 1,00
Yes 1,51 (1.04, 2.20) 0,95 (0.62, 1.47)
Alteration 0,030 0,59
No 1,00 1,00
Yes 1,59 (1.03, 2.47) 1,15 (0.70, 1.90)
Conserved Regions 0,010 0,47
Non Conserved/ WT p53 1,00 1,00
Cons. Region II, III, IV, V 1,66 (1.14, 2.42) 1,17 (0.77, 1.79)
% p53 IM (continuous) 0,13 0,40
0 1,00 1,00
10 1,03 (0.99, 1.08) 0,98 (0.93, 1.03)
20 1,07 (0.98, 1.16) 0,96 (0.87, 1.05)
50 1,18 (0.95, 1.46) 0,90 (0.71, 1.14)
Other Variables Unadjusted Adjusted
of Interest Relative Risk (95% CI) p-value[1] Relative Risk (95%CI) p-value[2]
Age [0] 0,019 0,032
50 1,00 1,00
60 1,19 (1.03, 1.38) 1,21 (1.02, 1.44)
70 1,42 (1.06, 1.90) 1,46 (1.04, 2.06)
Metastasis 0,057 0,63
None 1,00 1,00
Any 1,82 (1.02, 3.23) 1,16 (0.63, 2.15)
Lymph Node Status < 0.001 0,31
Free of Tumor 1,00 1,00
Infiltrated 4,84 (2.00, 11.73) 1,91 (0.76, 4.76)
Not Resected 3,57 (1.54, 8.29) 1,84 (0.76, 4.44)
Histology 0,18 0,37
Serous 1,00 1,00
Other 0,76 (0.51, 1.14) 1,23 (0.78, 1.95)
S-Phase 0,006 0,54
0.0 - 4.9% 1,00 1,00
5.0 - 14.4% 1,76 (0.83, 3.77) 1,44 (0.54, 3.84)
14.5% + 3,29 (1.51, 7.18) 1,79 (0.61, 5.25)
Ploidy 1,00 0,45
Diploid 1,00 1,00
Tetraploid / Aneuploid 1,00 (0.60, 1.68) 0,79 (0.43, 1.46)
* Based on a previous analysis, FIGO, residual disease, and histologic grade were selected for the baseline model
[0] Age, in years, fit as a continuous variable.
[1] P-values based on the likelihood ratio of the univariate model with no other variables.
[2] P-values based on the likelihood ratio with the variables included in the baseline model:
FIGO, residual disease, and histologic grade.
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Table 15: Multivariable proportional hazards Cox regression analysis for the identification of independent prognostic factors in overall
survival of patients with ovarian carcinoma.
Variables Univariate Analysis Multivariable Analysis
Variables in the Unadjusted Adjusted
Baseline Model * Relative Risk (95% CI) p-value[1] Relative Risk (95%CI) p-value[2]
FIGO < 0.001 0,002
I + II 1,00 1,00
III + IV 6,98 (3.51, 13.87) 3,59 (1.49, 8.66)
Residual Disease < 0.001 < 0.001
None 1,00 1,00
Any 4,77 (3.00, 7.58) 2,44 (1.46, 4.09)
Histologic Grade < 0.001 0.009
Well Differentiated 1,00 1,00
Moderately 3,99 (1.67, 9.50) 3,26 (1.13, 9.43)
Poorly 5,95 (2.58, 13.71) 3,87 (1.37, 10.88)
The p53 Variables Unadjusted Adjusted
Relative Risk (95% CI) p-value[1] Relative Risk (95%CI) p-value[2]
Immunostaining 0.056 0.73
No 1,00 1,00
Yes 1,45 (0.98, 2.14) 1,08 (0.70, 1.67)
Mutation 0.014 0.49
No 1,00 1,00
Yes 1,59 (1.09, 2.33) 0,86 (0.55, 1.33)
Alteration 0.005 0.47
No 1,00 1,00
Yes 1,88 (1.18, 3.00) 1,21 (0.72, 2.05)
Conserved Regions 0.007 0.8
Non Conserved / WT 1,00 1,00
Cons. Regions II,III,IV,V 1,70 (1.17, 2.47) 1,06 (0.69, 1.61)
Im p53 (continuous) 0.056 0.64
0 1,00 1,00
10 1,04 (1.00, 1.09) 0,99 (0.94, 1.04)
20 1,09 (1.00, 1.19) 0,98 (0.89, 1.07)
50 1,23 (0.99, 1.53) 0,95 (0.75, 1.20)
Other Variables Unadjusted Adjusted
of Interest Relative Risk (95% CI) p-value[1] Relative Risk (95%CI) p-value[2]
Age [0] 0.003 0.005
50 1,00 1,00
60 1,26 (1.08, 1.46) 1,29 (1.08, 1.55)
70 1,58 (1.17, 2.14) 1,67 (1.17, 2.40)
Metastasis 0.062 0.6
None 1,00 1,00
Any 1,77 (1.01, 3.10) 1,18 (0.64, 2.17)
Lymph Node Status 0,001 0,54
Negative 1,00 1,00
Positive 4,20 (1.82, 9.68) 1,54 (0.64, 3.71)
Not Resected 3,13 (1.42, 6.87) 1,26 (0.54, 2.94)
Histology 0.021 0.9
Serous 1,00 1,00
Other 0,78 (0.52, 1.16) 1,03 (0.65, 1.64)
S-Phase-Fraction 0.001 0.72
0.0 - 4.9% 1,00 1,00
5.0 - 14.4% 2,75 (1.13, 6.68) 1,47 (0.43, 5.07)
14.5% + 4,88 (1.95, 12.17) 1,68 (0.46, 6.19)
DNA-Ploidy 0.24 0.37
Diploid 1,00 1,00
Tetraploid / Aneuploid 1,38 (0.80, 2.37) 1,33 (0.71, 2.51)
* Based on a previous analysis, FIGO, residual disease, and histologic grade were selected for the baseline model
[0] Age, in years, fit as a continuous variable.
[1] P-values based on the likelihood ratio of the univariate model with no other variables.
[2] P-values based on the likelihood ratio with the variables included in the baseline model:
FIGO, residual disease, and histologic grade.
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4.2 Alterations of the mdm2 gene in ovarian cancer
4.2.1 Expression and absence of amplification of mdm2 in ovarian carcinomas
Fifty-six ovarian cancer cases were analyzed by Southern hybridization for
mdm2 DNA-amplification. The osteosarcoma cell line SA1 which is known to have
amplification and overexpression of mdm2 was used as a control (Fig. 21). Fifty-two
ovarian cancer cases did not show amplification of the mdm2 gene, independently of
p53 mutations and/or overexpression. In four cases, the result could not be interpreted.
All cases had been previously sequenced and analyzed for p53 protein overexpression.
In 21 of these cases, p53 wildtype had previously been found. Thirteen of these 21
cases showed p53 overexpression despite the wild type sequence. In 30 cases, p53 was
mutated, 26 of which also showed protein overexpression.





Fig. 21: Southern hybridization of genomic DNA with the mdm2 cDNA probe. The
sarcoma cell line SA1 which was used as a positive control shows amplification of
mdm2 DNA, while none of the ovarian cancer tissues shows DNA amplification.
mdm2-expression was also analyzed by Northern hybridization in 29 ovarian
cancer cases (Fig. 22). Only the sarcoma cell line SA1 but none of the ovarian cancer
cases showed overexpression of the mdm2 gene. In the sarcoma cell line as well as all
ovarian cancers, three different mRNA transcripts of 7.4 kb, 5.5 kb and 2.8 kb were
seen.  Ten ovarian cancer cases had previously been shown to have wildtype p53, of
which six overexpressed p53 as detected by immunohistochemistry. The remaining 19
cases had been identified to have a p53 mutation, 16 of which also showed protein
overexpression.
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Fig. 22: Northern hybridization of total mRNA with the mdm2 cDNA probe. The
sarcoma cell line SA1 which was used as a positive control shows overexpression of
mdm2 RNA, while none of the ovarian cancer tissues shows mdm2 overexpression.
4.2.2 mdm2 alternative and aberrant RNA splicing in ovarian carcinomas
PCR analysis of the reverse transcribed mRNA revealed the presence of the ex-
pected full length (1473) bp product of mdm2 as well as other, smaller products (Fig.
23). Among 92 cases analyzed, 76 (83%) had a full length 1473 bp RT-PCR product,
in some cases only weakly expressed. Only 18 cases (20%) had exclusive expression
of the normal mdm2 full length cDNA, while 58 cases (63%) had both the 1473 bp
product and smaller RT-PCR products (Table 16). Eight cases (9%) showed no mdm2
expression despite repeated RT-PCR analysis.
Amplification of the human β2-Microglobulin gene, a member of the
immunoglobulin gene superfamily, which is represented on the surface of nearly all
cells (Güssow et al. 1987), was used as a control for integrity and equal amounts of
RNA respectively cDNA. PCR analysis of the β2-Microglobulin showed strong
expression in all normal ovarian tissues and all ovarian carcinomas (Fig. 24).
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Fig. 23: mdm2 RNA splice variants in ovarian carcinomas. Total RNA was
ana-lyzed by RT-PCR, and PCR-products were separated on a 1.2% agarose gel. Cases
in lanes 1,2,6,7,9, and 10 show splice variants of different sizes. The case in lane 3
shows no mdm2 expression. (cDNA bands on the gel contain additional 53 bp of
flanking primer sequence)
Table 16: mdm2 RNA splicing in ovarian cancer as analyzed by reverse
transcriptase PCR and DNA Sequencing
RT-PCR result in ovarian carcinomas n (%) n (%)
normal mdm2 only 18 (20)
normal mdm2 and splice variants 58 (63)
normal mdm2 / mdm2-b 26 (28)
normal mdm2 / mdm2-b / mdm2 221 1 (1)
normal mdm2 / mdm2 221 8 (9)
normal mdm2 / other splice variants 23 (25)
splice variants only / no normal mdm2 8 (9)
mdm2-b only 3 (3)
other splice variants only 5 (5)




































Fig. 24: A-B: RT-PCR for ß2 microglobulin as a positive control for quality and
amount of RNA. (A) RNA was extracted from normal ovarian tissue. All cases show
equal amplification of a 898 bp ß2M PCR product. Lane 21 shows the PCR product of
cDNA from the SA1 sarcoma cell line. Lane 22 is the negative control. (B) RT-PCR
for ß2 microglobulin expression in ovarian cancer RNA. Except for case #2341 in lane
7 all cases show approximately equal expression of the ß2 microglobulin RNA.
Out of those cases which showed an approximately 700 bp band on the agarose
gel, six ovarian cancer cases, one borderline tumor, and one normal ovarian tissue
were sequenced and the 654 bp splice variant was confirmed. The typical
approximately 290 bp band on the agarose gel was confirmed as the 221bp splice
variant in 8 ovarian carcinomas, four tumors of borderline malignancy, one
cystadenoma, and four normal ovarian tissues.
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The mdm2 splice variant which we found most frequently was a 654 base
mdm2 cDNA. We found this splice variant in 38 (41%) ovarian cancer cases. It
comprises 654 bp of the open reading frame and splices out exon 4-11 (Fig. 23, Table
17). The 654 bases fragment misses a large portion of the mRNA, including 90% (81
of 90 amino acids) of the 3’ end of the p53 binding domain, and the entirety of the
nuclear localization signal and acidic domain (Fig. 25). This splice variant had been
named mdm2-b by Sigalas et al. (1996) and was described as a 707 bp product, since
he included the primer sequence which is outside the open reading frame of mdm2 into
the numbering (Sigalas et al. 1996). We named the fragment 654 bp, because we
counted only those bases between the start and the stop codon, but not the primers.
Another splice variant, which has been named mdm2-a (Sigalas et al. 1996)
splices out exon 4 through 9 and spans 888 basepairs of the open reading frame (Fig.
25, Table 17). This variant was seen in 4 cases (4 %). In both of these variants splicing
takes place at the exon/intron boundary and the truncated RNA is in frame.
In contrast to this in a small splice variant of 221 bp, which was seen in 15
cases (16%), splicing did not take place at the exon/intron boundary. We identified
three variations of this splice variant (Table 17).
We identified a total of 30 different splice variants. Fourteen of these (47%)
were only seen in ovarian carcinomas, while seven were identified both in ovarian
cancer and other histologies. Seven were seen only in borderline tumors or
cystadenomas, and two splice variants were found exclusively in normal ovarian
tissue.  Most of these splice variants should be classified as aberrant splicing because
they splice out parts of exon sequences (Table 17).
In only three splice variants of 888 bp (mdm2-a), 654 bp (mdm2-b) and 613 bp,
donor and acceptor splice site were found at exon-intron boundaries. The mdm2-a
splice variant splices out exon 4 through exon 9 and the mdm2-b splice variant splices
out exon 4 through exon 11. In the 613 bp splice variant the entire exon 5 is spliced out
the exon/intron boundaries as well as part of exon 9, exon 10, exon 11, and part of
exon 12 (Table 17). In the splice variants of 446 bp, 397 bp, 391 bp, 365 bp, 357 bp,
and 351 bp length, the donor splice site is at the exon/intron-boundary of exon 4, 5 or
6, while the acceptor splice site is an internal splice site in exon 12. The splice variants
of 391 bp and 357 bp splice out exon 5-11 and part of exon 12, the splice variants of
397 bp and 351 bp splice out exon 6-11 and part of exon 12, and the splice variants of
446 bp and 365 bp splice out exon 7-11 and part of exon 12.
All other splice variants would be considered aberrant splicing since they have
a donor splice site internally in exon 3-10 and an acceptor splice site internally in exon






































Fig. 25: Loss of functional regions in mdm2 splice variants in comparison to the full length mdm2
gene Above, functional domains of the MDM2 protein with corresponding amino acid residues are shown
(according to Freedman et al. 1999).  Below, splice variants of the mdm2 gene are shown.  Black lines
indicate the missing part of the sequence.
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Table 17: mdm2 RNA splice variants in ovarian cancer identified by RT-PCR and DNA sequencing. The table shows sizes of splice variants, splice sites and tissues in which the splice
variant was identified. (First nucleotide of coding sequence is #312, last nucleotide of coding sequence is #1784). The length of the splice variants includes only the coding sequence but not the
flanking primer sequence. (> indicates exon/intron boundary and < indicates intron/exon boundary)
Size of p53 Donor Donor Splice site sequence Acceptor Acceptor Overlap Frame Splice variant identified in
splice binding splice site splice site splice site splice site




888 partial 392 ex 3 > GAG ACC CTG ----- GAT CTT GAT < ex 10 978 G in frame + - - -
721 complete 1007 cryptic ex
10
AGT GAA CAT TCA ----- A ATG ATT cryptic ex 12 1760 ATTCA shift (+A..) + - - -
654 partial 392 ex 3 > GAG ACC CTG ----- GAC TAT TGG < ex 12 1212 G in frame + + - +
613 partial 467 ex 4 > ATG AAA GAG ----- G AAA ATA < ex 6 602 AGG shift (+G) - - + -
and and and
partial 856 cryptic ex 9 CGA CAA AGA A ----- GAC AAA GAA cryptic ex 12 1581 GACAAAGAA shift (+A)
571 complete 879 cryptic ex 9 GAT AGT ATT T ----- C CCC cryptic ex 12 1781 TATTT shift (+T,+C) + - - -
565 complete 807 cryptic ex 8 AGA GCA ATT A ----- AAG AAA AGG cryptic ex 12 1716 TA shift (+A) + - - -
541 complete 827 cryptic ex 9 GAA AAT TCA ----- A ATG ATT GTG cryptic ex 12 1760 AATTCA shift (+A) + - - -
533 partial 407 cryptic ex 4 ACC AAA GCC A ----- AA CTG GAA cryptic ex 12 1348 AAAGCCA in frame + - - -
520 partial 596 cryptic ex 5 CTC TGT GAA GAG ----- TTT GAA AGG cryptic ex 12 1550 TGTGAAGAG in frame - - + -
461 partial 510 cryptic ex 5 AAA CGA TTA T ----- T TAT AGC AGC cryptic ex 12 1523 ATTAT shift (+TT) + - - -
446 complete 650 ex 6 > AAT CAG CAG ----- GA CAT CTT ATG cryptic ex 12 1678 CAGGA shift (+GA) - + - -
442 partial 453 cryptic ex 4 AAA GAC ACT T ----- GAA GAC TAT cryptic ex 12 1485 T shift (+T) - - - +
421 complete 627 cryptic ex 6 ATC TAC AGG A ----- CAT CTT ATG cryptic ex 12 1680 ACAGGA shift (+A) + - - -
421 complete 683 cryptic ex 7 GTG AGT GAG ----- C CCA GTA TGT cryptic ex 12 1736 G shift (+C) - - + -
397 partial 601 ex 5 > GAG CAC AG ----- GA CAT CTT ATG cryptic ex 12 1678 ACAGGA shift (+GA) + - - -
391 partial 467 ex 4 > ATG AAA GAG ----- TTT GAA GGG cryptic ex 12 1551 TGAAAGAG in frame + - + -
378 partial 408 cryptic ex 4 CCA AAG CCA ----- TCA ACT TCT cryptic ex 12 1504 AGCCAT in frame + - - -
365 complete 651 ex 6 > AAT CAG CAG G ----- A ATG ATT GTG cryptic ex 12 1760- AAT shift (+GA) - - - +
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357 partial 467 ex 4 > ATG AAA GAG ----- AGT GTG GAA cryptic ex 12 1584 AAGAG in frame - + - -
351 partial 601 ex 5 > GAG CAC AG ----- G AAT AAG CCC cryptic ex 12 1724 AGGAA in frame + - - -
334 partial 597 cryptic ex 5 GTG AAA GAG C CCA GTA TGT AGA cryptic ex 12 1737 GC  (shift+C) - + - -
282 partial 522 cryptic ex 5 GAT GAG AAG C ----- TA AAGAAA cryptic ex 12 1714 AGAAGC in frame - + - -
279 partial 514 cryptic ex 5 CGA TTA TAT GA ----- G AAG CTA AAG cryptic ex 12 1712 A in frame + - - +
267 partial 447 cryptic ex 4  GCA CAA AAA G ----- GT TGC ATT AGA cryptic ex 12 1654 G in frame + - - -
266 partial 410 cryptic ex 4 AAG CCA TTG ----- AA CCT TGT cryptic ex 12 1618 AGCCATTG shift (+AA) + - - -
259 partial 551 cryptic ex 5 TGT TCA AAT GAT ----- T GTG CTA ACT cryptic ex 12 1766 TTCAAATGAT shift (+T) + - - +
221 partial 483 cryptic ex 5 TAT CTT G ----- C CCA GTA cryptic ex 12 1736 TG shift (+GC) + + + +
221 partial 484 cryptic ex 5 TAT CTT GGC ----- CCA GTA cryptic ex 12 1737 GCC shift (+GC) + - - -
221 partial 491 cryptic ex 5 TAT CTT GGC CAG TAT ----- GT AGA CAA cryptic ex 12 1744 CCAGTAT shift (+GT) + - - +
484 or TAT CTT GG ----- CCA GTA TGT AGA 1737
150 partial 455 cryptic ex 4 GAC ACT TAT ----- TTC CCC cryptic ex 12 1779 ACTTAT in frame + + - -
77 absent 338 cryptic ex 3 TCT GTA CCT ----- GC CCA GTA cryptic ex 12 1735 CCT shift (+GC) + - - -
52 absent 350 cryptic ex 3 GAT GGT GCT ----- A ACT TAT cryptic ex 12 1772 GTGCT shift (+A) + - - +
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4.2.3 Loss of p53 binding sequence in mdm2 splice variants
The binding site of the p53 protein has been suggested to be a region of approximately
84 amino-acids between aa 19-102 of the MDM2 protein (Chen et al. 1993). This
corresponds to base 366-617 of the mdm2 sequence. Out of 30 splice variants which
had been identified in ovarian tumors and normal ovarian tissue, only 8 splice variants
(27%) contained the complete p53 binding sequence, while 20 (67%) had only a
partial sequence and 2 (7%) of the splice variants were missing the entire p53 binding
site (Table 18, Fig. 25). The most frequent splice variant of 654 bp length (mdm2-b)
contains only 9 out of 84 amino acids of the p53 binding site, while the 221 bp splice
variant contains 39 amino acids of the binding site.
Table 18: Loss of p53 binding sequence in mdm2 splice variants
p53 binding site in
mdm2 splice variants
n (%) size of splice variant (bp)
Complete p53 binding site 8 (27%) 721,571, 565,541,446,421,421,365
Partial p53 binding site 20 (67%) 888,654,613,533,520,461,442,397,391,378,
357,351,334,282,279,267,266,259,221,150
Loss of p53 binding site 2 (7%) 77,52
30 (100%)
4.2.4 mdm2 splice sites and repeat sequences
Many of the splice variants show an interesting pattern of splicing, because the
donor and acceptor sites are in regions of exact sequence homology (Fig. 26). For
example in the 391 bp splice variant, which was seen in carcinomas as well as in
benign tissues, the 3’ end of the donor site ends with an eight base sequence of
TGAAAGAG which is also found at the non-transcribed downstream acceptor splice
site in exon 12 (Fig. 26). The acceptor splice site sequence would be
tgaaagagTTTGAAAGG. (The underlined sequence indicates the exact sequence
match. The uppercase letters indicate the coding bases).
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In the 221 bp splice variant, the splice site showed sequence overlaps with minor
variations in different cases which are shown in Table 17 and Fig. 26. Similar





























Fig. 26: A-D: Sequence overlaps in mdm2 RNA splice variants. (A-C) Splice site
sequences of the 391 bp and 221 bp mdm2 splice variants show overlaps of several
basepairs. The capital letters refer to transcribed bases that remain in the final mRNA
products, while the lower case letters refer to untranscribed bases which are spliced out
of the final mRNA product. The green boxes enclose the transcribed sequence at the
donor site and the blue boxes enclose the transcribed sequence at the acceptor site. The
yellow boxes indicate sequence homologies. D) As opposed to many of the aberrant
splice variants which show overlapping sequences at the splice site, no such sequence
homology is notable in the 654 bp mdm2-b splice variant which splices at exact
exon/intron boundaries of exon 3 and exon 12.
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Interestingly, the acceptor splice site of the 221 bp splice variant (nucleotide
1737) was shared by four different splice variants of 421 bp, 334 bp, 22 bp and 77 bp
length (Table 17). The same phenomenon was observed for other splice variants which
used the exact same sequence in exon 12 as acceptor site. The sequence match in all
three cases comprises a CAGGA sequence. The 446 bp splice variant has the donor
site at the exon 6/intron 6 boundary with an AAT CAG CAG gaa tca tcg sequence and
splices into exon 12 at base 1678 with a ggc aaa aca gGA CAT CTT ATG sequence.
The 421 bp splice variant has a donor site in exon 6 with an ATC TAC AGg
aac ttg gta sequence and splices into exon 12 at base 1678 with the same ggc aaa aca
gGA CAT CTT ATG sequence. And the 397 bp splice variant has the donor site at the
exon 5/intron 5 boundary with a GAG CAC AGg aaa ata tat sequence and splices into
the identical acceptor site in exon 12 (Table 17). All three splice variants are out of
frame. The donor sites were shared among the splice variants 888 (mdm2-a) and 654
(mdm2-b) (nucleotide 392), 613, 391, and 357 (nucleotide 467), and 397 and 351
(nucleotide 601).
Twelve of the thirty splice variants with a cDNA length between 888 and 150
bp were in frame, while all others were out of frame and therefore, either no protein or
only a truncated protein will be synthesized.
4.2.5 mdm2 alterations in ovarian cystadenomas and borderline tumors
RNA from six benign cystadenomas and nine ovarian tumors of low malignant
potential (LMP) was analyzed by RT-PCR for mdm2 alterations (Table 19 and 20, Fig.
27). Except for one cystadenoma which was completely lacking mdm2 expression, all
other cystadenomas showed the full length mdm2 as well as splice variants (Table 19).
None of the cases had only a full length mdm2 transcript. The 221 bp splice variant,
which had been described for ovarian carcinomas, was seen in one case. Four other
cystadenomas, though, showed splice variants which had not been found before in the
ovarian cancer cases. The length of these splice variants was 613, 520, 421 and 390
basepairs. The mdm2-b splice variant of 654 bp, which is frequent in ovarian
carcinomas, was not seen in any of the cystadenomas.
Among the nine borderline ovarian tumors (Table 20), only one case was found
to have only the full length mdm2 cDNA and one case had no mdm2 expression. The
other seven cases showed mdm2 alternative splicing, which was seen in six cases, in
addition to the normal length mdm2, and in one case as the only mdm2 cDNA.
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Fig. 27: mdm2 RNA splice variants in ovarian cystadenomas and tumors of
borderline malignancy. Total RNA was analyzed by RT-PCR and PCR-products
were
separated on a 1.2% agarose gel. Cases in lanes 1, 2, 5-8, and 10 show splice variants
of different sizes. The case in lane 3 shows no mdm2 expression despite normal
expression of the ß2-microglobulin control gene. (cDNA bands on the gel contain
additional 53 bp of flanking primer sequence).














2305 serous cystadenoma + - + -
2539 serous cystadenoma - - - -
2771 serous cystadenoma + - - 421
3456 serous cystadenoma + - - 613
3457 mucinous cystadenoma + - - 391
3462 serous cystadenoma + - - 520
n (%) 5 (83) 0 (0) 1 (17) 4 (67)
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2434 serous borderline + - + -
3084 serous borderline + - + -
3453 serous borderline + - - -
3454 serous borderline + - + 334, 150
3455 serous borderline + - + -
3458 mucinous borderline + - - 357, 282
3459 serous borderline - - - -
3463 mucinous borderline + - - 446
3465 serous borderline - + + -
n (%) 7(78) 1 (11) 5 (56) 3 (33)
The mdm2-b splice variant (654 bp) was seen in one (1/9) of the borderline
ovarian tumors (11%). Five cases had the 221 bp splice variant, which is also frequent
in ovarian carcinomas. Five splice variants of the sizes 446, 357, 334, 282 and 150 bp
were found in three cases of borderline tumors. The 150 bp splice variant was also
found in two ovarian carcinomas, while the other variants were only seen in the
borderline tumors.
4.2.6 mdm2 alterations in normal ovarian tissue
RNA from normal ovarian tissue was extracted and analyzed for mdm2 splice
products by RT-PCR (Fig. 28). The age of the patients, diagnosis at the time of
surgery, menopausal status or day of menstrual cycle respectively are demonstrated in
table 21. In nine cases the ovaries were removed in surgery for uterine fibroids. In one
patient the ovarian tissue was snap frozen at the time of autopsy for liver failure. Two
patients had ovarian cancer of the contralateral side, two patients had endometrioid
cancer, and two had cervical cancer.
Only 9/20 (45%) of the normal ovarian tissues showed expression of only the

































Fig. 28: mdm2 RNA splice variants in normal ovarian tissue. Total RNA of
ovarian tissue was analyzed by RT-PCR and PCR-products were separated on a 1.2%
agarose gel. Cases in lanes 3, 5, 7, and 8 show splice variants of different sizes. (cDNA
bands on the gel contain additional 53 bp of flanking primer sequence).
nine cases in addition to normal mdm2, and in two cases, which were lacking the full
length mdm2, as the only mdm2 cDNA.
The mdm2-b splice variant of 654 bp was found in one case of the normal
ovarian tissues. The most frequent splice variant was the 221 bp mdm2 cDNA, which
was seen in 40% of normal ovarian tissues. The 259 bp splice variant was found in
four cases (20%).
Interestingly, seven out of 12 patients who had undergone surgery for a benign
disease, mostly uterine fibroids, had expression of only normal mdm2. In contrast,
none of the six patients who had undergone surgery for a gynecological cancer had
exclusively expression of the full-length mdm2 in the normal ovarian tissue. In five of
these cases we found one or several splice variants, besides the full-length mdm2
expression, and in one case only two splice variants and no full length mdm2 cDNA.
This result reached statistical significance. The finding of mdm2 RNA splicing in the
unaffected normal ovary was significantly correlated with the diagnosis of a
gynecological cancer, either in the contralateral ovary, or in the uterine cervix or
endometrium (p=0.017).
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ov51 41 endometrial cancer pre 12 + - + 365
ov56 48 unknown ? ? + - - -
ov63 54 endometrial cancer post - + - + 279, 259
ov65 37 cervical cancer pre 42 - - - 279, 259
ov97 39 unknown pre 19 + - - -
ov98 37 uterine fibroids pre 7 + - - -
ov105 40 uterine fibroids pre 20 + - - -
ov108 39 uterine fibroids pre 10 + - + -
ov119 61 uterine fibroids post - + - - -
ov120 37 uterine fibroids pre 2nd half + - - -
ov127 39 uterine fibroids pre 23 + - - -
ov172 41 uterine fibroids pre 11 + - - -
ov214 39 uterine fibroids pre ? + - + -
402A 50 ovarian cancer Ia ? ? + - + -
2150 60 normal ovary post - + - + 259
3106 43 cervical cancer pre ? + - + 52
3119 41 liver failure pre ? - + - -
3294 42 normal ovary pre ? + - - 442
3539 - contralateral
ovarian cancer Ia
? ? + - + -
73595 50 uterine fibroids post - + - - -
n
(%)








4.2.7 In vitro expression of p53 and MDM2 splice variant proteins
Transient transfection of HeLa cells with the pcDNA3 expression vector
containing the mdm2 cDNA of interest was used for expression of MDM2 and p53
proteins (Fig. 29). The cDNA sequence had been inserted into the pcDNA3 plasmid
such that it came under the control of the T7 RNA polymerase promoter (pT7). The
HeLa cells were previously infected with the recombinant vaccinia virus vTF7-3
which expresses the bacteriophage T7 RNA polymerase gene. During incubation, the
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gene of interest is transcribed with high efficiency by T7 RNA polymerase (Panicali
and Paoletti, 1982, Mackett et al. 1982, Moss and Flexner, 1987).
A full length p53 cDNA, a full length mdm2 cDNA, and three splice variants of
654 bp, 351 bp, and 52 bp were amplified by PCR using a primer pair designed for
cloning the cDNA of interest into a pcDNA3 expression-vector. The pcDNA3
expression vector had been modified such that it contained a myc-epitope respectively
a HA-epitope at the 3’ end of the DNA-insert. The amplified DNA was ligated into the
pcDNA3 vector and transformation of electro-competent E. coli bacteria was carried
out through electroporation. The correct size of the insert was verified by digestion of
the plasmid by the NcoI restriction enzyme. (Fig. 8b).
HeLa cells were infected with the vaccinia virus strain vTF7-3 and
subsequently, transient transfection of the infected HeLa-cells with the expression
vector plasmid was carried out through incubation with a DNA-liposome-complex
(Fig. 9).
After harvesting the cells, proteins were analyzed by SDS-polyacrylamide gel
electrophoresis. We were able to express the full length p53 protein (53 kDa), the full
length MDM2 protein (90 kDa), and the protein of the mdm2-b-splice variant (40kDa)
in vitro in HeLa-cells (Fig. 29).  The clones containing the splice variants 351 bp and
52 bp did either not express a protein, or it was undetectable due to small amounts or
rapid degradation.
Co-immunoprecipitation was carried out by transient transfection of vTF7-3
infected HeLa-cells with both the full length p53 cDNA and the mdm2-b splice variant
cDNA, respectively with p53 and full length mdm2 cDNA as a control, followed by
SDS-PAGE and immunoprecipitation with the anti-myc respectively anti-HA-
antibody. We were able to demonstrate that the full length MDM2 protein binds to the
p53 protein (results not shown). However, co-expression and co-immuno-precipitation
of the p53 protein and the mdm2-b splice variant protein were not successful so far.
Further experiments will be needed to clarify, whether p53 binds to the mdm2 splice
variant proteins.
4.2.8 Correlation of mdm2 and p53 alterations
Out of 92 ovarian cancer cases analyzed for mdm2 splice variants, 50 (54%)
had p53 mutations, and 52 (57%) had p53 overexpression including 13 cases with






































654bp  351bp 52bp
mdm2 splice variants
A CB
Fig. 29: Cytoplasmic expression of p53 and MDM2 proteins by transient transfection of pcDNA3 vector constructs into
vaccinia virus infected HeLa cells
A: Expression of the full length p53 protein (53 kDa). B: Expression of the full length MDM2 protein (90 kDa).
C: Expression of  a 40 kDa protein of the splice variant mdm2-b (654 bp). No protein could be expressed from the mdm2 splice
variants of 351 bp and 52 bp. Proteins were analyzed by Western blotting and anti-myc respectively anti-HA immunodetection.
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mdm2 splicing. In cases with p53 mutation, 22% (11/50) had no detectable full length
mdm2, 72% (36/50) had splice variants, 48% (24/50) expressed the mdm2-b splice
variant and 12% (6/50) expressed the 221 bp splice variant.
Out of 52 cases with p53 protein overexpression, 7 (14%) had no detectable
full length mdm2, 41 (79%) had splice variants, and 9 (17%) expressed the 221 bp
mdm2 variant. The only significant difference was seen for the mdm2-b splice variant
which was present in 52% of the cases with p53 overexpression but only in 28% of
cases with no immunohistochemically detectable p53 protein (p=0.018).
In cases with p53 overexpression despite wildtype sequence, mdm2 splicing
was seen more frequently (11/13, 85%) than in cases with normal p53 expression and
wildtype p53 sequence (19/29, 65%). However, the results did not reach statistical
significance.



















3 (10) 7 (24) 18 (62) 1 (3) 29 (32)
wildtype /
overexpression
0 (0) 2 (15) 10 (77) 1 (8) 13 (14)
mutation /
normal expression
2 (18) 3 (27) 3 (27) 3 (27) 11 (12)
mutation /
overexpression
3 (8) 6 (15) 27 (69) 3 (8) 39 (42)
8 (9) 18 (20) 58 (63) 8 (9) 92 (100)
p = 0.23
4.2.9 Correlation of mdm2 alterations with histopathological and clinical data
If mdm2 results were classified into full length mdm2, altered, and no
expression of mdm2, we did not find any correlation with clinical or histological
characteristics of the ovarian tumors (Table 23). A comparison of the most frequent
splice variants though, the 654 bp and the 221 bp variant, showed some interesting
correlations.
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Table 23: Clinico-pathologic characteristics  of patients with ovarian cancer and mdm2 alterations
mdm2 Alterations Splice variant 654 bp Splice variant 221 bp
 (mdm2-b)
Characteristic mdm2 altered no mdm2 P absent present P absent present P
full length mdm2 expression value* value* value*
Patients - no. (%) 18 (20%) 66 (71%) 8 (9%) 54 (59%) 38 (41%) 77 (84%) 15 (16%)
Median age - yrs 58 55 50 55 57 55 57
Histological Subtype - no. (%)
Serous 12 (67%) 25 (39%) 3 (38%) 0.10 24 (44%) 16 (43%) 0.90 35 (46%) 5 (36%) 0.50
Other 6 (34%) 40 (61%) 5 (62%) 30 (56%) 21 (57%) 42 (54%) 9 (46%)
Clinical stage - no. (%)
FIGO I 6 (33%) 19 (29%) 3 (38%) 0.50 20 (37%) 8 (21%) 0.066 20 (26%) 8 (53%) 0.017
FIGO II 2 (11%) 3 (5%) 0 4 (7%) 1 (3%) 4 (5%) 1 (6%)
FIGO III 8 (44%) 36 (54%) 3 (38%) 24 (44%) 23 (61%) 41 (53%) 6 (40%)
FIGO IV 2 (11%) 8 (12%) 2 (25%) 6 (11%) 6 (16%) 12 (16%) 0
Grade of Differentiation - no. (%)
I (well) 7 (39%) 11 (17%) 3 (37%) 0.41 17 (31%) 4 (10%) 0.04 17 (22%) 4 (27%) 0.31
II (moderate) 3 (17%) 23 (35%) 0 14 (26%) 12 (32%) 20 (26%) 6 (40%)
III (poor) 8 (44%) 32 (48%) 5 (63%) 23 (43%) 22 (58%) 40 (52%) 5 (33%)
Residual Tumor - no. (%)
No residual tumor 13 (76%) 36 (58%) 5 (63%) 0.65 37 (76%) 17 (45%) 0.004 44 (59%) 10 (77%) 0.12
< 2 cm 2 (12%) 16 (26%) 2 (25%) 8 (16%) 12 (32%) 17 (23%) 3 (23%)
> 2 cm 2 (12%) 10 (16%) 1 (13%) 4 (8%) 9 (24%) 13 (18%) 0
Lymph nodes - no. (%)
Negative 6 (35%) 13 (21%) 1 (13%) 0.89 14 (29%) 6 (16%) 0.45 17 (23%) 3 (23%) 0.99
Positive 4 (24%) 20 (32%) 3 (37%) 14 (29%) 13 (34%) 23 (31%) 4 (31%)
Not resected 7 (41%) 29 (47%) 4 (50%) 21 (42%) 19 (50%) 34 (46%) 6 (46%)
DNA-ploidy - no. (%) (n=88)
Diploid 8 (44%) 33 (55%) 4 (57%) 0.51 26 (51%) 19 (51%) 0.97 36 (49%) 9 (60%) 0.45
Aneuploid 10 (56%) 30 (45%) 3 (43%) 25 (49%) 18 (49%) 37 (51%) 6 (40%)
S-Phase-Fraction - no. (%) (n=88)
low ( < 5%) 5 (28%) 17 (27%) 1 (14%) 0.72 17 (33%) 6 (16%) 0.016 16 (22%) 7 (47%) 0.056
intermediate ( 5% - 14.4%) 8 (44%) 27 (43%) 5 (71%) 24 (47%) 16 (43% 32 (44%) 8 (53%)
high ( > 14.5%) 5 (28%) 19 (30%) 1 (14%) 10 (20%) 15 (41%) 25 (34%)
Treatment - no. (%)   **
Cisplatin - Cyclophosphamide 3 (17%) 14 (21%) 2 (25%) 1.0 9 (17%) 10 (26%) 0.19 16 (21%) 3 (20%) 0.66
Carboplatin - Cyclophosphamide 4 (22%) 13 (13%) 1 (12%) 9 (17%) 9 (24%) 16 (21%) 2 (13%)
Other regimens 4 (22%) 12 (18%) 1 (12%) 12 (22%) 5 (13%) 14 (18%) 3 (20%)
No chemotherapy 5 (28%) 21 (32%) 3 (38%) 16 (30%) 13 (34%) 25 (33%) 4 (27%)
No information - no. 2 (11%) 6 (9%) 1 (12%) 8 (15%) 1 (3%) 6 (8%) 3 (20%)
* Chi-Square test for two categories, Mantel-Haenszel test for three or more categories
** Chemotherapy regimens are described in the methods section
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Presence of the 654 bp splice variant (mdm2-b) was significantly correlated
with poor grade of differentiation (p=0.04), a residual tumor mass after surgery
(p=0.004) and high S-phase fraction (p=0.016). It was also more frequent in tumors of
advanced stage (p=0.066) (Table 23). The mdm2-b splice variant thus seems to be
significantly associated with histologically and clinically more aggressive tumors.
As opposed to this the presence of the splice variant 221 bp was significantly
correlated with early stage tumors (p=0.017), and was more frequently identified in
grade I or II tumors, tumors without residual mass after surgery, and tumors with low
S-phase fraction, though the latter results did not reach statistical significance (Table
23) (Table 23).
4.2.10 mdm2 alterations and clinical outcome in ovarian cancer
mdm2 splice variant findings were furthermore compared with the response to a
platinum based chemotherapy (Table 24). Details of chemotherapy regimen and
evaluation of response were described in the methods section. If full length mdm2 was
present in the ovarian carcinomas, the majority of tumors (64%) were sensitive to
Table 24: Response to platinum-based chemotherapy in ovarian cancer











mdm2 full length present 27 (64) 3 (7) 12 (29) 42 (84)
mdm2 full length absent 2 (25) 5 (63) 1 (13) 8 (16)
29 8 13 50 p = 0.001
no mdm2 expression 1 (25) 2 (50) 1 (25) 4 (8)
normal mdm2 expression 8 (80) 0 (0) 2 (20) 10 (20)
normal and splice variants 19 (59) 3 (9) 10 (31) 32 (64)
only splice variants 1 (25) 3 (75) 0 (0) 4 (8)
29 (58) 8 (16) 13 (26) 50 (100) p=0.006
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platinum-based chemotherapy (27/42), whereas in cases with no detectable full
length transcript, only 2/8 cases were sensitive (25%), while the majority of cases was
resistant or refractory (p=0.001) (Table 24). Similarly, presence of mdm2 splicing in
general was significantly correlated with poor response to chemotherapy (p=0.006)
(Table 24).
mdm2 alterations were analyzed for their impact on the clinical outcome of the
patients by log-rank statistical survival analysis (Fig. 30A-F). Presence or absence of
alternative splicing as opposed to full length mdm2 cDNA, absence of mdm2-
expression, and the site of RNA splicing at exon-intron boundaries as opposed to
cryptic exon splice sites, did not have a significant influence on survival after
diagnosis of ovarian cancer (Fig. 30A,B). The size of the splice variants had some
influence on survival but did not reach statistical significance (Fig. 30C,D). However,
analysis of the splice variant 654 bp showed a trend to poor clinical outcome for
patients with expression of this splice variant in the ovarian tumor (p=0.17, Fig. 30E).
The only significant difference was seen for patients with expression of the 221 bp
splice variant (Fig. 30F), who had a better survival prognosis than patients without
expression of the 221 bp splice variant (p=0.048).
122







no mdm2 expression (n=8)
splice variants +/- full
length mdm2 (n=66)



















































Fig. 30: A-B: Clinical outcome of ovarian cancer patients dependent on mdm2
 alternative RNA splicing (n=92) as analyzed by RT-PCR and DNA sequencing.
A) Overall survival in patients with expression of the full length mdm2 RNA
transcript,
versus mdm2 splice variants, versus absence of mdm2 RNA expression.
B) Overall survival in patients with aberrant splicing in the donor and acceptor or only
the acceptor site, versus patients with full length mdm2 and/or alternative splicing at
exon/intron boundary of exon 3 and 9 (mdm2-a, 888 bp) or exon 3 and 11 (mdm2-b,
654 bp).
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Fig.30 C-D: Clinical outcome of ovarian cancer patients dependent on mdm2
RNA alternative splicing (n=92) as analyzed by RT-PCR and DNA sequencing.
C) Overall survival in patients with expression of small splice variants of <300 bp
versus expression of the mdm2-b splice variant (654 bp) or full length mdm2
D) Overall survival in patients with expression of small splice variants (<300 bp)
versus expression of mdm2 splice variants of >300 bp in the presence or absence of the
full length mdm2 transcript. Cases with expression of the the mdm2-b splice variant
(654 bp) were not included in this analysis.
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Fig.30 E-F: Clinical outcome of ovarian cancer patients dependent on mdm2 RNA
alternative splicing (n=92) as analyzed by RT-PCR and DNA sequencing.
E) Overall survival in patients with expression of the mdm2-b splice variant (654 bp)
versus absence of the mdm2-b splice variant.
F) Overall survival in patients with expression of a small splice variant of 221 bp was




5.1 Alterations of the p53 tumor suppressor gene in ovarian cancer
5.1.1 p53 mutations
Our study includes a large cohort of primary ovarian carcinomas and addresses
several issues relevant to p53 sequence alterations and protein overexpression. First,
we analyzed, as in our previous study (Wen et al. 1999), frozen tissue in order to avoid
problems related to loss of antigenicity that is observed with immunohistochemistry in
paraffin-embedded tissue. Secondly, we assessed the frequency of mutations
throughout the entire coding region of the gene by analyzing exons 2-11 by SSCP and
subsequent sequencing of cases with alterations, as opposed to most other studies
which are limited to exons 5-8. Thirdly, information on adjuvant treatment was
available and the results of the p53 sequence analysis and immunohistochemistry were
compared to the response to chemotherapy, in order to evaluate the role of p53 for the
sensitivity of platinum based chemotherapy. Finally, clinical follow-up information
concerning outcome was available in 96% of the cases and information about the
progression of the disease was available in 78% of the patients, which allows the
evaluation of the prognostic relevance of p53 alterations in a sufficient number of
cases.
We found a total of 100 p53 mutations in 99 out of 178 ovarian carcinomas
(56%), which is higher than the percentage in most other studies. The frequency of p53
mutations in studies using frozen tissues including our previous study is 50% and
ranges from 20% to 73% (Mazars et al. 1991, Kihana et al. 1992, Kohler et al. 1993a,
Milner et al. 1993, Sheridan et al. 1994, Fujita et al. 1994, Lee et al. 1995, Casey et al.
1996, Sakamoto et al. 1996, Skilling et al. 1996, Schuyer et al. 1998, Wen et al. 1999).
In studies using paraffin-embedded tissues, the frequency of mutations was 47%,
ranging from 26% to 79%. (Teneriello et al. 1993, Kupryjanczyk et al. 1993, Wertheim
et al. 1994, Niwa et al. 1994, Zheng et al. 1995, Kappes et al. 1995).
Several studies have analyzed part of the p53 coding region for mutations and
found mostly between 20% and 52% mutations (Milner et al. 1993, Teneriello et al.
1993, Wertheim et al. 1994, Fujita et al. 1994, Niwa et al. 1994, Zheng et al. 1995,
Kappes et al. 1995) with the exception of Kohler et al. (1993a) who found a percentage
of 73% and Jacobs et al. (1992) who found 66% mutations. Three studies analysing
exon 4-9 found 20-37% mutations (Kim et al. 1995, Lee et al. 1995, Sakamoto et al.
1996) and one study found 26% mutations in exon 4-8 (Niwa et al. 1994).
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The mutations were located predominantly (92%) in exons 5-8 and their
associated splice junctions. Eight mutations (8%) though, were found outside of exons
5-8. These eight mutations were located in exon 4 and the exon 4/intron 4 splice
junction (4 mutations) and in exon 9 and the intron 8/exon 9 splice junction (4
mutations). These results demonstrate that the evaluation of codons 126 to 307 (182
codons) provided 92 of 100 (92%) of the mutations, while eight mutations (8%) could
only be identified by evaluation of codons 1 to 125 and 308 to 393 (211 codons).
The percentage of mutations in studies analysing the entire coding region of
p53 is overall 59% (207/349) and varies from 52% to 79%, which is consistent with
our own results (Kihana et al. 1992, Kupryjanczyk et al. 1993, 1995, Skilling et al.
1996, Casey et al. 1996, Wen et al. 1999). The frequency of mutations in exons 2-4
and 9-11 was reported to be between 0% and 20% with an overall average of 11%
(24/258) (Kihana et al. 1992, Kupryjanczyk et al. 1993, 1995, Skilling et al. 1996,
Casey et al. 1996, Wen et al. 1999). This means that studies analysing only exons 5-8
of the p53 gene will miss approximately 11% of the mutations.
In our previous study (Wen et al. 1999) exons 2-11 were first screened by
SSCP in 105 ovarian carcinomas and cases with suspicious band patterns were
sequenced. Out of 50 cases with normal SSCP band patterns, 42 were subjected to
complete sequence analysis of the open reading frame by automated sequencing (Wen
et al. 1999, Wang-Gohrke et al. 1998). A total of 60 mutations (57%) were identified
in this study with only 5% mutations outside exons 5-8. Skilling et al. (1996) identified
61% mutations in 64 cases with 34/39 mutations located in exon 5-8 and only 5
mutations (13%) outside these exons. Kihana et al. (1992) reported that two of 10
mutations (20%) identified in 14 ovarian carcinomas were outside exons 5-8, although
the codon for one of the two mutations was not specified. Kupryjanzcyk et al. (1993)
analyzed 38 ovarian carcinomas and found 31 mutations in 30/38 tumors (79%) by
PCR-SSCP and sequencing, which is the highest percentage so far reported in the
literature. Three of these mutations were located outside exon 5-8.
Excluding nonsense and frameshift mutations, 222 of the 393 codons of the
human p53 gene have been described as the targets of at least 698 different mutations
(Beroud et al. 1996).  While some codons, such as codon 190, are the target of only
one mutational event, others such as codon 179 have been the target of multiple
mutational events. In our study, the codons most frequently mutated were codons 175,
179, 234, 242, 248, 273, 275, and 281, which were each mutated in three or more
different carcinomas.  No mutations have been identified in codons 92-112, the region
which has been recently identified as the degradation signal in p53/MDM2 interaction
(Gu et al. 2000).
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In our study we identified 72% missense mutations. This is consistent with the
results of most other authors who found between 62% and 85% missense mutations
(Milner et al. 1993, Kupryjanczik et al. 1993, Niwa et al. 1994, Skilling et al. 1996,
Casey et al. 1996, Righetti et al. 1996, Schuyer et al. 1998). Deletions are usually
described in a percentage of 7%-13% (Kupryjanczik et al. 1993, Milner et al. 1993,
Righetti et al. 1996, Schuyer et al. 1998, Wen et al. 1999), which is similar to our
findings of 10% deletions. But some authors found deletions in a percentage as high as
22% by SSCP of exon 2-11 and sequencing (Skilling et al. 1996) and 27% of all
mutations by sequencing exon 2-11 (Casey et al. 1996). Insertions have been found
less often and have been described by Skilling et al. (1996) as 2.5%, Casey et al.
(1996) as 6%, and Milner et al. (1993) as 3% of the mutations in ovarian cancer.
Several studies with smaller case numbers do not describe insertions at all. We
identified 3 insertions (3%), one of which was combined with a deletion. Splice
junction mutations are considered rare mutations and so far only 12 splice junction
mutations have been described in the ovarian cancer literature including our previous
study, with a percentage of usually 1-5% (Kupryjanczik et al. 1993, Niwa et al. 1994,
Skilling et al. 1996, Casey et al. 1996, Righetti et al. 1996, Schuyer et al. 1998).
Including three previously published splice junction mutations (Wen et al. 1999) we
found eight splice junction mutations accounting for 8% of all mutations identified,
which is higher than in any of the other studies.
5.1.2 p53 mutations in evolutionary highly conserved domains
The majority of mutations in this study (61/99 carcinomas, 62%) were located
within highly conserved domains of p53 (domains II, III, IV and V) (Cho et al. 1994,
Soussi and May, 1996). These domains are almost equivalent to the loop-sheet-helix
(domains II and V), loop 2 (domain III), and loop 3 (domain IV) regions of p53 (Cho
et al. 1994, Soussi and May, 1996). The loop-sheet-helix is responsible for direct DNA
interactions with the major groove; loop 3 is responsible for direct interactions with
the minor groove of DNA, and loop 2 and 3 together are responsible for maintaining
the needed 3-dimensional conformation (Cho et al. 1994, Prives 1994, Soussi and
May, 1996, Arrowsmith and Morin, 1996). Mutations in these conserved domains have
been observed to confer more aggressive behavior in patients with breast carcinomas
or colon carcinomas than mutations in other regions of p53 (Bergh et al. 1995, Goh et
al. 1995). Similarly, in our study, comparisons of overall survival for women with
mutations in highly conserved domains together did show a statistically significant
difference in survival compared to those with mutations in non-conserved regions or
wildtype p53 sequence (p = 0.007).
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5.1.3 p53 polymorphisms and intron alterations
Several p53 constitutional polymorphisms have been reported. These are
located in codon 21 (exon 2) (Ahuja et al. 1990), codon 36 (exon 4) (Felix et al. 1994),
codon 72 (exon 4) (Harris et al. 1986, Matlashewski et al. 1987), codon 213 (exon 6)
(Carbone et al. 1991), intron 1 (Ito et al. 1994), intron 2 (Pleasants and Hansen 1994,
DiCioccio and Piver 1996, Ge et al. 1998, Verselis and Li, 2000), intron 3 (Lazar et al.
1993) and intron 6 (Peller et al. 1995).
p53 polymorphisms can cause abnormal bands in single-strand conformation
polymorphism (SSCP) analysis, which is widely used as a screening technique for p53
mutations and can therefore be mistaken for mutations, if they are not confirmed by
DNA sequencing (Carbone et al. 1991).
Among the 178 ovarian carcinomas, which were analyzed by SSCP and DNA
sequencing, we identified 100 mutations (Table 8) and 45 polymorphisms in exons 4,
6, and 7, and in the intron sequences, which were flanking exons 3, 6, 10, and 11. We
observed four polymorphisms in codon 36 (CCG to CCA), codon 213 (CGA to CGG),
codon 224 (GAG to GAA), and codon 231 (ACC to ACA). The frequency of each of
these polymorphisms was 0.6% in our study cohort. The codon 36 polymorphism was
first described by Felix et al. 1994 and was present in the heterozygous state in 4% of
100 individuals. Carbone et al. (1991) first described the polymorphism at codon 213
(CGA→CGG), which doesn´t result in an amino acid exchange but causes the loss of a
Taq I restriction site. It was found in a frequency of 3.2% in lung cancer and breast
cancer and caused an SSCP alteration (Carbone et al. 1991). The sequence alterations
at codon 224 (exon 6) and 231 (exon 7) have not been previously described in the
literature. They may be polymorphisms or silent mutations since they do not result in
an amino acid exchange. But in these cases, no normal tissue DNA was available, so
that we could not verify whether this is a polymorphism.
Five percent (9/178) of all the cases had a CCG→CCC polymorphism at codon
72 resulting in an arginine to proline amino acid exchange. Codon 72 of the p53 gene
has been described to be the site of a primary structure polymorphism with an amino
acid residue which could be an arginine, proline or cysteine (Harris et al 1986,
Matlashewski et al. 1987). The majority of Caucasian individuals express the arginine-
containing p53 protein as opposed to African-Americans who express predominantly
the proline-containing p53 protein (Weston et al. 1992, Själander et al. 1995). We
therefore considered the arginine-72 p53 as the normal sequence and the proline-72
p53 as the polymorphic sequence.
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Overall, the percentage of polymorphisms identified in our study seems low
compared to the literature. This may be due to the fact that this cancer cohort was not
systematically screened for p53 polymorphisms. Only cases with SSCP band
alterations were sequenced. Therefore polymorphisms, which do not cause SSCP
alterations, may have been missed.
The codon 72 p53 polymorphism is presently discussed to play a role for
cancer predisposition. In breast cancer patients, a significant increase in the codon 72
proline allele frequency was observed, which was most pronounced in highly
differentiated breast cancer (Själander et al. 1996). In ovarian cancer, probands
homozygous for the arginine allele have been found to develop ovarian cancer at an
earlier age and have a survival advantage compared to arginine/proline heterozygote
and proline homozygote patients (Buller et al. 1997). When a loss of heterozygosity
occurred in patients with invasive ovarian cancer, the proline allele was lost
preferentially and tumors which retained a proline allele were significantly more prone
to mutation than tumors without a proline allele (Buller et al. 1997).
Storey et al. described a significant overrepresentation of homozygous
arginine-72 p53 in human papilloma-virus-associated cervical carcinoma compared
with the normal population which makes individuals homozygous for arginine 72
about seven times more susceptible to HPV associated tumorigenesis than
heterozygotes (Storey et al. 1998). They conclude that the arginine-encoding allele
represents a significant risk factor in the developement of human papilloma-virus-
associated cervical carcinoma. This finding was corroborated in two independent
studies (Zehbe et al 1999, Agorastos et al. 2000), however, refuted by others (Helland
et al. 1998, Hildesheim et al. 1998; Josefsson et al. 1998, Lanham et al. 1998). Inter-
laboratory variation in p53 genotyping may have contributed to the inconsistent
findings across studies (Makni et al. 2000). Makni et al. observed odds ratios of 8.0
(95% CI: 2.3-28.5) for the Arg/Arg genotype and cervical cancer when they excluded
individuals which were differently genotyped in three independent laboratories (Makni
et al. 2000). Recently a differential effect of the p53 codon 72 variants on interaction
of mutant p53 with p73 has been published (Marin et al. 2000). The binding of the
arginine isoform to p73 tended to be stronger than that observed for the proline
isoform, with a neutralizing effect on p73-induced apoptosis. The presented data also
suggested the codon 72 polymorphism to modify the response of selected tumor cells
to chemotherapy. In some tumors, such as squamous cell cancers, the authors found
evidence for preferential mutation and expression of the arginine form of p53 in
arginine/proline heterozygotes (Marin et al. 2000).
Compared to the expected frequency of the arginine and the proline allele, the
arginine allele was clearly overrepresented in our study population which consisted
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predominantly of caucasian individuals. A correlation between the proline allele and
p53 overexpression was not identified.
Various intron alterations of unknown significance have been found in the p53
gene. A polymorphism in intron 3, which consists of a single repeat of 16 nucleotides
starting at nucleotide 11951 of the p53 gene, was first described by Lazar et al. (1993)
and was identified in its heterozygote form in 28% of 82 individuals in lymphozyte
DNA. The polymorphism was not associated with a predisposition to breast cancer.
We found this 16 bp repeat polymorphism in 14% of the ovarian cancer cases. The
presence of the polymorphism was not associated with a higher percentage of p53
overexpression, but was found in eight of nine cases with the codon 72 proline
polymorphism. According to Själander et al. (1995), significant ethnic differences
have been found for the codon 72 and the intron 3 16 bp repeat polymorphism
(Själander et al. 1995). The most common finding in a northern european population
was the codon 72 arginine allele combined with absence of the 16 bp repeat
polymorphism and was therefore considered the „wild-type„ haplotype (Själander et
al. 1995).
The biological significance of the intron 3 16 bp repeat polymorphism remains
unclear. Homozygosity of the p53 intron 3 polymorphism was suspected to be highly
associated with sporadic ovarian cancer by Runnebaum et al. (1995). The authors
found an overall frequency of 24.1% heterozygous and 1.7% homozygous PIN 3
polymorphism in normal controls, while the frequency was 30.6% and 11.3%
respectively in ovarian cancer patients, which was a 6.7 fold increase of the
homozygotes in ovarian cancer (Runnebaum et al. 1995).  However, no such
association was observed by others in 82 ovarian carcinomas (Lancaster et al. 1995).
The frequency of this polymorphism in our study cohort was lower than that
mentioned by Runnebaum et al. (1995). In a study of breast cancer patients and normal
controls, no significant difference was found for the frequency of the 16 bp repeat
polymorphism (Själander et al. 1996).
Further intron polymorphisms have been described in the literature to be
associated with cancer predisposition. An intron 6 polymorphism, a G to A transition
at position 61, has been found significantly more frequently in ovarian carcinomas as
compared to normal controls (Mavridou et al. 1998). This was confirmed in a second
study, where an association of this intron 6 polymorphism and the strongly linked 16
bp polymorphism in intron 3 with ovarian cancer has been established, however, only
in women not carrying BRCA1 or BRCA2 germline mutations (Wang-Gohrke et al.
1999). Furthermore Peller et al. (1995) described a 8bp polymorphic sequence in
intron 6 of the p53 gene, which was identified in the heterozygotic form in 32% of
normal blood samples. Patients with gastric cancer and breast cancer demonstrated a
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higher incidence of heterozygosity (50%). Therefore the authors suggested an
association between this polymorphism and cancer predisposition and susceptibility
(Peller et al. 1995).
We describe three intron alterations, which to our knowledge have not been
described in the literature. One g→ c alteration was identified in intron 6 at position
13964 of the p53 gene in two ovarian cancer cases. Both cases had shown SSCP band
shifts. In one case, a p53 mutation was identified. Since no normal tissue was available
in these two cases, we can not proove that this is a polymorphism, but we found this
alteration in only 1% of the cancer cases, while the other cases, which were sequenced
because of SSCP band shifts, revealed the normal sequence at this location.
We identified two new polymorphisms in intron 10, which have not previously
been described. An a→ t polymorphism was found at position 17708 of the p53 gene
in two cases in the flanking region of exon 10. In one of the cases, normal tissue was
available and DNA sequencing confirmed the polymorphism. In three other ovarian
cancer cases which showed only a weak SSCP band shift in the exon 10 and flanking
intron region, a normal sequence at nucleotide 17708 was identified.
The other intron 10 polymorphism was found in the flanking sequence of exon
11. Four out of eight cases with SSCP band shifts revealed the polymorphic sequence,
a c→ t nucleotide exchange at position 18550 of the p53 gene. In three out of these
four cases, the polymorphic sequence could be confirmed in normal cervical tissue of
the patient. We therefore conclude, that both intron 10 sequence alterations are
polymorphisms. Since none of the cases with intron 10 alterations had a mutation in
exon 10 or exon 11, we assume that the SSCP band shift was caused by the
polymorphism. These two polymorphisms have not been described in the literature so
far.
Interestingly, out of eight cases with intron 6 or intron 10 alterations, seven
showed p53 overexpression, though p53 mutations and p53 wildtype, respectively,
were evenly distributed among these cases. Though the case number was very small,
the result almost reached statistical significance. Intron polymorphisms may affect
transcription and splicing processes and may therefore cause alterations in protein
expression, stability and/or activity. For variations in p53 introns functional relevance
has been suggested (Beenken et al. 1991; Avigad et al. 1997). The actual allele
frequencies and possible association with p53 overexpression of the here newly
identified intron alterations need to be clarified by screening larger case numbers.
The biological significance of p53 polymorphisms is unclear at this point, since
conflicting results regarding cancer predisposition have been reported. But there is
increasing evidence, that some polymorphisms or defined constellations of
polymorphisms (haplotypes) may be important for processes relevant for cancer risk
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and treatment outcome, as has been suggested for the codon 72 polymorphism as
intragenic modifier of mutant p53 behaviour (Marin et al. 2000). It might therefore be
worthwhile, to screen a large cohort of patients with ovarian cancer in comparison to
unaffected individuals for several p53 polymorphisms to possibly define risk and
prognostic factors for ovarian carcinoma.
5.1.4 p53 protein overexpression
Several investigators have used frozen ovarian carcinoma specimens for
immunohistochemical analysis of p53 and found p53 overexpression in 32% - 84%
with an average percentage of 51% (Marks et al. 1991, Kihana et al. 1992, Eccles et al.
1992, Kohler et al. 1993a, Kiyokawa et al. 1994, Henriksen et al. 1994, Sheridan et al.
1994, Lee et al. 1995, Casey et al. 1996, Skilling et al. 1996, Buttitta et al. 1997,
Geisler et al. 1997, 2000, Schuyer et al. 1998, Wen et al. 1999). We found p53
overexpression in 62% of the cases. A few authors have performed both
immunohistochemical and mutation analysis (Marks et al. 1991, Kihana et al. 1992,
Sheridan et al. 1994, Lee et al. 1995, Casey et al. 1996, Skilling et al. 1996, Buttitta et
al. 1997, Wen et al. 1998). Only four of the latter studies involved more than 50
carcinomas (Casey et al. 1996, Skilling et al. 1996, Buttitta et al. 1997, Wen et al.
1999).
Many studies have used formalin-fixed, paraffin-embedded material for
immunohistochemistry. In those studies, which analyzed more than 50 cases of FIGO
I-IV ovarian carcinomas, the frequency of p53 overexpression ranged from 26% to
70% with an overall frequency of 48% (Bosari et al. 1993, Sheridan et al. 1994, Inoue
et al. 1994, Niwa et al. 1994, Hartmann et al. 1994, Kupryjanczyk et al. 1994, van der
Zee et al. 1995, Klemi et al. 1995, Herod et al. 1996, Reles et al. 1996, Viale et al.
1997, Dong et al. 1997, Eltabakkah et al. 1997, Röhlke et al. 1997, Anttila et al. 1999,
Ferrandina et al. 1999, Werness et al. 1999). In one study, p53 overexpression was
identified immunohistochemically in only 14% of the cases (Marx et al. 1998).
With the exception of four studies (Kupryjanczyk et al. 1993, Casey et al. 1996,
Lee et al. 1995, Teneriello et al. 1993), three of which were of a small number of
cases, the frequency of p53 overexpression is consistently higher than the frequency of
p53 mutations. Our observations of a 62% immunostaining rate and a 56% mutation
rate for p53 were consistent with these generalizations.
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5.1.5 Correlation of p53 overexpression with p53 mutations
A strong correlation was observed between p53 immunostaining and p53
mutations (p < 0.001), but this was mainly an effect of the high rate of immunostaining
of missense mutations (94%). However, only 46% of nonmissense mutations were
identified by immunostaining and this percentage was not significantly different from
the percentage of staining in wildtype p53 cases (38%) (p=0.43). Therefore it can be
concluded that immunohistochemistry is not suitable for the detection of nonmissense
mutations, which is consistent with the findings of other authors (Casey et al. 1996,
Skilling et al. 1996, Schuyer et al. 1998). The low rate of immunostaining in cases
with nonmissense mutations is assumed to be caused by alteration and truncation of
the protein due to introduction of a stop codon in nonsense mutations, frameshifts
caused by deletions or insertions, and alterations of transcribed RNA in splice site
mutations. Since the antibody used for immunohistochemistry (DO-7) recognizes an
epitope near the amino-terminus of the protein between amino acid 19 and 26, one
would expect the antibody to have the potential to recognize nearly all of the mutant
p53 proteins. But p53 protein may not only be qualitatively altered but also
quantitatively reduced, possibly because of destruction of the messenger RNA as a
result of sequence changes.
A high percentage of cases with wildtype p53 sequence (38%) showed
overexpression of the p53 protein. Since this can not be explained by sequence
alterations, the stabilization and accumulation of a presumably normal p53 protein is
most likely caused by other genes interacting with p53. Alterations of the mdm2 gene,
which downregulates p53 in an autoregulatory feedback and promotes degradation of
the p53 protein (Kubbatat et al. 1997, Haupt et al. 1997, Kubbutat et al. 1999) may
play an important role in these cases. In fact, we found mdm2 alternative splicing in a
high percentage of cases with p53 overexpression despite wild-type p53 sequence, and
p53 overexpression was significantly correlated with the presence of a 654 bp splice
variant (mdm2-b), which has lost most of the p53 binding sequence (see chapter 5.2.8).
5.1.6 p53 alterations and response to chemotherapy
Cell culture experiments have shown that the sensitivity of tumor cells to
various chemotherapeutic agents depends on the efficient induction of apoptosis
mediated by a functional p53 protein and that loss of p53 can enhance resistance to
chemotherapy (Lowe et al. 1993, Vasey et al. 1996, Vikhanskaya et al. 1997).
The wildtype p53-expressing A2780 human ovarian cancer cell line acquired
cross resistance to Cisplatin and Doxorubicin by transfection with a dominant negative
mutant p53 gene, while it retained sensitivity to Taxol (Vasey et al. 1996). In another
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study (Vikhanskaya et al. 1997), Cisplatinum caused strong induction of p53, WAF1
and Bax in the Cisplatin sensitive A2780 cell line, while there was no such effect in a
Cisplatin resistant cell line A2780-DX3, which furthermore showed a significant
proportion of potentially inactive p53 protein located in the cytoplasm instead of the
nucleus.
However, some of the studies using cell culture experiments report
contradictory results. In a panel of cell lines, cisplatin was more efficient against
mutant/null p53 cell lines than wildtype cell lines, while the novel platinum analogue
DACH-aceto-Pt was considerably more toxic in wild-type p53 cell lines (Hagopian et
al. 1999). Similarly, in isogenic A2780 human ovarian cancer cell lines that differ only
in p53 function by transfection of HPV-16 E6, the p53-deficient cell line was more
sensitive to cisplatin and the novel platinum agent ZD0473 (Pestell et al. 2000).
Recently, genetic suppressor elements (GSEs) have been identified which
correspond to various regions within the p53 gene and can act as dominant negative
peptides or antisense RNA molecules (Gallagher et al. 1997). A synthetic peptide,
representing the predicted amino acid sequence of this GSE, conferred resistance to
Cisplatin when introduced into A2780 cells and inhibited the sequence specific DNA
binding activity of p53 protein in vitro. This indicates that inactivation of p53 function
confers Cisplatin resistance in these ovarian tumor cells.
The hypothesis that ovarian cancer cells with functional p53 are more sensitive
to Cisplatin is furthermore supported by the findings of gene therapy studies.
Introduction of wildtype p53 via adenovirus gene transfer into A2780/CP cisplatinum
resistent cells significantly sensitized these cells to platinum cytotoxicity, indicating
that p53 was involved in resistance to cisplatin (Song et al. 1997).
Further strong evidence for the importance of a functional p53 protein for the
efficacy of Cisplatin and Carboplatin is given by a database of the National Cancer
Institute on drug activity in cell lines (Weinstein et al. 1997). This database compares
activity patterns of chemotherapeutic agents and possible targets or modulators of
activity in the cells, such as oncogenes, tumor-suppressor genes, drug-resistance-
mediating transporters and others for more than 60.000 compounds against a panel of
60 human cancer cell lines. The results show a strong correlation between p53
wildtype sequence respectively p53 function in a yeast based assay and efficacy of
Cisplatin and Carboplatin (Weinstein et al. 1997). As opposed to this, antimitotic
tubulin-active agents such as Taxol show a strong negative correlation between p53
wildtype as well as p53 function and activity of the drug (Weinstein et al. 1997).
Since a dysfunctional p53 can not mediate the apoptotic process, tumors with
p53 mutations or altered p53 protein may become resistant to platinum-based
chemotherapy (Lowe et al. 1994). In our study in a subgroup of 72 patients, who
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received Cisplatin or Carboplatin / Cyclophosphamide combination therapy, we found
a significant correlation between p53 protein overexpression and resistance to
platinum-based chemotherapy (p=0.001). If all p53 mutations were taken into account,
there was only a trend but not a significant association with treatment response
(p=0.071). Interestingly though, we found that missense mutations, when compared to
wildtype p53 or other mutations, were correlated with a high percentage of
chemotherapy resistance in this cohort (p=0.008). This is consistent with the results of
two other studies which have demonstrated a correlation between p53 alterations and
resistance to platinum-based chemotherapy in ovarian cancer (Righetti et al. 1996,
Buttitta et al. 1997). One study analyzed p53 overexpression and mutations in 32 cases
of ovarian cancer FIGO stage III and IV and found a higher frequency of
chemotherapy-resistance both in p53 overexpressing tumors and in tumors with
missense mutations (Righetti et al. 1996). Another study, analysing 33 cases of
advanced ovarian cancer FIGO III and IV found a significant association between
chemotherapy-resistance and p53 immunostaining, as well as SSCP alterations
(Buttitta et al. 1997). These results are further supported by two immunohistochemical
studies. p53 overexpression was found to be associated with poor response to either
paclitaxel/platinum or cyclophosphamide/ platinum chemotherapy in 54 stage III and
IV patients with results approaching statistical significance (Goff et al. 1998). A higher
frequency of early tumor progression was found in 28/59 patients who had received
either cisplatin and treosulfan or treosulfan alone (Petty et al. 1998). In one
immunohistochemical study, a dose-dependent response to platinum-based
chemotherapy was found only in p53 negative, but not in p53 positive tumors (Marx et
al. 1998). And a more recent study, which analyzed 168 primary stage III-IV ovarian
carcinomas showed p53 overexpression to be significantly correlated with resistance to
a platinum based chemotherapy in those patients who underwent pathologic
assessment of response (Ferrandina et al. 1999). However, three other studies using
immunohistochemistry (van der Zee et al. 1995, Herod et al. 1996, Viale et al. 1997)
and one study using temperature gradient gel electrophoresis and
immunohistochemistry (Röhlke et al. 1997) did not find a difference in treatment
response between patients with or without p53 alterations.
Interestingly, missense mutations seem to have a different effect on p53
function in terms of apoptosis than other mutations. Recently, it was shown that certain
types of mutations such as the p53His175 mutant and the p53His179 mutant
substantially reduce the rate of etoposide-induced apoptosis, whereas other mutations
had a much milder effect (Blandino et al. 1999). This suggests that certain types of
mutation may have a selective gain of function, which may compromise the efficacy of
cancer chemotherapy.
136
Recently, small synthetic molecules have been identified which not only
promote the stability of wild-type p53 protein but also allow mutant p53 to maintain an
active conformation (Foster et al. 1999). Further work on these compounds may open
new perspectives to overcome an impaired p53 function in combination with
chemotherapy.
In contrast to these findings, sensitivity to Taxol appears to be increased
through the absence of functional p53 protein because of increased G2M arrest and
p53 independent apoptosis (Wahl et al. 1996, Vikhanskaya et al. 1998). Interestingly,
though numbers are very small, the only patient in our study who was sensitive to
Taxol/Carboplatin had high overexpression of p53 protein and a missense mutation in
exon 5, while three out of four patients with resistant or refractory disease were
immunohistochemically negative and two had wild type p53 sequence.
5.1.7 p53 alterations as a predictor of time to progression and overall survival
To date, only p53 protein overexpression but not p53 mutations have been
shown to be a predictor of poor clinical outcome in ovarian cancer. Several studies
have found a correlation between p53 overexpression and shortened survival (Bosari et
al. 1993, Henriksen et al. 1994, Hartmann et al. 1994, van der Zee et al. 1995, Klemi et
al. 1995, Levesque et al. 1995, Herod 1996, Viale et al. 1997, Eltabakkah 1997,
Geisler et al. 1997, 2000, Röhlke et al. 1997, Anttila et al. 1999, Werness et al. 1999),
but only few studies have identified p53 as an independent prognostic factor for
overall survival (Klemi et al. 1995, Herod et al. 1996, Geisler et al. 1997, 2000,
Röhlke et al. 1997) respectively recurrence-free survival (Anttila et al. 1999) in
multivariate analysis. However, p53 protein expression was not a significant predictor
of poor outcome in seven other studies (Marks et al. 1991, Kohler et al. 1993a,
Kupryjanczyk et al. 1993, Sheridan et al. 1994, Niwa et al. 1994, Reles et al. 1996,
Ferrandina et al. 1999, Wen et al. 1999). Only five studies found a correlation between
p53 overexpression and time to recurrence (van der Zee et al. 1995, Levesque et al.
1995, Röhlke et al. 1997, Werness et al. 1999, Anttila et al. 1999).
p53 overexpression is relatively rare in tumors of low malignant potential but
has been identified in 13% of advanced (stage II and III) borderline ovarian tumors
and was found to be strongly associated with increased probability of recurrence or
progression (Gershenson et al. 1999).
Seven of eight studies though which analyzed p53 sequence alterations and
clinical follow-up data did not find a significant correlation between p53 mutations
and shortened relapse-free or overall survival (Mazars et al. 1991, Kohler et al. 1993a,
Kupryjanczyk et al. 1993, Niwa et al. 1994, Sheridan et al. 1994, Buttitta et al. 1997,
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Skomedal et al. 1997). Only our previous study found p53 mutations to be associated
with shortened overall survival, but the results reached only marginal statistical
significance (p=0.049) (Wen et al. 1999).
Most of the p53 studies examined either p53 expression or p53 mutations but
not both in study populations of limited size. In our study p53 overexpression reached
only marginal statistical significance as a predictor of poor clinical outcome (p=0.056).
p53 mutations and especially those, which were located in highly conserved domains,
were clearly correlated with poor overall survival (p=0.014 and p=0.007). An
association between p53 mutations and overexpression was observed (p<0.001) and
the most favourable prognosis with a significantly longer time to progression and
overall survival was seen in patients with neither p53 mutation nor overexpression
(p=0.035, p=0.007).
Summarizing these results, we analyzed p53 protein expression and p53
sequence alterations in the entire coding region of the gene in 178 frozen ovarian
cancer tissues with complete clinical follow-up information. We could demonstrate
that p53 mutations and especially those in evolutionary conserved domains correlate
with shortened time to progression and shortened overall survival. Most importantly,
evaluation of adjuvant treatment showed that p53 overexpression as well as p53
missense mutations were correlated with resistance to platinum-based chemotherapy.
This provides further clinical evidence, that the sensitivity of ovarian cancer cells for
Cis- or Carboplatin depends on the efficient induction of apoptosis mediated by a
functional p53 protein.
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5.2 Alterations of the mdm2 gene in ovarian cancer
5.2.1 mdm2 expression and absence of amplification in ovarian cancer
Since mdm2 is upregulated by p53 in response to DNA damage and
subsequently inhibits p53 function and promotes p53 protein degradation, it seemed
interesting to analyze mdm2 alterations in ovarian cancer cases with known p53
mutations and overexpression.
We analyzed the mdm2 gene by Southern and Northern hybridization but we
found neither DNA amplification nor RNA overexpression in any of the 56 ovarian
carcinomas analyzed, independently of p53 status. Since accumulation of mutant p53
protein has been shown to depend on a lack of mdm2 induction (Haupt et al. 1997,
Kubbutat et al. 1997) one would expect that p53 protein accumulation despite wildtype
p53 might induce mdm2 overexpression. Vice versa in cases with p53 mutation but
undetectable p53 expression a possible mechanism might be the rapid degradation of
p53 through higher levels of MDM2. But none of the p53 alterations in ovarian cancer
cases caused mdm2 alterations detectable by Southern or Northern analysis.
This is consistent with findings in other epithelial tumors. Though mdm2 has
been found to be amplified in more than 30% of sarcomas and amplification was
correlated with overexpression of the MDM2 protein (Oliner et al. 1992),
amplification in epithelial tumors is rare (as reviewed by Momand and Zambetti 1997).
In breast cancer, gene amplification was noted in only 1.7-7.7% (McCann et al. 1995,
Marchetti et al. 1995a, Quesnel et al. 1994), and in HPV negative cervical cancer in
2% (Ikenberg et al. 1995). In ovarian cancer, amplification has not been found in any
case (Foulkes et al. 1995). MDM2 protein overexpression is rare in ovarian cancer
(Foulkes et al. 1995), but has more recently been described in 40% of borderline
ovarian tumors (Palazzo et al. 2000).
RNA overexpression was found in sarcomas which showed amplification of the
gene (Oliner et al. 1992) and in 6% of non-small cell lung carcinomas (Marchetti et al.
1995b) but is generally rare in epithelial tumors. In ovarian cancer, absence of mdm2
expression was identified in 18/90 ovarian carcinomas (22%), while 66% showed
weak expression and 12% showed strong expression (Tanner et al. 1997). Absence of
mdm2 expression was found to be an independent predictor of poor survival in FIGO
III and IV ovarian cancer patients (Tanner et al. 1997) and in non-small cell lung
cancer (Ko et al. 2000). Low levels as opposed to high levels of mdm2 mRNA were
found, furthermore, to be associated with poor clinical outcome in soft tissue sarcomas
(Taubert et al. 2000).
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We found three RNA transcripts of approximately 7.4 kb, 5.5 kb, and 2.8 kb by
Northern blot analysis in the ovarian cancer cases. In sarcomas and lung cancers, only
a single 5.5 kb transcript had been observed (Oliner et al. 1992, Marchetti et al. 1995b)
while in mammary epithelial cell lines, multiple messenger RNAs, ranging in size
from 4.5 to 12.5 kilobases, were found. (Gudas et al. 1995). These different sizes of
RNA transcripts may be the result of alternative splicing which has been described
when mdm2 was originally cloned and more recently in ovarian and bladder
carcinomas (Oliner et al. 1992, Sigalas et al. 1996).
5.2.2 mdm2 alternative and aberrant splicing in ovarian carcinomas
PCR analysis of the reverse transcribed mRNA and sequencing of the cDNA
products revealed numerous mdm2 splice variants, which were present either instead
of, or in addition to, the full length mdm2 transcript in ovarian cancer tissue. Only 20%
of the ovarian carinomas expressed exclusively the full length mdm2 RNA and some
cases (9%) had no expression while the majority of cases (72%) expressed splice
variants. We identified 30 different splice variants and the sizes ranged from 52 bp to
888 bp.
Alternative splicing has been previously described for the mdm2 gene (Oliner
et al. 1992) but only few splice variants were identified in ovarian cancer (Sigalas et al.
1996). The results were not analyzed with regard to p53 sequencing and
immunohistochemistry. Alternative splicing is a common occurrence in a number of
different genes and can create isoforms of proteins with extensive sequence overlap
but different functions. This has been well described for example for the troponin T
gene of rat muscle which exists in an α and β form depending on splice variants
(Lewin, 1994). These splice variants include alternatively, either the α or the β exon
besides three other exons which are identical in both mRNA transcripts. Another
example is the APC (adenosis polyposis coli) gene, a tumor suppressor gene altered
early in colon carcinogenesis, which is expressed both with and without exon 1 at
equivalent levels in brain, heart, and skeletal muscle in humans and mice (Santoro et
al. 1997). The resulting APC proteins with different amino-terminal domains
potentially have different functions in interaction with other proteins. The expression
of APC isoforms is dependent on tissue differentiation indicating that alternative
splicing occurs in response to tissue dependent signals as well as signals to
differentiate (Santoro et al. 1997).
In ovarian cancer we observed alternative and aberrant splicing. In some of the
splice variants, the splice site was located at the exon-intron boundaries, but in others
splicing took place within the exon sequence and should therefore be classified as
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aberrant splicing.  Aberrant splicing, in contrast to alternative splicing, is the splicing
of mRNA which is misdirected and does not occur at de facto splice sites. Both the
tumor susceptibility gene 101 (TSG 101) and the fragile histidine triad gene (FHIT)
mRNAs show evidence of alternative and aberrant splicing (Gayther et al. 1997).
In ovarian cancer, deletions of several hundred basepairs of the TSG 101 gene,
a putative tumor suppressor gene, have been found in 40% of the cases and are thought
to be due to aberrant splicing. The breakpoints of these deletions were located at
genuine or cryptic splice sites therefore most likely being the result of aberrant
splicing (Gayther et al. 1997).
Deletions of the FHIT gene which is also thought to be a tumor suppressor
gene, occured in 42% of ovarian carcinomas at exon/intron boundaries and were
suspected to be due to alternative splicing (Gayther et al. 1997).  Evidence of both
alternative and aberrant splicing was furthermore described in breast (Negrini et al.
1996), lung (Fong et al. 1997), head and neck tumors (Virgilio et al. 1996).
In this investigation of malignant, as well as benign ovarian tumors, and normal
tissue, we found evidence of expression of normal mdm2 (1473 bp) coexisting with
both alternative and aberrant splicing. We found alternative splicing at the exon/intron
boundary in two variants (888 bp, 654 bp) which were missing exon 4-9 and exon 4-
11, respectively. These two splice variants had been described previously in ovarian
carcinomas but not in normal ovarian tissue and had been named mdm2-a and mdm2-b
(Sigalas et al. 1996). Both variants were found to have transforming ability in NIH
3T3 cells (Sigalas et al. 1996). We found the 654 bp splice variant in almost half of the
ovarian carcinomas, but also infrequently in borderline tumors (1/9), and even in one
normal ovarian tissue (1/20). The presence of this variant is therefore strongly, but not
exclusively, associated with carcinomas.
All other RNA transcripts of 721 bp to 52 bp size resulted from aberrant
splicing.  Exon 10 and 11 were spliced out completely in all but one of these splice
variants and the cryptic acceptor splice site was consistently located within exon 12.
The donor splice sites were located at the exon/intron boundaries of exon 4, exon 5, or
exon 6 in seven of the splice variants but in the majority of variants within the
sequence of exon 3 to exon 9. In one splice variant of 613 bp, the complete exon 5 as
well as parts of exon 9, 10 and 11 were deleted, while exon 6,7 and 8 were contained.
All splice variants except, for the 888 bp and the 721 bp variant, completely lose the
acidic domain which was suggested to be involved in the regulation of ribosome
metabolism (as reviewed by Piette et al. 1997).
Only 13/30 splice variants were spliced in frame. This means that no protein
can be synthesized from the 5’ RNA fragment. Among the splice variants, which were
in frame, all had spliced out the putative nuclear localization signal which is thought to
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be located at aa 181-185 (Fakharzadeh et al. 1991), and the nuclear export signal
(NES) which is thought to be located at aa 191-199 (Fig. 5, Fig. 24, Table 17). This
suggests that even if these RNA transcripts were translated into truncated proteins,
there is no function of these MDM2 variants in the nucleus, especially no possible
MDM2/p53 interaction.  Most importantly though, the majority of splice variants
(22/30) lack part or all of the p53 binding sequence at the N-terminal end of the
protein, therefore most likely being unable to inhibit and degrade p53 protein. Some of
the splice variants splice out the zinc-finger-like sequence which is as yet of unknown
function. Other splice variants have lost part or all of the RING finger motif, which
was shown to specifically bind to RNA and suggested to play a role for cell cycle
regulation (Elenbaas et al. 1996, Argentini et al. 2000).
Furthermore, different mdm2 transcripts containing or skipping exon 2
according to different promoters have also been described. Translational enhancement
of mdm2 involved a preferential increase in mdm2 transcription that was initiated from
an internal p53-responsive promoter region of the gene (Landers et al. 1994).
Occurrence of multiple MDM2 proteins has been noted in different tissues and
is thought to result from alternative splicing. Protein variants of sizes between 78 kD
and 12 kD have been found in non-small cell lung cancer and oral squamous cell
carcinomas (Maxwell, 1994, Ralhan et al. 2000). The p74 protein, which lacks the N-
terminus and does not bind to p53 (Olson et al. 1993) is expressed in response to UV
light in a p53-dependent manner (Saucedo et al. 1999). Both internal initiation at AUG
codon 50 and alternate splicing can give rise to p76 in cells (Saucedo et al. 1999). A
p76 MDM2 protein was found to antagonize the ability of MDM2 to stimulate the
degradation of p53 and lead to an increase in the level of p53 (Perry et al. 2000).
Since most of the mdm2 splice variants lack various functional domains of the
gene such as the p53 binding site and the nuclear localization signal, the purpose of the
alternative splicing remains unclear. But the fact that splicing is found in the majority
of ovarian carcinomas and splice variants of identical sequence occur throughout this
cancer cohort as well as in benign tissues suggests that these splice variants have
distinct, as yet unknown functions and are not only a by-product of RNA processing.
5.2.3 Loss of p53 binding sequence in mdm2 splice variants
The MDM2 protein binds to p53, inhibits its function and promotes rapid
degradation of the p53 protein (Momand et al. 1992, Haupt et al. 1997, Kubbutat et al.
1997). The p53 binding domain has been located to an N-terminal region of aa 19-102
which is critical for stable interaction with p53 protein in vitro (Chen et al. 1993).
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Out of 30 splice variants in ovarian tumors, 20 (67%) were partially and 2 (7%)
completely missing the sequence coding for the p53 binding region at aa 19-102.
Mapping experiments of the MDM2/p53 interaction domain had shown that N-
terminal deletions in MDM2 mutants or internal deletions affecting part or all of this
entire region resulted in significantly reduced or absent binding to p53 protein (Chen
et al. 1993). Similar binding regions were found by Oliner et al. (1993) who identified
a protein sequence of codons 1-118 of MDM2 to be able to interact with full length
p53 (Oliner et al. 1993). Other experiments located the p53 binding domain to amino
acids 14- 154 (Leng et al. 1995).
Further experiments, though, suggested that amino acid sequences outside of
the region between residues 19 and 102 contribute to MDM2/p53 binding, since the
smallest mutant that could bind to p53 protein contained amino acids 1 to 294 (Chen et
al. 1993). The MDM2 protein sequences which were suggested to be additionally
necessary for a stable MDM2/p53 interaction may comprise either amino acids 102 to
294 or 294 to 491 (Chen et al. 1993). Other studies though, showed that the N-terminal
154 amino acids of MDM2 are sufficient for p53 binding in vivo (Leng et al. 1995).
Furthermore, p53 binding can not only be prevented by large deletions but also
by point mutations in the mdm2 sequence (Freedman et al. 1997). Though the wild-
type (1-115) fragment of MDM2 was clearly able to bind specifically to p53, two
MDM2 mutants with an amino acid exchange at residue 58 and 77, respectively, did
not show any detectable level of binding to p53. By binding to conformation-
dependent antibodies it was shown that these two MDM2 mutants are not grossly
misfolded. Site directed mutagenesis yielded mutations of two additional amino acids
of MDM2 (D68 and V75) that prevented binding to p53 in vitro. In a functional essay
MDM2 with the point mutations also failed to regulate p53 dependent transactivation
of target genes, which is consistent with the assumption that a physical interaction
between the two proteins is required for MDM2’s inhibition of p53 activity (Freedman
et al. 1997).
Given these experimental results, most of the splice variants which we found in
ovarian cancers would be expected to be unable to bind p53. Only eight splice variants
contained the complete p53 binding sequence. All of these were spliced with a frame
shift so that only a 5’ portion of 316 to 696 basepairs could potentially code for a
protein that binds to p53, comprising 105 to 232 amino acids of the N-terminal portion
of the protein. These splice variants, though containing the entire p53 binding
sequence, still lack additional supportive protein sequences which may be required for
MDM2/p53 interaction.
In mapping experiments (Chen et al. 1993) the smallest MDM2 mutant that
could bind to p53 comprised aa 1-294, while two smaller mutants comprising aa 1-222
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and 6-204 were unable to bind to p53. In ovarian cancer five mdm2 splice variants
have previously been identified that were all lacking part of the p53 binding sequence
(Sigalas et al. 1996). Interestingly though, the smallest of the splice variants which
retained the largest part of the p53 binding domain consisting of a 5’ portion of 225
basepairs of the coding region was clearly shown to bind to p53 in co-
immunoprecipitation experiments (Sigalas et al. 1996). This is in contradiction to the
hypothesis that a complete p53 binding sequence plus additional protein sequences are
required for binding (Chen et al. 1993).
Recently, a highly conserved mdm2 exon α has been identified in human and
dog DNA (Veldhoen et al. 1999). The exon is located between exon 4 and 5 of mdm2
and codes for additional 29 amino acids. Expression of exon α disrupts in vitro
translation of the p53 binding domain of MDM2. The putative MDM2 α protein lacks
the N-terminus of MDM2 and shows little if any binding capacity to p53 (Veldhoen et
al. 1999).
Nevertheless, among the splice variants identified in this ovarian tumor cohort,
those which were found most frequently were all missing a large portion of the p53
binding sequence making a MDM2/p53 interaction probably impossible. Some rare
splice variants contained the full binding sequence, but these sequences are probably
still too short to allow a stable MDM2/p53 interaction. Therefore, we assume that the
splice variants which we see in ovarian tumors do not play a role for p53 inhibition,
but may possibly fulfill other as yet unknown functions.
5.2.4 mdm2 splice sites and repeat sequences
The pattern of splicing in many of the variants was interesting since the splice
donor and acceptor sites were in regions of exact sequence homology.  A sequence of
up to 10 bp as for example TTCAAATGAT in the 259 bp splice variant was found at
the 3’ end of the donor site as well as at the untranscribed end of the downstream
acceptor splice site.  The pattern of deletions between short direct repeats was similar
to data from a DNA polymerase delta (pol 3) in Saccharomyces cerevisiae (Tran et al.
1996). A mutation of pol 3 caused an approximately 1000-fold increase in 7-61
deletions between repeat sequences. To clarify whether the deletions in mdm2 cDNA
could also result from genomic deletions in the DNA sequence, we performed PCR at
the expected site of loss, but did not identify any deletions in genomic mdm2 DNA
(data not shown).
Interestingly several splice variants, though different in length shared either an
identical cryptic acceptor site sequence or donor site sequence.  This has been
observed for three donor sites and two acceptor sites, each of which are identical for
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two, three or four splice variants. An identical donor site had been described
previously for mdm2-a (888 bp) and mdm2-b (654 bp) (Sigalas et al. 1996). Similar
observations have been made for splice variants of the TSG101 gene sharing proximal
or distal breakpoints in ovarian cancer (Gayther et al. 1997).
5.2.5 mdm2 alterations in ovarian cystadenomas and borderline tumors
In ovarian cystadenomas and ovarian tumors of borderline malignancy
alternative and aberrant splicing of mdm2 was also frequent, but the pattern of splicing
was different from ovarian carcinomas. Expression of full length mdm2 was usually
present except for three cases, two of which had no detectable mdm2 mRNA at all.
Besides full length mdm2, expression of small splice variants was frequent. The 221 bp
splice variant was even notable in 5/9 LMP tumors (56%) as opposed to 16% of the
ovarian carcinomas. The mdm2-b splice variant though, which is not only frequent in
ovarian cancer (41%) but also correlated with poor grade of differentiation and other
unfavourable prognostic criteria, was rarely seen in borderline tumors (1/9) and in no
case of cystadenomas.
Little is known about mdm2 splicing in benign tumors of the ovary and nothing
about LMP tumors. Only five cases of benign ovarian tumors have been analyzed for
splice variants and one out of these was described to have alternative splicing without
mentioning the exact size of the splice variant (Sigalas et al. 1996).
Our results clearly show that the mdm2-b splice variant predominantly, but not
exclusively, occurs in ovarian carcinomas, while small splice variants are frequently
seen coexisting with the full length transcript in tumors of borderline malignancy and
benign ovarian tumors. This suggests that the mdm2-b splice variant is either involved
directly in carcinogenesis or that RNA processing is indirectly affected by alterations
of other cell cycle related genes, leading to mdm2 alterations.
5.2.6 mdm2 alterations in normal ovarian tissue
Surprisingly, mdm2 alternative splicing also occurred in normal ovarian tissue.
Full length mdm2 was, like in ovarian cancer, missing in 2/20 cases (10%). In almost
half of the cases small splice variants were noted besides the full length transcript.
This is in contrast to previous reports which only found the full length mdm2 transcript
in normal tissue (Sigalas et al. 1996).
mdm2 is thought to be expressed under normal conditions only during, but not
after embryonic development. During early embryogenesis, the expression of xdm2,
the xenopus laevis homolog of mdm2, increases from oocyte stage I/II to reach its
maximum in oocyte stage V/VI in unfertilized eggs and then becomes undetectable by
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Northern blot analysis in various differentiated normal tissues after embryonic
development (Marechal et al. 1997). Since p53 is stored as a cytoplasmic pool until
fertilization, xdm2 expression is possibly independent of transcriptional activation by
p53 (Marechal et al. 1997). In the normal ovarian tissue cases of our study, mdm2
expression patterns did not correlate with pre- or postmenopausal status. Therefore,
presence or absence of oocytes does not seem to have an influence on mdm2
expression and mdm2 splicing.
Alternative splicing in normal tissue is well known under physiological
conditions, for example for muscle proteins such as troponin, but has also been noted
for other genes which are typically involved in tumorigenesis. Aberrant splicing in up
to 50% of normal tissue or cells including peripheral blood, immortalized B-cell lines
and lung parenchyma has been described for the TSG 101 gene (Gayther et al. 1997,
Lin et al. 1998). Some of the splice variants were found more frequently in normal
cells and the spectrum of splice variants seemed to differ between tumor and normal
samples (Gayther et al. 1997). Deletions that are thought to result from alternative
splicing were also found for the FHIT gene in normal lymphocytes (Druck et al. 1997).
However, concerning other genes which are involved in tumorigenesis, alternative
splicing still remains to be a rare phenomenon in normal cells. In normal peripheral
blood samples, no mis-splicing of BRCA1, BRCA2, BRUSH1, hMSH2, IGF2 receptor
PGDB or RB was seen (Gayther et al. 1997).
In our study 221 bp splice variant was found in 40% of the normal ovaries.
This is interesting since this variant is rare in ovarian carcinomas and if present, is
associated with a more favourable outcome in terms of survival. Remarkably, the
splice variant mdm2-b which seems to be clearly associated with a more aggressive
type of ovarian carcinomas, was found in abundance and as the sole transcript in the
normal ovary of one woman who died of liver failure. Generally, presence or absence
of splicing in normal ovarian tissue was not related to age, day of menstrual cycle or
menopause. Interestingly though, if the uterus and ovaries had been removed for a
benign disease, mdm2 splicing was rare as opposed to those cases in which the
contralateral ovary or the uterus had been affected by cancer.
The presence of mdm2 splice variants in normal ovarian tissue suggests that
mdm2 splicing is not generally associated with malignant transformation of cells. It
remains unclear though, which possible function a splice variant of 221 bp could have
that splices out most of the functional regions of the gene and in addition is spliced out
of frame. The fact that it occurs predominantly in normal tissue and borderline tumors
raises the question whether it is a waste product of RNA processing in an otherwise
normally functioning mdm2 gene. Interestingly though, a distinct pattern of splice
variants in normal tissue as opposed to ovarian cancer is notable.
146
5.2.7 In vitro expression of p53 and MDM2 proteins
Full length MDM2, p53 and mdm2 splice variant sequences were cloned into
the pcDNA3 expression vector and transient transfection of vaccinia virus infected
HeLa cells with the vector construct was used to express MDM2 and p53 proteins. We
were able to express the full length MDM2 and p53 protein as well as a 40 kD protein
from the mdm2-b (654 bp) splice variant. Two smaller splice variants, both spliced in
frame, did not express a protein detectable on Western blot, possibly due to
degradation of the protein. Most of the splice variants were not suitable for these
experiments at all because of out of frame splicing.
We attempted to analyze binding of the splice variants to p53 by co-
immunoprecipitation experiments and were able to show binding between full length
MDM2 and full length p53, which is a requirement for further binding experiments
(data not shown). The co-immunoprecipitation experiments of p53 and mdm2 splice
variants though, could not be successfully completed yet. Mapping studies have
already shown that the N-terminal region between aa 19 and 102 is most likely
necessary for p53 binding (Chen et al. 1993). Co-immunoexpression experiments have
shown that mdm2-b and other splice variants which lack a major portion of the p53
binding site are unable to bind p53 (Sigalas et al. 1996).
Different sizes of MDM2 proteins have been noted previously in cells and have
been suggested to stem from alternative splicing. Besides the normal size MDM2
protein of 90 kD, four additional polypeptides (p85, p76, p74, and p58-p57) were
identified in mouse cells (Olson et al. 1993). Antibody binding experiments revealed
that p76/74 have lost the N-terminal epitopes and the p58/p57 protein is missing the
carboxy-terminus epitope (Olson et al. 1993). Similar sizes of proteins of 76/78 kD,
57/59 kD and 46 kD which were identified in non small cell lung cancer were
associated with different nuclear substructures and may potentially interact with
transcription factors other than p53 (Maxwell, 1994). The presence of distinct MDM2
proteins of 54kD-68kD was also confirmed in breast epithelial cells (Gudas et al.
1995). In oral carcinomas three isoforms of MDM2 (90 kD, 76 kD, and 57 kD) were
identified and showed differential compartmentalization in the cells (Ralhan et al.
2000).
The splice variants though, which we found by RT-PCR and sequencing, were
mostly much smaller in size. One of the larger variants of 654 bp codes for an
approximately 40kD protein, but we were unable to express smaller proteins which
may have been too unstable.
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5.2.8 Correlation of mdm2 and p53 alterations
p53 mutations often lead to accumulation of the altered protein due to a
prolonged half-life. However, protein accumulation was also seen in 38% of the
ovarian carcinomas which had the wildtype p53 sequence. Since MDM2 promotes
nuclear export and degradation of the p53 protein, our hypothesis was that cases with
p53 protein overexpression in the absence of mutation might have mdm2 alterations,
which cause accumulation of normal p53 protein. In fact, in this group we found mdm2
alterations in 11/13 cases (85%). Cases with p53 mutation and p53 overexpression also
had a high proportion of abnormal mdm2 (71%). Cases without normal p53 expression,
regardless of whether they had a wildtype or mutated p53 sequence, had a lower
percentage of mdm2 alterations (63%), but the results did not reach statistical
significance.
p53 mutations were not correlated with any form of mdm2 alternative or
aberrant splicing. However, p53 protein overexpression was found significantly more
often in cases with the mdm2-b splice variant. Wildtype p53 protein stabilization
through mdm2 splicing has also been found in glioblastomas (Kraus et al. 1999). This
is consistent with findings in MDM2 mutant experiments. Expression of the MDM2
mutant (∆ 222-437) not only failed to target degradation of p53, but also resulted in a
significant elevation of p53 levels (Kubbutat et al. 1997). Since these cells express
endogenous full length MDM2, it was suggested that the MDM2 mutant can, at
significantly high levels of overexpression, act in a dominant negative manner,
protecting p53 from degradation by endogenous MDM2 protein (Kubbutat et al. 1997).
These results are corroborated by recent findings about p76 MDM2, a protein
which lacks the first 49 amino acids of p90 MDM2. Overexpression of p76 MDM2
was shown to antagonize the ability of MDM2 to stimulate the degradation of p53 and
lead to an increase in the levels and activity of p53 (Perry et al. 2000). Furthermore,
the mdm2-P2 promoter which is a transcriptional target of p53, was found
overexpressed in oral carcinomas which both overexpressed MDM2 and p53 proteins
despite wild-type p53 sequence. The authors suggest that enhanced translation of
mdm2-P2 transcripts may represent an important mechanism of overexpression,
subsequent stabilization and functional inactivation of p53 (Ralhan et al. 2000).
Although we observed expression of both full length and splice variant mdm2,
especially the mdm2-b splice variant is present in abundant quantity in many cases of
ovarian cancer. It may therefore, have a dominant negative effect even if it coexists
with the full length mdm2 transcript. Since this splice variant has lost the p53 binding
ability, it may cause accumulation of the p53 protein despite p53 wildtype sequence.
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5.2.9 Correlation of mdm2 alterations with histopathological and clinical data
The mdm2-b splice variant (654 bp) was not only the most frequent mdm2
alteration in ovarian cancers and rare in borderline tumors as well as normal tissues. It
was also significantly correlated with more aggressive tumors of high grade, high S-
phase fraction and presence of residual tumor after surgery. All of this is contributing
to a poorer outcome of these tumors in terms of survival. This confirms the results of a
previous study in which mdm2 splice variants were associated with poor differentiation
and advanced stage (Sigalas et al. 1996).
These findings indicate that this specific form of mdm2 splicing plays a role in
tumorigenesis and tumor progression. Similar observations were made for astrocytic
neoplasms. mdm2 splice variants, predominantly mdm2-b, were significantly more
often found in glioblastomas than in lower grade astrocytomas (Matsumoto et al.
1998). The mdm2-b splice variant, as well as other variants, were found to have
transforming ability in NIH 3T3 cells (Sigalas et al. 1996).
Given that most of the splice variants lack a major part of the p53 binding
domain, we assume that they cannot inhibit p53 function. But since p53 itself is
dysfunctional through mutations in most of the ovarian cancer cases, this does not lead
to a more stable p53 function for cell cycle control and apoptosis. Mechanisms which
cause mdm2 splicing though might be an attempt to disrupt MDM2/p53 interaction in a
cell that has undergone DNA damage in order to prevent mdm2 mediated p53
inhibition and degradation.
5.2.10  mdm2 alterations and clinical outcome in ovarian cancer
Absence of the full length mdm2 transcript and presence of splice variants was
significantly associated with increased resistance to platinum-based chemotherapy in
ovarian cancer. This is, though numbers are small, an interesting but unexpected result.
Current knowledge about platinum based chemotherapy and cell cycle regulation
suggests that a functional p53 is necessary to induce apoptosis (Lowe et al. 1993).
Resistance to chemotherapy has been found in our study and by others more frequently
in tumors with p53 overexpression and p53 missense mutations. A functional MDM2
would inhibit p53 and therefore, potentially make the tumor less prone to undergo
apoptosis after treatment with chemotherapy. In contrast, mdm2 splice products which
have lost p53 binding ability, might indirectly contribute to p53 stability and enhance
its function. Recent experiments with fibroblasts from p53/mdm2 null mice have
shown, that loss of mdm2 can induce the p53-dependent apoptotic pathway in vivo (de
Rozieres et al. 2000).
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However, the opposite was suggested by our results. Tumors with functional
mdm2 were more sensitive to chemotherapy than those with splice variants. Among
tumors resistant to platinum based chemotherapy is a high percentage of cases with
p53 alterations. Mutant p53 though, does not induce mdm2 in the same manner as
wildtype p53, possibly leading to undetectable amounts of mdm2 full length transcript.
The underlying regulatory mechanisms for this result remains presently unclear.
Further studies would be needed to clarify whether chemotherapy-sensitivity actually
depends on a functional mdm2, or whether the above described findings are indirectly
influenced by p53 alterations.
In terms of prognosis, no correlation was found between presence of full length
mdm2 nor presence of mdm2 alterations in general, and clinical outcome. A trend
though, towards poorer outcome was noted in cases that expressed the mdm2-b splice
variant, which also correlated with clinical and histopathological indicators of poor
prognosis such as grading and residual tumor after surgery. The clinical correlations of
mdm2-b though, suggest that this splice variant is associated with tumorigenesis and
tumor progression.
Interestingly, presence of the splice variant 221 bp, which was more frequently
seen in benign and normal tissues, was significantly associated with better outcome.
Though this splice variant has lost most of the important functional domains, we
assume that its occurrence is associated with a relatively intact cell cycle regulation
and less aggressive tumors. However, further studies will be necessary to clarify
whether alternative and aberrant splicing of mdm2 is important in tumorigenesis and
progression of ovarian cancer, or whether these transcripts are merely a product of
altered mRNA splicing fidelity that occurs more commonly and in a different pattern
in tumors as compared to normal tissues.
Summarizing these results, we could demonstrate that mdm2 alternative and
aberrant RNA splicing is frequent in ovarian tumors as well as normal ovaries. Distinct
splicing patterns were identified in ovarian carcinomas as opposed to benign tumors
and normal tissue. The most frequent of the splice variants, mdm2-b, correlates with
p53 protein accumulation in ovarian cancer as well as features of biologically more
aggressive tumors.
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6. SUMMARY AND CONCLUSIONS
Background: The p53 tumor suppressor gene, the ‘guardian of the genome’
(Lane, 1992), is involved in key responses to genotoxic stress and plays a central role
in the maintenance of genomic stability. Activation of p53 in response to DNA damage
is associated with a rapid increase in its level and with an increased ability of p53 to
bind DNA and mediate transcriptional activation. Upon low or repairable levels of
DNA damage, p53 mediates delay or arrest of replication to give the cell the
opportunity to repair the damage before its fixation and propagation. Upon high or
irreparable DNA damage, p53 promotes apoptosis. Mutations of the gene which
inactivate some or all of p53´s functions provide a selective advantage for clonal
expansion of neoplastic cells.
Functional p53 must be tightly regulated and the mdm2 (murine double minute
2) gene plays an important role in this regulation. The transcription of the mdm2
oncogene is induced by the p53 gene after DNA damage. The MDM2 protein then
binds to p53 and downregulates it in an autoregulatory feedback loop. MDM2 inhibits
p53 transcriptional activity, promotes nuclear export to the cytoplasm and rapid
degradation of the p53 protein. It, therefore, plays a crucial role as a regulator of p53 in
early embryonic development and for recovery of cellular proliferation after repair of
DNA damage.
The aim of this study was to analyze the frequency and type of p53 and mdm2
alterations in ovarian cancer and to correlate the results with clinico-pathological
variables, response to chemotherapy and clinical outcome of the patients.
Methods: 178 cases of primary epithelial ovarian cancer, snap frozen and
stored at -80°C, were used in this study. Mutations of the entire p53 coding sequence
(exons 2-11) were analyzed by SSCP (Single Strand Conformation Polymorphism) and
DNA-sequencing. p53 protein expression was analyzed immunohistochemically with
the monoclonal Ab DO7 in frozen tissue sections. p53 was considered to be overex-
pressed, if more than 10% of the nuclei in the sections showed immunostaining.
Clinical follow-up of the ovarian cancer patients was documented up to 12 years. In
the total cohort, the median time of follow-up was 31 months and among the survivors,
52 months. 74 patients who received Cis- or Carboplatin in combination with
Cyclophos-phamide were evaluated for platinum-sensitivity.
Analysis of the mdm2 gene for alternative splicing was performed by using
PCR amplification of full length mdm2 cDNAs. Total RNA was reverse transcribed
into cDNA, and then the cDNA was amplified by nested PCR. Cases with RT-PCR
products other than the full length mdm2 cDNA were cloned into a pCR 2.1 vector and
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sequenced or the PCR products were directly sequenced. p53 and mdm2 splice variant
cDNAs were cloned into a pcDNA3 expression vector. p53 and MDM2 full length and
mdm2 splice variant proteins were expressed in vitro by transient transfection of the
pcDNA3 constructs into HeLa-cells. The HeLa cells had been previously infected with
the vTF7-3 virus, a recombinant vaccinia virus encoding bacteriophage T7 RNA
polymerase.
Results: p53 mutations were seen in 56% (99/178) of the ovarian cancer cases
of which 72% were missense mutations. p53 overexpression (> 10% positively stained
nuclei) was seen in 62% (110/178) of cases. 62% of the p53 mutations were located in
the evolutionary highly conserved domains of the gene. p53 mutations were
significantly correlated with shortened time to progression (p=0.028) and poor overall
survival of the patients (p=0.015). Comparing clinical outcome of patients with
mutations in highly conserved domains with those who had either wildtype p53 or a
mutation in a nonconserved domain, the difference in time to progression (p=0.007)
and overall survival was even more obvious (p=0.005).  Furthermore, time to
progression and overall survival were seen to be shorter in patients with p53
overexpression as compared to normal p53 expression, but the results only reached
marginal statistical significance (p=0.073, p=0.058). Patients with p53 overexpression
(p=0.001) or p53 missense mutations (p=0.008) were significantly more often
platinum resistant than patients without p53 alterations. Overall, the most favorable
prognosis in terms of overall survival was seen in patients who had wildtype p53
sequence and normal p53 expression, as opposed to those who had either one or both
alterations of the p53 gene and protein (p=0.007).
Besides p53 mutations 45 sequence alterations were identified and considered
polymorphisms. The codon 72 arginine→proline polymor-phism was identified in 5%
(9/178) of the cases. Furthermore, alterations were found at codon 36 (exon 4), codon
213 (exon 6), codon 224 (exon 6), and codon 231 (exon 7). The 16 basepair repeat
polymorphism of intron 3 was identified in 14% (24/178) of the cases. Three novel
intron alterations were identified by sequencing the introns 6 and 10. A g→c
nucleotide exchange at position 13964 in intron 6 was found in two cases. An a→t
polymorphism was found at nucleotide 17708 of intron 10 in a frequency of 1.1% and
a c→t polymorphism at nucleotide 18550 of intron 10 in a frequency of 2.3%. Both
intron 10 polymorphisms were confirmed in normal tissue of the patients. Most of the
cases (7/8) with intron 6 or intron 10 polymorphisms showed p53 over-expression.
The mdm2 gene was neither amplified nor overexpressed in any of the ovarian
cancer cases. An mRNA transcript of 7.4 kb, 5.5 kb and 2.8 kb was seen at normal
levels in all ovarian carcinomas. However, mdm2 alternative or aberrant splicing was
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seen in 66/92 (72%) of the ovarian carcinomas, 7/9 (78%) of borderline tumors, 5/6
(83%) of benign ovarian cystadenomas and 11/20 (55%) of the normal ovarian tissues.
A total of 30 splice variant sequences were identified. 67% of these had a partial and
7% a complete loss of the p53 binding site.  28/30 splice variants do not splice at
exon/intron boundaries but use cryptic splice sites within exons and were therefore
considered aberrant splice variants.
A 654 bp splice variant (mdm2-b) was expressed in 41% of ovarian
carcinomas, but only in 1/9 (11%) borderline tumors, none of the benign
cystadenomas, and 1/20 (5%) normal ovaries. This splice variant splices out exon 4-
11, including 90% (81 of 90 amino acids) of the 3’end of the p53 binding domain as
well as the nuclear localization signal (NLS) and the nuclear export signal (NES).
Expression of this splice variant in ovarian carcinomas was significantly correlated
with poor grade of differentiation (p=0.004), residual tumor after surgery (p=0.004),
and high S-phase fraction (p=0.016) of ovarian carcinoma. Presence of mdm2-b was
furthermore correlated with p53 protein overexpression (p=0.018). A small splice
variant of only 221 bp, which has lost most of the functional mdm2 domains was
present in only 16% of the ovarian carcinomas but in 5/9 (56%) of borderline tumors,
1/6 of the cystadenomas, and interestingly also in 8/20 (40%) of the normal ovarian
tissues. The 221 bp splice variant was correlated with early stage of ovarian cancer
(FIGO I and II) and longer overall survival (p=0.048).
The absence of the full length mdm2 transcript respectively, the presence of
mdm2 splice variants in general were correlated with a higher proportion of ovarian
carcinomas, which were resistant or refractory against a platinum-based chemotherapy
but were not correlated with survival.
Depending on the diagnosis for which the patient underwent surgery, different
mdm2 RNA splicing patterns were seen in normal ovarian tissue. The presence of
splice variants in the unaffected normal ovary was significantly correlated with the
diagnosis of gynecological cancer, either in the contralateral ovary or in the uterine
cervix or endometrium (p=0.017).
Conclusions: p53 mutations are present in more than 50% of epithelial ovarian
carcinomas and are associated with early progression and shortened overall survival.
Mutations in evolutionary conserved domains correlate with significantly shorter
survival, compared to mutations in nonconserved regions and p53 wildtype sequence.
p53 protein overexpression reached only marginal statistical significance as a predictor
of clinical outcome. With multivariable analysis however, p53 alterations were not an
independent prognostic factor. Evaluation of adjuvant treatment showed that p53
overexpression as well as p53 missense mutations were correlated with resistance to
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platinum-based chemotherapy. This provides further clinical evidence that the
sensitivity of ovarian cancer cells for Cis- or Carboplatin depends on the efficient
induction of apoptosis mediated by a functional p53 protein.
mdm2, which inhibits p53’s transcriptional activity and downregulates it in an
autoregulatory feedback-loop by promoting nuclear export and rapid degradation of
the protein, was found to be frequently altered in ovarian carcinomas. mdm2
alternative and aberrant splicing was found in the majority of ovarian carcinomas and
borderline tumors, but also in cystadenomas and normal ovarian tissue. A distinct
difference in patterns of splice variants was notable in comparing benign and
malignant tissues. While the mdm2-b splice variant was found in nearly 50% of the
ovarian carcinomas and was associated with more advanced and histologically more
aggressive tumors, smaller size variants were typically seen in early stage ovarian
carcinomas and benign tissues.
The mdm2 splice variants mostly lack part, or all of the p53 binding sequence.
mdm2 alterations appear to stabilize p53 protein and may cause p53 accumulation in
the absence of p53 mutation. If these results are corroborated by other investigators,
alterations of mdm2 may be considered to be an important step in carcinogenesis and
may have important implications for the response to chemotherapy and clinical course
of ovarian carcinomas.
Since most of the mdm2 splice variants lack various functional domains of the
gene, such as the p53 binding site and the nuclear localization signal, the purpose of
the alternative splicing remains unclear. But the fact that splicing is found in the
majority of ovarian carcinomas and splice variants of identical sequence occur
throughout this cancer cohort and in benign tissues, suggests that these splice variants
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